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THE INGENIOUS INTESTINAL MUCOSA: DISRUPTED IN INFLAMMATORY 
BOWEL DISEASE
The human gut must perform a constant balancing act, as it needs to transport nutrients, 
vitamins and ions from the luminal side to different tissues, while on the other hand it keeping 
out toxic and harmful pathogens. Furthermore, the mucosal immune system needs to 
tolerate microorganisms that are not pathogenic, whilst reacting robustly against pathogenic 
microorganisms. Underneath the mucus layer hides an interplay of numerous cells with highly 
specialized functions to execute these tasks. Surprisingly, these processes work well in most 
people, but dysregulation lies in wait, as is seen in patients with an inflammatory bowel disease 
(IBD) 1. Patients with IBD suffer from a chronic inflammation of the gastrointestinal tract which 
causes a lifelong, debilitating disease. 
INFLAMMATORY BOWEL DISEASE: EPIDEMIOLOGICAL AND CLINICAL 
ASPECTS
IBD encompasses Crohn’s disease (CD), ulcerative colitis (UC) and IBD unclassified (IBDU). The 
disease affects about one in two hundred people in high-income countries, and incidence is 
rapidly increasing 2,3. In Western Europe, UC emergence coincided with the industrial revolution 
in the 1800s, and its incidence slowly increased in the early 1900s 3. From 1950 onwards, there 
was a rapid expansion of the incidence of IBD in Westernized countries, explained by factors 
like increased awareness, improved medical access and environmental exposures associated 
with Westernization of the population (e.g. smoking, changing diet). Since 1990, IBD incidence 
has stabilised in the Western world 4. However, globalization at the end of the 20th century, with 
Westernization of parts of Asia, the Middle East, and South Africa, was again paralleled by an 
explosive increase in IBD incidence and prevalence. Recent data on a (South-Limburg) cohort 
of the Dutch population revealed an incidence of IBD in 2010 of 40.36 per 100.000 people, 
with CD and UC incidence of respectively 17.49 and 21.47 per 100,000, with a nationwide IBD 
prevalence estimated to be 613 per 100,000 inhabitants (approximately 80,627 people) 5.
Patients with IBD suffer from a chronic disease characterised by unpredictable episodes 
of relapse and remission, inflicting symptoms like diarrhoea, blood in their stool, urgency, 
abdominal pain, weight loss, fever and fatigue. The diagnosis IBD is usually established 
between the ages of 20-40 and based on a combination of clinical, endoscopic, histological 
and radiological criteria according to internationally accepted guidelines 6-9. IBDU is diagnosed 
in 10-15% of patients, when there is diagnostic uncertainty, and in the absence of surgical 
resection material of ileum or colon 10,11. The disease characteristics of CD and UC are described 
in table 1. Treatment consists primarily of anti-inflammatory (immunosuppressive) drugs and 
surgery when there is lack of response to medical treatment. The IBD drug regime currently 
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consists of: 5-aminosalicylic acid, corticosteroids, thiopurines, methotrexate, biological 
treatment targeting cytokines (anti-TNF/anti-IL12/23 p40) and anti-integrin treatment targeting 
leukocyte trafficking (anti-α4β7), with several emerging treatment options nearly entering the 
stage.
Table 1. Characteristics of Crohn’s disease and ulcerative colitis
Crohn’s disease ulcerative colitis
Disease location Mouth to anus involving all gut layers 
(mucosa to serosa)
Colon, only involving mucosa
Endoscopy findings Segmental distribution, rectum 
frequently spared, aphthous ulcers, 
deep fissuring ulcers, cobblestoned 
appearance bowel wall, perianal 
disease, strictures, fistulas
Diffuse and continuous erythema from 
the rectum upwards, friability, loss of 
vascular pattern 
Radiology Small bowel abnormalities, ileal 
abnormalities, skip areas, strictures, 
fistulas
Normal small bowel, (pan)colitis, no 
skip areas dilatation of colon in toxic 
megacolon
Histology Pathognomic non-caseating 
granulomas, patchy cryptitis, crypt 
abscesses, ileitis, inflammation 
extends through the mucosa and 
muscle of the bowel
Cryptitis, crypt abscesses or 
architectural distortion, granulomas 
absent, inflammation confined to 
mucosa
Clinical findings Abdominal pain, diarrhoea, rectal 
bleeding, weight loss, anorexia, 
fever, fatigue, extra-intestinal 
manifestations
Bloody diarrhoea, abdominal pain, 
weight loss, fever, fatigue extra-
intestinal manifestations
Uncomplicated mucosal inflammation is present in 70-80% of CD patients at diagnosis, 
whereas 20-30% already have complicated disease behaviour with penetrating or stricturing 
lesions, leading to fistulae, abscesses or obstruction12-14. The latter percentage extends up to 
50% after 20 years in a population-based cohort and 88% in a referral-based population 12-14. 
Half of the CD patients require surgical resection during the first 10 years of disease, but this 
risk is decreasing over time in an era of changing medical therapy 15. Frequently described 
clinical determinants at presentation of CD associated with a complicated disease course are 
younger age (<40), perianal or stricturing disease, involvement of the upper gastrointestinal 
tract, penetrating disease and smoking 16,17. However, the clinical spectrum of CD is very 
heterogeneous and cannot be predicted precisely.
UC also has great clinical heterogeneity between patients. Colectomy is a sign of a complicated 
disease course in UC and is required in approximately 10% of patients in the first 10 years 
of disease 18. Extensive colitis at presentation, as well as severe systemic symptoms, were 
found to be predictors of colectomy 19,20. Proximal extension of disease (from proctitis/left-sided 
colitis to extensive colitis) occurs in 14-28%, and is associated with a greater risk of undergoing 
colectomy than patients with extensive disease at diagnosis 19. Cumulative incidence of a 
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colorectal carcinoma in UC patients was initially reported to be 0.4% after 10 disease years, 
and 1.1% after 20 years of follow-up 21. These rates are declining over time, probably related to 
improved medical treatment and better patient care 22.
Patients with IBD suffer from disease symptoms as well as from long term complications, 
both caused by the disease as by different medical and surgical treatments. Physical and 
psychosocial functioning may be impaired and future perspective uncertain, which will 
have consequences for general quality of life, personal relations and professional career. 
Furthermore, IBD leads to substantial financial costs, with annual costs of per-patient-care of 
€7.835 for CD and €3.600 for UC patients in the Netherlands 23.
Currently, both our ability to predict disease behaviour in individual patients, as well as our 
insight in response of patients to different medications is limited. Historically, treatment is 
based on generic protocols, lacking individual profiles. Therapy is based on disease activity or 
the development of complications. Adequate monitoring is therefore essential to make timely 
decisions. As the population of IBD patients represents a heterogeneous group with great 
diversity in clinical presentation, severity, progression and response to therapy, therapeutic 
requirements vary considerably and an optimal personalized medicine approach is warranted 24 -26. 
Another important argument for the necessity of personalized medicine in IBD is the frequent 
discordance between symptoms and the presence or severity of mucosal inflammation, more 
so in CD patients than in UC. On one hand, patients present themselves with symptoms without 
actual mucosal inflammation, which can lead to overtreatment. On the other hand, patients with 
active mucosal inflammation may not experience any symptoms, leading to undertreatment and 
potentially progression to complicated disease. This renewed focus on mucosal inflammation 
urges the identification of biomarkers of inflammation to implement personalized treatment. 
Invasive and costly procedures such as ileocolonoscopy and cross-sectional imaging inform 
the clinician about the inflammatory state of disease. The use of laboratory tests in monitoring 
disease activity and predicting complicated disease or treatment response would be more 
convenient, non-invasive, standardized, rapid, reproducible and inexpensive. Until now, the most 
extensively studied non-invasive biomarkers are serum CRP levels and faecal calprotectin levels, 
but these merely reflect (potential) disease activity rather than predicting disease course 27. 
On top of the list of key research priorities regarding optimization of IBD treatment strategy 
are selection of the right patient group and phase of disease and identification of markers for 
patient stratification regarding disease course 28. 
INFLAMMATORY BOWEL DISEASE: PATHOGENESIS
As in most autoimmune diseases, the aetiology of IBD is explained by multifactorial 
contributions requiring interactions between environmental factors, a disturbance of the gut 
microbiome, genetic predisposition and dysregulation of the immune system 29,30. Environmental 
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determinants include external factors like cigarette smoking, antibiotic use in childhood, and 
changing diet 3. Even though some risk factors have been identified, it has not yet been shown 
that modifying exposure actually prevents IBD development. Imbalance of the composition of 
the gut microbiome, the ecosystem of microorganisms residing in mucosal surfaces (internal 
environment), has also been proposed as pathogenic factor 31. However, identification of an 
altered microbiome is complicated by intra- and inter-individual variation, even present in 
healthy individuals 32. Much of the current literature on microbiome in IBD concerns patients 
with established disease and therefore under immune modulating treatment, which must 
be considered when interpreting results 33. These results underscore impaired managing of 
microbial antigens by the intestinal immune system in IBD, but no single species has been 
proven to be exclusively causative 34,35. Currently, no predictive statements can be made based 
on the microbiome of IBD patients. Genome-wide association studies in IBD patients start to 
shed more light on associated risk alleles 36. Since nucleotide oligomerisation domain 2 was 
identified as the first susceptibility gene for CD in 2001 37, over 200 susceptibility loci for IBD 
have been found. However, the largest performed genotype-phenotype study in IBD found only 
three loci associated with phenotypes of disease location in IBD and most individuals with IBD-
associated genetic risk variants remain healthy. This large study did not find any association with 
disease behaviour. Genetic predictors may therefore only explain a small fraction of phenotypic 
variance, and they cannot be used as a predictor in individual patients 38. The inflammatory 
processes in IBD are executed primarily by immune cells. Therefore, this factor has dominated 
the investigation of IBD pathogenesis, with focus on antibody responses, T cells, cytokines as 
well as innate immunity. As this thesis focuses on the disrupted immunological processes in 
IBD, this will be described in to more detail separately. The complex of interacting aetiological 
aspects of IBD may be responsible for the clinical heterogeneity of the disease. 
Figure 1. The intestinal immune system in health and inflammatory bowel disease. 
In healthy state (left panel) the lamina propria contains a diverse array of immune cells which maintain 
a homeostatic balance (innate cells like macrophages and dendritic cells (DCs) as well as adaptive cells 
including B lymphocytes and T lymphocytes like regulatory T lymphocytes (Treg), and T helper lymphocytes 
(Th1, Th2, Th17)), and both pro- and anti-inflammatory cytokines/chemokines. DCs can be activated by 
intestinal bacteria, they present antigens to naïve CD4+ T cells in secondary lymphoid organs like the 
mesenteric lymph node, where the phenotype of the DC as well as the cytokine milieu modulate CD4 
subgroup differentiation and its characteristic cytokine profile. These activated T cells then circulate to the 
lamina propria to carry out their effector function. In patients with inflammatory bowel disease patients 
(right panel) the homeostatic balance is disturbed at all levels of defence with a disrupted mucus layer, 
increased epithelial permeability, disturbed innate immune mechanisms, exaggerated T cell responses, 
excessive cytokine/chemokine production and the production of autoreactive T and B cells inducing marked 
expansion of the lamina propria with the increased number of immune cells.
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HUMAN INTESTINAL IMMUNE HOMEOSTASIS AND ITS DISRUPTION IN IBD 
PATIENTS
In healthy individuals, the intestinal immune system contains a diverse spectrum of immune 
cells and cytokines to maintain a homeostatic balance 29,39,40. This includes pro-inflammatory 
mediators to limit excessive entry of microorganisms in a defence against pathogens, and anti-
inflammatory mediators to down-regulate immune responses. Numerous microorganisms 
inhabit the gut lumen; pathogens and commensals, the latter contributing to the maintenance 
of homeostasis. The first line of defence against pathogenic microorganisms in the gut 
is the epithelial barrier; a single layer of enterocytes and specialized epithelial cells held 
together by tight junctions and covered on the luminal side by a thick mucus layer embedded 
with commensal microbes (figure 1). Besides being a physical barrier, by preventing the 
penetration of macromolecules and bacteria, epithelial cells can also secret bactericidal 
agents called defensins. 
Beneath the epithelial layer lies the loose connective tissue of the lamina propria. Cells from 
the innate immune system can be found here, including dendritic cells (DCs), macrophages 
and neutrophils, which can sense danger signals leading to their production of cytokines and 
antimicrobial peptides. Cytokines are involved in the regulation, development and activation of 
immune cells to mediate the inflammatory response. After antigen recognition, DCs can be 
activated to mature and perform its function as antigen presenting cell activating the adaptive 
immune response. Adaptive immune cells, also present in the lamina propria, include T 
lymphocytes and B lymphocytes. Directed by the DCs, they can either act in an inflammatory 
way to fight off pathogens or in a regulatory fashion to maintain tolerance to self-antigens. 
This delicate equilibrium is not always perfect, as autoimmune diseases are characterized 
by an excess of T and B cell reactivity. T and B cells, as well as monocytes and DCs, enter the 
periphery by homing to secondary lymphoid organs, awaiting antigen activation. In the gut 
these organs are collectively called gut associated lymphoid tissue (including Peyer’s patches 
and mesenteric lymph nodes). Activated T lymphocytes circulate to the intestinal lamina 
propria, through the intestinal blood vessels, where they can carry out their regulatory and 
effector functions.
In IBD there is an inappropriate response of the intestinal immune system to luminal antigens 
and the homeostatic balance is disturbed at all levels of defence, showing leaky epithelial 
barriers, disturbed innate immune mechanisms, excessive cytokine/chemokine production, 
incorrect recognition of commensal antigens by DCs and disturbed clearance of autoreactive T 
and B cell populations (figure 1). Circulating antimicrobial antibodies in IBD patients indicate 
B cell reactivity. An exaggerated T lymphocyte response is often implicated as key mediator 
in the development and maintenance of IBD 41. The main focus of research on T lymphocytes 
in IBD has been directed on the activated CD4+ T effector lymphocytes (Th1, Th2, and Th17) 
and regulatory T cells (Tregs), and was largely based on cytokines detected in the gut mucosa 
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
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of mice models and longstanding treated IBD patients 42-45. Previously, our group studied T 
lymphocytes in the inflamed gut mucosa of IBD patients at diagnosis, and identified patient 
subgroups according to different stages of T cell maturation 46. These different subgroups 
might have predictive value for treatment response. 
AIMS OF THIS THESIS
Studies in adult IBD patients on immunological responses are mainly cross-sectional, often 
single-time-point studies, in longstanding IBD, after complications have already occurred and 
under immunosuppressive medication. Baseline results at the onset of disease are scarcely 
available. We believe that there is a small window of opportunity to study early inflammatory 
processes and candidate biomarkers in IBD patients at initial diagnosis, just before treatment 
is initiated. Therefore, at Crohn’s and Colitis Centre Rijnstate, we prospectively enrolled IBD 
patients solely at the moment of diagnosis, all with endoscopic confirmed inflammation, and 
studied intestinal biopsy specimens as well as venous blood samples drawn directly after 
endoscopic evaluation. Patients were longitudinally followed-up, and a second venous blood 
sample was collected at an arbitrary visit to our hospital, as well as a second analysis of biopsy 
specimens when endoscopy was performed according to standard care, to study stability 
and behaviour of different immunological profiles over time. We identified immunological 
profiles regarding mucosal T lymphocyte subsets, serum antibodies and other serum analytes 
(cytokines/chemokines) at presentation and assessed changes over time (from diagnosis to 
follow-up) as well as relations to disease activity, severity, course and response to therapy. This 
may enable individualization of patient care.
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OUTLINE 
Chapter 1 introduced the background information and framework of this thesis. A review on 
the literature on maturation and migration of T lymphocytes in and around the gut mucosa 
in homeostasis and IBD can be found in chapter 2. We hypothesize on the potential role of 
tertiary lymphoid organs (TLOs) in the gut mucosa to facilitate the influx of certain T lymphocyte 
subsets in IBD patients through high endothelial venules (HEVs) in chapter 3. The presence of 
these HEVs and TLOs in the inflamed gut mucosa was evaluated in newly diagnosed, untreated 
IBD patients; in relation to intestinal T lymphocytes. In chapter 4 we investigate the behaviour 
of mucosal T lymphocyte subsets in IBD patients at diagnosis and over time, and related them 
to disease activity and -outcomes. We explore the physiological, and potential pathological, 
roles of (mucosal) immune cells expressing integrin αEβ7 (mainly T lymphocytes) in health 
and IBD (chapter 5) as it is targeted by anti-β7 treatment. We question the pathological role of 
αEβ7+ T lymphocytes in IBD patients in chapter 5a and provide a detailed background overview 
on this topic in chapter 5b. Serum antibodies in newly diagnosed IBD patients, as well as 
their presence over time, were assessed in chapter 6 in relation to disease phenotype and 
course. We identified candidate serum markers in CD patients at presentation and during their 
follow-up associated with disease activity and –course in chapter 7. This thesis is completed 
in chapter 8 with a summary of the results and a discussion on the future perspectives on 
mucosal T lymphocyte subsets and other potential markers in IBD patients. 
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
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ABSTRACT
Little is known about different phases of T cell maturation in gut mucosa. Based on current 
knowledge about the migratory pathways of naïve and memory T cells, it is believed that access 
to peripheral, non-lymphoid tissues is restricted to memory T cells. Surprisingly, there is 
increasing evidence of high numbers of naïve T cells in the chronically inflamed gut tissue of 
patients with inflammatory bowel disease. This could partially be explained by new formation 
of ectopic lymphoid organs. Ongoing recruitment of naïve T cells at inflammatory sites might 
play a role in the immunopathogenesis of inflammatory bowel disease.
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INTRODUCTION
Inflammatory bowel diseases (IBD) are believed to result from aberrant inflammatory responses 
to the intestinal bacterial antigens in a genetically susceptible individual. Available evidence 
argues an important role for the adaptive immune system in IBD. Most research has focused 
on increased migration and proliferation of activated or memory T cells (Th1, Th2, Th17 and 
regulatory T cells) in the inflamed gut mucosa 1,2. As naïve T cells (TN) are normally thought to 
be excluded from inflamed tissue, the maturation process at extra-lymphoid effector sites like 
the inflamed gut mucosa in IBD, has received less attention. However, TN are the initiators of 
the inflammatory cascade of activated T cell expansion and differentiation, and may therefore 
play a central role in inflammatory processes. 
Lymphoid progenitors originating from bone marrow stem cells undergo maturation and 
selection in the thymus to become functional CD4+CD8- or CD4-CD8+ (single positive) T 
lymphocytes. In this thymic selection process, T cells that can recognize peptide in the context 
of self-MHC molecules are positively selected whereas auto-reactive T cells are deleted in the 
thymus 3. Of all T cells entering the thymus, the stringent thymic selection leaves only 3% 4. The 
TN cells leaving the thymus still have to experience antigen driven post-thymic maturation before 
they proliferate and differentiate into memory T cells 5. The classical view states that TN cells 
exclusively recirculate between secondary lymphoid organs (SLOs, e.g. lymph nodes, Peyer’s 
patches (PPs) and the spleen) through lymph and blood, whereas only memory T cells are able 
to enter non-lymphoid organs 6. However, recent evidence has shown that TN cells routinely 
traffic through non-lymphoid organs and might be activated outside the confined lymphoid 
complex 7-16. These findings shed new light on the role of TN cells in autoimmune disease. 
This review summarizes the current knowledge of the involvement of TN cells in IBD. We focus 
on the migration and activation of these cells in the non-lymphoid, healthy and inflamed gut. 
T-CELL SUBSETS: MATURATION AND ACTIVATION
Human T cells can be subdivided into different sets, either according to their immunophenotype 
(expression of leukocyte differentiation markers) or to their functionality (production of 
chemokines). Considering phenotypic characterization, the two main categories are TN cells, 
which have not yet encountered any (foreign) antigen, and memory T cells, which are antigen-
experienced. The phenotypic changes during the antigen driven maturation and activation 
process are depicted in table 1 and figure 1. 
TN cells can be subdivided in two subsets: recent thymic emigrants (RTEs), also called ‘truly 
naïve’ and mature naïve T cells (TMN) 
4. RTEs have not yet met the antigen for their specific T cell 
receptor (TCR) and have no proliferation history. TMN cells are also ‘antigen-inexperienced’ but 
underwent proliferation in response to homeostatic survival signals 17. RTEs can be identified 
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by the expression of CD45RA, CD31, CD27, CD28, CCR7, and CD62L 18 and are enriched with 
TCR excision circles (TRECs) 4. TRECs are non-replicative circular excision DNA products 
of TCR gene rearrangement 17,19. Post-thymic proliferation of RTEs causes diminishing of 
TRECs, downregulation of a set of surface markers (CD31, PTK7) generating ‘proliferative-
experienced’ TMN cells 
4. 
Table 1. Different maturation stages of human T cells are distinguished by various cell surface 
markers.
Surface markers RTE TMN TCM TEM TEMRA
CD31 + - - - -
CD45RA + + - - +
CCR7 + + + - ±
CD62L + + + - -
CD27 + + + ± -
CD28 + + + ± -
CD45RO - - + + -
Immunophenotypical subsets of T cells: RTE = recent thymic emigrant; TMN = mature naïve T cell; TCM = 
central memory T cell; TEM = effector memory T cell; TEMRA = effector memory T cell re-expressing CD45RA. 
Surface markers: CD = cluster of differentiation; CCR7 = chemokine receptor 7, CD62L = L-selectin. 
Normal expression (+), moderate expression (±), no expression (-).
T cells that have encountered antigen, can immunophenotypically be subdivided into central 
memory T cells (TCM), effector memory T cells (TEM) and effector memory T cells re-expressing 
CD45RA (TEMRA). During maturation, TCM express CD45RO instead of CD45RA, but retain CCR7 and 
CD62L, which are important homing markers for lymphoid tissue. During further maturation, 
TEM cells downregulate both CCR7 and CD62L and acquire new adhesion markers such as the 
gut-homing markers α4β7 and CCR9 
20-22. A subset of effector memory T cells, known as TEMRA 
cells (re)express CD45RA and occasionally also CCR7, but remain distinguishable from TN cells 
by their lack of CD27, CD28 and CD62L. When defining TN cell subsets by immunophenotype, 
the use of at least two markers is recommended 18. Different combinations have been 
suggested: CD45RA and CD27/CD28 18, or CCR7 and CD27 23. Unfortunately, this is not yet 
common practice and T cells are often defined as naïve or memory solely by the expression of 
CD45RA/RO. This makes the distinction between TN cells and TEMRA cells practically impossible. 
Contamination of the TN cell subset with TEMRA cells may lead to inaccurate conclusions and 
hamper comparability between studies.
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Figure 1. Human T cell maturation subsets.
Immunophenotypical subsets of T cells by expression of several cell surface markers. Intensity of colour 
of markers indicates level of expression. RTE = recent thymic emigrant; TMN = mature naïve T cell; TCM = 
central memory T cell; TEM = effector memory T cell; TEMRA = effector memory T cell re-expressing CD45RA; 
CCR7 = chemokine receptor 7; CD62L = L-selectin. 
Migration of naïve T lymphocytes during homeostasis
Migration of immune cells is a process referred to as homing. The general belief before 1964 
was that lymphocytes randomly circulate through the body. The first signs hinting otherwise 
were found in rats and mice 24,25, showing that certain lymphocytes only homed to the lymph 
node or the spleen. Thirty years later, these findings were confirmed in sheep. Additionally 
distinct migratory routes for naïve and memory T cells were suggested 6. Most of our further 
understanding on T cell migration and proliferation is still based on research in animal models 
although it is obvious that these models (with a lifespan of several months up to a few years, 
in pathogen-free conditions) cannot reflect the human exposure to multiple pathogens over 
decades 26. Human studies are still limited, as only peripheral blood or tissues from surgical 
resection material are easily accessible. 
The formerly accepted migration model with distinct routes for naïve and memory T cells turns 
out not to be as segregated as suggested before. TN cells do not only circulate through blood 
and lymph between SLOs but also enter non-lymphoid organs, which were first thought to be 
exclusively confined to memory T cells. TN cells have recently been identified in non-lymphoid 
tissue of healthy individuals, representing approximately 10% of the T cells at the intestinal 
sites (jejunum, ileum and colon) 14. Additionally, up to 50% of the T cells in non-lymphoid organs 
of the gut in steady-state mice were shown to express CCR7 (TN, TCM, and TEMRA) 
10. An immune-
surveillance or tolerance-induction role of TN cells entering the non-lymphoid tissues has been 
advocated 11. Although central tolerance during thymic selection eliminates most of the auto-
reactive T cells, some of them might escape and migrate to the periphery. In this way, naïve 
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auto-reactive T cells (RTEs and TMN) could enter healthy tissues; become activated and initiate 
chronic inflammation. On the other hand, influx of TN cells in non-lymphoid tissue possibly 
induces tolerance to organ-specific antigens within the tissue itself 17.
Antigen-presentation to TN cells takes place primarily in the SLOs. Following antigen 
recognition, further maturation of TN cells evolves towards memory T cells, which express 
tissue-specific surface receptors. TCM cells express the same lymph node homing molecules as 
TN cells, namely L-selectin (CD62L) and chemokine receptor 7 (CCR7, also known as CD197), 
and therefore also have the potential to home to SLOs 27. TEM cells are CCR7
-CD62L- and express 
tissue homing molecules like α4β7 which binds to mucosal adressin-cell adhesion molecule-1 
(MAdCAM-1), and CCR9 which interacts with chemokine (C-C motif) ligand 25 (CCL25) in the 
gut endothelium 12. 
TN cells do usually not express tissue-specific homing receptors on their surface, with 
exception of moderate levels of α4β7. They enter the lymph node and PPs across specialized 
post-capillary venules called high endothelial venules (HEV). HEV endothelial cells are cuboidal 
and are surrounded by multiple layers of fibroblastic reticular cells that produce various 
extracellular matrix components forming a thick basal lamina. Microscopically they can easily 
be distinguished from normal venules, which have flat endothelium and a thin basal lamina 
28. HEV endothelium expresses molecules that function in lymphocyte trafficking. This occurs 
through interaction between surface molecules on the lymphocytes with their HEV-expressing 
ligand counterparts: CD62L on the T cells with peripheral lymph node addressin (PNAd) and 
MAdCAM-1; CCR7 on the T cell with CCL21; and lymphocyte function-associated antigen 1 
(LFA-1, also known as CD11aCD18) on the T cell with intercellular adhesion molecule 1 (ICAM-
1 also known as CD54) (figure 2a) 12,29. In contrast to HEV in peripheral lymph nodes, HEV in PPs 
do not express PNAd. In PPs, the tethering/rolling step is mediated by the interaction of CD62L 
and α4β7 with MAdCAM, while further adhesion and migration of T-cells happens through LFA-
1 and ICAM-1 (figure 2b) 30. The binding of CD62L to MAdCAM-1 is dependent on the presence 
of specific carbohydrate ligands on the MAdCAM-1 31,32. Evidence supporting this interaction is 
demonstrated in mice studies, but is still missing for human. 
ON NAIVETY OF T CELLS IN INFLAMMATORY BOWEL DISEASE: A REVIEW
29
2
TMN
TCM
1
32
L-selectin
CCR7
LFA-1
PNAd CCL21 ICAM-1
a. High Endothelial Venule in lymph node 
TMN
TCM
1a
3
1b
L-selectin
CCR7
LFA-1
MAdCAM-1 CCL21 ICAM-1
b. High Endothelial Venule in Peyer’s patch 
α4β7
α4β7
2
Smids et al, figure 2
Figure 2. Migration of mature naïve (TMN) and central memory (TCM) T cells during homeostasis.
a.  TMN and TCM cells migrate into a lymph node by interaction with surface receptors on high endothelial 
venules (HEV). (1) CD62L binds with peripheral lymph node addressin (PNAd); (2) chemokine receptor 
7 (CCR7) binds with chemokine (c-c motif) ligand 21 (CCL21) and (3) lymphocyte function-associated 
antigen 1 (LFA-1) binds with intercellular adhesion molecule 1 (ICAM-1).
b.  TMN and TCM cells migrate into Peyer’s patches by interaction with surface receptors on HEV. Tethering 
and rolling is mediated by interaction of mucosal addressin-cell adhesion molecule 1 (MAdCAM-1) and 
CD62L (1a) and αβ7 integrin (1b). Further adhesion and migration occurs through CCR7 with CCL21 (2) 
and LFA-1 with ICAM-1 (3).
MIGRATION OF NAÏVE T LYMPHOCYTES IN IBD
Tertiary Lymphoid Organs
There is increasing evidence for primary T cell responses independent of SLOs. Chronic 
inflammation and solid tumours have been found to induce formation of HEV-like vessels in 
non-lymphoid inflamed tissue and tumour tissue, organizing around so called tertiary lymphoid 
organs (TLOs) 33-37. These TLOs are ectopic accumulations of lymphoid cells, arising at a non-
lymphoid location, through a process called lymphoid neogenesis. Contrarily, primary and 
secondary lymphoid organs are found at specific, predefined, sites that seem to be genetically 
fixed and develop before birth 38. TLOs morphologically resemble SLOs, since they also have T 
and B cell compartments, lymphoid chemokines, antigen presenting cells (like dendritic cells) 
and HEV-like vessels and are therefore also able to recruit TN cells.
How and why TLO formation occurs is unclear. HEV-like vessels presumably facilitate 
lymphocyte influx into TLOs, but it is also possible that TN cells gain initial access to non-
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lymphoid tissues via regular blood vessels and that HEVs are formed later in the process 8. 
Lymphotoxin α1β2 (LTα1β2, TNF family member) may have a prominent role in regulating the 
formation of (secondary and tertiary) lymphoid organs and is crucial for HEV development and 
maintenance 39,40. After priming, TN CD4
+ cells induce LTα1β2 expression on their surface 
41,42. 
The presence of ectopic CCL21 on blood vessels during inflammation may trigger the influx 
of CCR7+ T cells (TN and TCM). This provides a source of LTα1β2, perpetuating CCL21 expression 
and facilitating the formation of HEV-like vessels and TLOs. Notably, blocking the lymphotoxin 
(LT) pathway in colitis mouse models reduced the severity of inflammation and was equally 
efficacious as anti-TNFα therapy 43,44. 
Clinical significance of TLOs has already been described in other diseases like colorectal 
cancer and rheumatoid arthritis. In early-stage colorectal cancer, TLOs are associated with a 
better prognosis 45, and are suggested as a possible marker for prognosis 46. In patients with 
rheumatoid arthritis, TLOs were present in 49% of synovial tissue, and its presence coincided 
with longer disease duration and lower response to therapy (more refractory disease) 47. 
Reversal of TLOs was a good marker of response to therapy.
Tertiary lymphoid organs in IBD
Recent studies have shown that TLOs might play a role in chronic inflammation of the gut in 
IBD. Ectopic CCL21 on blood vessels and PNAd-expressing HEV-like vessels has been detected 
in inflamed gut tissue of patients with ulcerative colitis (UC). A positive correlation between 
CCL21 expression and influx of TN cells was observed 
8. CCL21 production was demonstrated 
in inflamed tissue of patients with Crohn’s disease (CD) and UC, and lymphoid aggregates were 
found in 50% of their intestinal biopsy samples 35. HEV-like vessels in the active phase of UC 
and CD were identified only in inflamed gut tissue, compared to a scarce presence of these 
vessels in non-inflamed colon or during remission of IBD 48,49. Furthermore, the formation of 
ectopic lymphoid follicles or TLOs was found in diseased ileal segments of CD patients 50. In 
contrast to the chronically inflamed IBD tissue, acute inflammation was not accompanied by 
the induction of lymphoid aggregates and HEV-like vessels 48. MAdCAM-1+ intestinal lamina 
propria venules are increased in UC, both in active disease and remission, compared to normal 
controls 51. There was great co-expression of PNAd among MAdCAM-1+ vessels in patients 
with active disease (66.5%) when compared to patients in remission (7.62%) and PNAd was not 
detected in the colonic mucosa of normal controls. In a recent study in mice with chronic ileitis, 
the induction of ectopic lymphoid tissue has been demonstrated in the inflamed intestine, with 
a statistically significant increase of CCL21 expression and accumulation of TN cells, TEM and 
TCM cells in the terminal ileum, compared to healthy wild type mice 
15. 
Thus far, it remains difficult to distinguish gut-associated lymphoid tissue (GALT) from TLOs 
and an unambiguous definition is lacking 33. Nonetheless, chronically inflamed gut induces 
organized structures that cannot be observed in the gut of healthy controls. These structures, 
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referred to as TLOs, are present in the deeper layers of the epithelium and contain PNAd-
expressing HEV-like vessels, that distinguishes them from the submucosal PPs 48,50,51.
NAÏVE T CELLS IN IBD
Mice: the T cell transfer model
Immunodeficient mice (CB17 severely combined immunodeficient/recombinase activating gene-
1-/-) develop chronic, severe intestinal inflammation, after transfer of naïve (CD4+CD45RBhigh) 
donor T cells into their peritoneal cavity 52. Co-transferring memory (CD4+CD45RBlow) T cells 
inhibits the development of intestinal inflammation 53 and single transfer of the memory subset 
does not cause inflammation 54. One could expect that the transferred TN cells are primed within 
GALT and mesenteric lymph nodes (MLNs) before inducing colitis. However, the induction of 
colitis by transfer of TN cells was also demonstrated in mice deficient of SLOs (GALT, MLN and 
spleen) 55. This study underlines that SLOs are not required for priming TN cells into colitogenic 
effector T cells to initiate colitis, leaving the site of priming in these models to be defined. As the 
pattern of exacerbation and remission of human IBD has not been perfectly phenocopied in these 
mouse models, the presence and the role of TN cells in the gut of IBD remains to be elucidated 
56. 
The potential role of naïve T cells in human IBD
The first suggestions indicating a potential role of (maturation of) TN cells in the pathogenesis of 
IBD came from a few (case-)reports showing the effectiveness of thymectomy in adult patients 
with IBD 57-60. Thymectomy has been performed in UC patients with thymic hyperplasia and 
was successful for maintaining remission in patients refractory to conventional therapy 58,60. 
Additionally, thymectomy was also performed in a CD patient developing myasthenia gravis, 
leading to remission of her CD activity 59. No further publications have arisen on the potential 
of thymectomy in IBD.
Already in 1995 it was revealed that chronic inflammation in CD induced migration of TN cells to 
inflamed sites. The study involved ileal samples of CD patients and bowel samples of controls 
with colon carcinoma. In the intestines of controls, blood vessels were only found in the lamina 
propria and beneath the muscularis mucosa, and they exhibited the characteristics of normal 
(flat) venules. The inflamed intestines of CD patients showed numerous dilated and highly 
activated small vessels with HEV characteristics, extending from the superficial mucosa layers 
throughout the deep submucosa. These vessels and the perivascular and mucosal infiltrates 
all harboured mainly macrophages and T cells. The majority of T cells within the (sub)mucosal 
infiltrates were TN (CD45RA
+CD31+CD62L+CD27+) and TCM (CD45RO
+CD31-CD62L+CD27+) cells. 
The normal intestinal mucosa of controls was predominantly populated by TEM cells (CD45RO
+ 
CD31-CD62L- CD27-) 7. 
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The expression of maturation markers on CD4+ T cells was analysed in the intestinal mucosa 
of both CD and UC patients with active disease. Almost all patients were using corticosteroid 
medication and were included at the time they underwent partial resection of the intestine. 
Non-involved bowel segments of patients undergoing bowel resection for cancer treatment 
were used as control. The numbers of CD45RA+ T cells were increased in the intestine of IBD 
patients (49.0% in UC and 27.7% in CD) as compared to controls (4.5%). The CD45RA+ cells 
found in IBD patients were mainly located in ‘follicular structures’ 9.
Another study aimed to characterize T cells present in the intestine of IBD patients before 
and after therapy. Sigmoid-derived biopsy specimens of IBD patients (CD as well as UC) with 
distal active colitis were evaluated. Patients that were in remission with mucosal healing 
showed a reduction of >50% of CD4+CD45RA+ T cells, compared to inflamed mucosa of patients 
with active disease. There was no difference in the amount of memory T cells in the inflamed 
mucosa when compared to non-inflamed mucosa 16. 
Regarding RTEs in IBD patients, increased TREC levels in mucosal but not peripheral blood 
lymphocytes were found in UC patients, indicating direct recruitment of RTEs into the inflamed 
mucosa 13. However these results have not yet been duplicated.
We recently studied the maturation of T cells in the gut mucosa in a large group of newly 
diagnosed, untreated IBD patients. Remarkably high frequencies of TN were identified in 
a subgroup of CD as well as UC patients (naïve profile). This group of patients expressed 
different pro-inflammatory cytokine levels (higher TNF-alpha and lower interferon-gamma) 
compared to the group of patients with high frequencies of TEM. Furthermore, there was an 
association between the naïve profile and extended disease location in CD (61). We elaborated 
on the possible correlation between differences in the maturation of the T cell subsets early in 
disease course and disease heterogeneity. An extended follow-up of this cohort may elucidate 
the prognostic value of different maturation profiles at primary diagnosis. 
CONCLUSIONS
Contrarily to previous ideas, there is increased evidence that TN cells migrate to non-lymphoid 
organs in homeostasis and even more in chronic inflammation. During chronic inflammation, 
migration of TN cells could be facilitated by TLOs. Formation of these TLOs appears dependent 
on LTα1β2; however the signals triggering these mechanisms are waiting to be characterized. 
Presence of TLOs implies an ongoing recruitment of TN and TCM cells to the gut mucosa, 
maintaining a continuous inflammatory process. The relevance of targeted therapy against this 
phenomenon has not yet been studied. It is conceivable that a process involving dissolution of 
TLOs could restore immunologic homeostasis. 
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SUMMARY
Naive and central memory T lymphocytes (TN and TCM) can infiltrate the inflamed gut mucosa 
in Inflammatory Bowel Disease (IBD) patients. Homing of these subsets to the gut might be 
explained by ectopic formation of tertiary lymphoid organs (TLOs), containing high endothelial 
venules (HEVs). We aimed to evaluate the presence of HEVs and TLOs in inflamed intestinal 
mucosa of newly diagnosed, untreated, IBD patients in relation to the presence of TN and TCM 
lymphocytes. IBD patients (n=39) and healthy controls (n=8) were prospectively included. Biopsy 
samples of respectively inflamed and normal intestine were analyzed by immunohistochemistry 
for lymphocytes (CD3/CD20), blood vessels (CD31) and PNAd expression (MECA-79). TN and 
TCM lymphocyte subsets were identified by flowcytometric immunophenotyping. A higher 
number of HEVs was found in the inflamed colon of patients with ulcerative colitis (median 
3.05 HEV/mm2; (IQR 0-6.39) and ileum of Crohn’s disease patients (1.40; 0-4.34) compared 
to healthy controls (both 0; P=0.033). A high density of colonic HEVs (HEVhigh) was associated 
with increased infiltration of TN and TCM in the inflamed gut (median 87%; IQR 82-93% of T 
cell population), compared to HEVlow patients (58%; 38-81%; P=0.003). The number of colonic 
follicles was higher in HEVhigh patients (median 0.54/mm2; IQR 0.28-0.84) compared to HEVlow 
patients (0.25/mm2; 0.08-0.45; P=0.031) and controls (0.31/mm2; 0.23-0.45; P=0.043). Increased 
homing of TN and TCM lymphocytes to inflamed gut tissue in IBD patients might be facilitated by 
ectopic formation of extrafollicular HEVs and TLOs in a subgroup of patients.
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INTRODUCTION
Lymphocyte activation and homing of lymphocytes to target organs are key phenomena in 
chronic inflammation, including Inflammatory Bowel Diseases (IBD). Lymphocyte activation 
is triggered by interaction of antigen receptors with cognate antigens. The initial priming of 
naive T lymphocytes (TN) occurs in secondary lymphoid organs (SLOs; spleen, lymph nodes, gut 
associated lymphoid tissue (GALT; Peyer’s patches, isolated lymphoid follicles and appendix)). 
SLOs are genetically encoded, specialized environments for optimal antigen presentation, and 
lymphocyte activation. Upon antigen priming in the SLO, activated T lymphocytes migrate to 
non-lymphoid tissue sites, where they may exercise effector (proinflammatory or regulatory) 
functions upon renewed antigen encounter. It is well known that activated effector memory 
T lymphocytes (TEM) travel to the gut mucosa following α4β7/MAdCAM-1 and CCR9/CCL25 
interaction at the level of post-capillary venules 1,2.
In physiological conditions, TN and central memory T lymphocytes (TCM) are thought to migrate 
exclusively to SLOs 1,3. Specialized vessels, so-called high endothelial venules (HEVs), direct 
tissue migration of circulating TN and TCM into SLOs. This process is guided by different 
vascular addressins, such as MAdCAM-1 and peripheral lymph node addressin (PNAd). PNAd 
on endothelial cells is the ligand of L-selectin, which is expressed on TN and TCM lymphocytes, 
while practically absent on the majority of TEM or effector memory T cells re-expressing CD45RA 
(TEMRA). PNAd can be identified by the monoclonal antibody MECA-79 
4,5. Distribution of these 
addressins differs between peripheral lymph nodes, mesenteric lymph nodes and Peyer’s 
patches. MAdCAM-1 is constitutively displayed on HEVs in Peyer’s patches, on mesenteric 
lymph nodes and on flattened venular endothelial cells in the intestinal lamina propria 6. PNAd 
is predominantly present on HEVs in peripheral lymph nodes, mesenteric lymph nodes and at 
very low levels on the abluminal side of HEVs in Peyer’s patches 4.
We and others have demonstrated the presence of TN and TCM lymphocytes in non-lymphoid 
gut tissue 7-11. In our previous work we identified three subgroups of newly diagnosed IBD 
patients with either increased percentage of mucosal TN, TCM or TEM 
7. It is still unclear how 
homing of these TN and TCM lymphocytes to non-lymphoid tissue is established.
Processes occurring during chronic inflammation, and formation of solid tumours, were 
shown to induce ectopic formation of HEV-like vessels, in inflamed non-lymphoid and tumour 
tissue, constituting the so-called tertiary lymphoid organs (TLOs) 12-15. Little is known about 
PNAd+ HEV-like vessels in IBD pathogenesis (reviewed in 16), since published data is limited to 
patients with long-standing disease under anti-inflammatory treatment 5,17.
We aimed to investigate the presence of HEVs and their relation to lymphoid follicles in the 
inflamed intestinal mucosa of newly diagnosed, untreated, IBD patients. Furthermore, since 
TN and TCM lymphocytes are known to express L-selectin 
7,18,19, we aimed to determine whether 
the infiltration of these cells is correlated with the presence of HEVs and TLOs in the inflamed 
intestinal mucosa. 
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MATERIAL AND METHODS
Patients and samples
At the IBD centre of the Rijnstate Hospital, Arnhem, The Netherlands, 39 newly diagnosed 
adult IBD patients and eight healthy controls were prospectively included in the study. The 
diagnosis of IBD was based on a combination of clinical, endoscopic, histologic and radiologic 
internationally accepted criteria. Intestinal biopsy specimens of the macroscopically most 
inflamed ileal and colonic mucosa (when ulcerations were present these biopsy specimens 
were taken from the edge of this ulceration) were obtained at the moment of diagnosis, before 
the initiation of any medical treatment. Thus, when disease was located in the ileum, only 
ileal biopsies were analysed; when disease was located in the colon, only colonic biopsies 
were analysed and when the disease was located in ileum and colon both ileal and colonic 
biopsies were analysed. Besides regular histopathological analysis, four samples were used 
to immunophenotype the mucosal lymphocyte population. Patient characteristics were 
documented and disease phenotype was assessed.
Ileal and colonic biopsy specimens were obtained from eight control subjects undergoing 
ileocolonoscopy for iron deficiency anaemia or polyp surveillance. Biopsy specimens of controls 
were taken from macroscopically non-affected, non-inflamed ileal and colonic areas. Regular 
histopathological examination confirmed that these areas had no signs of inflammation. 
Besides regular histopathological analysis, four samples were used to immunophenotype 
the mucosal lymphocyte population. Parallel venous blood samples were drawn following 
endoscopic evaluation at primary diagnosis. Serum samples were coded and stored at -20°C 
until analysis. 
Immunohistochemistry
Immunohistochemistry was carried out on 3 µm thick sections from formalin-fixed, paraffin-
embedded archived blocks of biopsied specimen of ileal and colonic mucosa. The following 
monoclonal antibodies were used for immunostaining: MECA-79 (identifies 6-sulfo sialyl 
Lewis on core-1 branched O-linked sugars (PNAd) which binds L-selectin, Sanbio, Uden, The 
Netherlands), CD31 (monoclonal, identifies human CD31 to demonstrate endothelial cells, 
Sanbio, Uden, The Netherlands), CD3 (clone LN10, identifies human CD3 to demonstrate 
T-cells, Leica Microsystems B.V., Eindhoven, The Netherlands) and CD20 (clone L26, identifies 
human CD20 to demonstrate B-cells, Leica Microsystems B.V., Eindhoven, The Netherlands). 
Slides were incubated with the primary antibody in an automatic immunostainer (Bond, Leica 
biosystems Nussloch GmbH 2016, Eindhoven, The Netherlands).
Stained slides were scanned with an Intellisite high-resolution scanner (Philips ultra-fast 
scanner 1.6 RA, Philips Digital Pathology, Best, The Netherlands) and analysed with the 
Intellisite IMS image analyser. Quantification was done by two independent observers who 
were blinded to the clinical outcome and flowcytometric analyses. The total surface area of 
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each slide was measured in square millimetre (mm2). Absolute numbers of CD31+ vessels 
and MECA-79+ HEVs were determined by optical counting of vessel numbers on all slides. The 
location of HEVs relative to lymphoid follicles was determined on CD3 and CD20 immunostained 
sections and absolute numbers of intra- and extrafollicular HEVs were quantified. The density 
of extrafollicular HEVs (MECA-79+ vessels/mm2 excluding the surface of follicles) and the ratio 
of HEVs among all vessels (MECA-79+ vessels/CD31+ vessels) were calculated. In malignancy, a 
cut-off point for increased density of HEVs has been described in patients with breast cancer 20. 
However, in chronic inflammation, no such approach has been undertaken. We discriminated 
patients with a high and a low density of HEVs using a cut-off point set at the median density of 
extrafollicular HEVs/mm2 in the inflamed colon of UC patients.
Presence of inflammation was established for all sections based on known architectural 
changes and inflammatory features such as crypt distortion, decreased crypt density, erosions, 
ulcers, increased lamina propria cellularity, crypt abscesses and epithelioid granuloma. 
Lymphoid follicles were defined as a dense nodular lymphocyte aggregates containing B and T 
cell compartments. Their presence was assessed on CD3 and CD20 immunostained sections. 
The number of follicles was counted. In absence of a clear-cut definition of TLOs in the gut, we 
defined TLO as additional follicles in patients compared with the number of follicles in controls. 
Furthermore, it is our interpretation that the presence of extrafollicular HEVs represent early 
phase of lymphoid neogenesis (TLOs).
Immunophenotyping the mucosal lymphocytes
Intestinal biopsy specimen were sampled and analysed as described earlier 7. Briefly, besides 
the standard histopathological analysis of biopsy specimens, four samples of the most 
inflamed regions of colon and ileum were used for flowcytometric immunophenotyping. Biopsy 
specimen were kept in phosphate-buffered saline solution at 2-8°C and processed within 8 
hours. Specimens were finely minced in Hanks’/1% bovine serum albumin using a 70-mm gaze 
and spatula followed by Ficoll density gradient centrifugation.
The homogenate was resuspended, after washing, in 0.5 mL Hanks’/1% bovine serum 
albumin. The cell number was estimated by microscopic counting with a KOVA glasstic slide 
(Hycor Biomedical Ltd., Penicuik, United Kingdom). For flow cytometric analysis 200 mL of the 
total cell suspension was used, disregarding absolute cell number. Single cell suspensions 
of the biopsies were analysed using a FACS Canto (BD Biosciences). Mucosal lymphocyte 
subpopulations were differentiated: B cells (CD19+), T cells (CD3+), regulatory T cells 
(CD3+CD25highFoxP3+), mucosal T cells (CD3+CD103+), T-helper cells (CD3+CD4+) and cytotoxic 
T cells (CD3+CD8+) and expressed as percentages of the whole lymphocyte population (CD45+/
low side scatter). The maturation state of T cells was assessed by using CD45RA and CD27 21, 
defining naive T cells (TN: CD45RA
+CD27+), central memory T cells (TCM: CD45RA
-CD27+), 
effector memory T cells (TEM: CD45RA
-CD27-) and T effector memory cells re-expressing 
CD45RA (TEMRA: CD45RA
+CD27-). We also analysed groups of T cells according to their known 
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migration phenotypes. TN and TCM lymphocytes are known to enter HEVs through the ligand 
PNAd, as they are L-selectin+ 18,19 and were analysed both independently as well as taken 
together. The same analysis was performed for TEM and TEMRA lymphocytes, which are known 
to be L-selectin- 18,19
Multiplex immunoassay
In a subgroup of the current patient cohort we analysed serum chemokines using Multiplex 
immunoassays, including CXCL-13 and CCL-19, which are known to be required for lymphoid 
organogenesis 22. These assays were performed at the MultiPlex Core Facility of the Laboratory 
of Translational Immunology (UMC Utrecht, The Netherlands) using an in-house validated 
platform (ISO9001). Briefly, color-coded magnetic beads (MagPlex Microsperes, Luminex, 
Austin, Texas) were conjugated to analyte-specific antibodies and incubated with standard 
dilutions or sample for 1 hour during continuous shaking in the dark. Pre-treatment of samples 
with HeteroBlock (Omega biologicals, Inc., Bozeman, Montana, USA) was performed, to 
prevent interference by binding of heterophilic antibodies. Plates were washed (Bio-Plex Pro II 
Wash Station; Bio-Rad, Hercules, California, USA) and a corresponding cocktail of biotinylated 
detection antibodies was added followed by streptavidin-phycoerythrin (PE) incubation. 
Fluorescence intensity of PE was measured with a Flexmap 3D system (Luminex) and analysed 
by BioPlex Manager Software (version 6.1; Bio-Rad, USA) using 5-parameter curve fitting. 
Statistical analysis
Data of ileal biopsy specimens of CD patients was compared to ileal biopsy specimens of healthy 
controls. The data of colonic biopsy specimens of UC and CD patients were compared to the 
colonic biopsy specimens of healthy controls. Ileum and colon were not mutually compared 
because of anatomical and physiological differences, including the influence of the microbiome. 
Data was collected and analysed with SPSS statistics (version 21.0.0.0; IBM Corp). Differences 
between groups were tested using non-parametric tests. Continuous variables were described 
as median with interquartile range (IQR, 1st quartile-3rd quartile). Mann-Whitney U test was 
used to identify differences in continuous variables. Categorical variables were described 
as absolute frequencies. Kruskal-Wallis analysis was used followed by the Dunn test when 
applicable. Spearman rank correlation was performed to measure the degree of association 
between variables. Statistical significance was defined as a P-value less than 0.05.
Ethical Considerations
Written informed consent was obtained from each participating patient. The procedures 
were performed in accordance with the Declaration of Helsinki. The regional medical ethics 
committee approved the protocol, according to Dutch Law (NL28761.091.09). 
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RESULTS
Ten newly diagnosed patients with ulcerative colitis (UC) and 29 newly diagnosed IBD patients 
with Crohn’s disease (CD) were included in this study. In addition eight healthy controls were 
studied. Baseline characteristics of patients are outlined in table 1.
Table 1. Baseline characteristics.
CD (n=29) CU (n=10)
Age at diagnosis in years, median (IQR) 28 (20-44) 28 (20-35)
Female, n (%) 21 (72%) 7 (70%)
Symptoms before diagnosis in months
• 0-3
• 3-6
• >6
10 (35%)
9 (31%)
10 (35%)
7 (70%)
1 (10%)
2 (20%)
Follow-up period in months, median (IQR) 55 (23-62) 44 (22-48)
Family with IBD, n (%) 4 (14%) 4 (40%)
Smoking status 
• Never
• Current
• Ceased
• Unknown
17 (59%)
10 (34%)
2 (7%)
-
8 (89%)
1 (11%)
-
-
HBI score, median (IQR) 9 (6-13) -
CD disease location (Montreal)
• Ileal, n (%)
• Colonic, n (%)
• Ileocolonic, n (%)
• + Upper GI involved, n (%)
• + Perianal disease, n (%)
8 (28%)
5 (17%)
16 (55%)*
10 (39%)
5 (17%)
-
CD disease behaviour (Montreal)
• Inflammatory, n (%)
• Stricturing, n (%)
• Penetrating, n (%)
21 (72%)
7 (24%)
1 (4%)
-
SES-CD score, median (IQR) 14 (8-22) -
SES-CD severity
• Mild (4-10), n (%)
• Moderate (11-19), n (%)
• Severe (>19), n (%)
11 (38%)
9 (31%)
9 (31%)
-
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Table 1. continued
CD (n=29) CU (n=10)
UC clinical score (Montreal)
• Remission, n (%)
• Mild, n (%)
• Moderate, n (%)
• Severe, n (%)
-
-
1 (10%)
4 (40%)
5 (50%)
UC disease location (Montreal)
• Proctitis, n (%)
• Left-sided, n (%)
• Pancolitis, n (%)
- -
-
-
10 (100%)
UC endoscopic severity (Mayo)
• Normal, n (%)
• Mild, n (%)
• Moderate, n (%)
• Severe, n (%)
-
-
2 (20%)
4 (40%)
4 (40%)
CD = Crohn’s disease, UC = ulcerative colitis, IQR = interquartile range, IBD = inflammatory bowel disease, 
HBI= Harvey-Bradshaw Index, SES-CD = simple endoscopic score for Crohn’s disease
* One patient was excluded from the analyses of colon biopsies because of technical failure of MECA-79 
staining.
Number of blood vessels and follicles was comparable in patients and controls
In each sample, we determined the absolute number of blood vessels (CD31+ vessels and MECA-
79+ vessels, hereafter denoted as HEVs) and follicles by immunohistochemical staining. HEVs 
were determined by optical counting of MECA-79+ vessel numbers on all slides. The location 
of these HEVs relative to lymphoid follicles was determined on CD3 and CD20 immunostained 
sections and absolute numbers of intra- and extrafollicular HEVs were quantified. The density 
of extrafollicular HEVs (MECA-79+ vessels/mm2 excluding the surface of follicles) and the ratio 
of HEVs among all vessels (MECA-79+ vessels/CD31+ vessels) were calculated. Overall, we 
observed high heterogeneity in patient results. No statistical significant difference was found 
when comparing the entire patient group and controls for the number of vessels or follicles 
in biopsy specimen (see table 2). In addition, the number of HEVs within these follicles was 
comparable. However, in UC there was a trend towards more HEVs in the inflamed colon (4.80/
mm2, (0.45-6.14)) than in the colon of healthy controls (0.71/mm2, (0-1.85), P=0.109).
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Table 2. Blood vessels and follicles in gut mucosa of IBD patients and controls.
CD 
(inflamed)
UC 
(inflamed)
Healthy controls 
(non-inflamed)
P-value
Number of CD31+ vessels/mm2 
colon, median (IQR)
84 (60-107) 125 (63-139) 71 (43-89) NS
Number of CD31+ vessels/mm2 
ileum, median (IQR)
93 (70-114) - 87 (69-102) NS
Number of HEVs/mm2 colon, 
median (IQR)
0.35 (0-5.17) 4.80 (0.45-6.14) 0.71 (0-1.85) NS
Number of HEVs/mm2 ileum, 
median (IQR)
1.58 (0.34-6.69) - 1.23 (0-5.19) NS
% MECA-79 expressing CD31+ 
vessels colon, median (IQR)
0.85 (0-4.80) 4.63 (0.38-12.24) 0.79 (0-2.59) NS
% MECA-79 expressing CD31+ 
vessels ileum, median (IQR)
2.02 (0.39-6.82) - 1.02 (0-8.99) NS
Colonic follicles/mm2 tissue, 
median (IQR)
0.27 (0.12-0.51) 0.51 (0-0.82) 0.31 (0.23-0.45) NS
Ileal follicles/mm2 tissue, 
median (IQR)
0.35 (0.15-0.57) - 0.37 (0-0.55) NS
CD = Crohn’s disease, UC = ulcerative colitis, IQR = interquartile range
Increased extrafollicular HEV expression in IBD patients compared to controls
Next, we calculated the percentage and density of extrafollicular HEVs and found that colon 
samples of healthy controls did not show any, whereas the inflamed colon of UC patients 
showed a high percentage (median 3.71% (IQR 0-6.23%), P=0.033, figure 1) and a high median 
density (3.05 /mm2 (IQR 0-6.39), P=0.033) of extrafollicular HEVs. In the inflamed colon of CD 
patients, we observed a trend towards a higher number of extrafollicular HEVs (median 0.10 
(IQR 0-2.98),) compared to healthy controls (median 0 (IQR 0-0), P=0.092).
In the ileum of CD patients, the percentage of extrafollicular HEVs was higher in inflamed 
ileum (median 1.17% (IQR 0-3.77%)) compared to ileum of healthy controls (median 0% (IQR 
0-0.4%)) (P=0.028). These samples showed a median density of 1.40 extrafollicular HEVs/mm2 
(IQR 0-4.34), whereas in healthy controls only a few HEVs/mm2 (0%, IQR 0-0.50) were observed 
(P=0.033). The presence of extrafollicular HEVs in the inflamed ileum and colon of IBD patients 
might represent an early phase of TLO formation.
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Figure 1. HEVs in inflamed colonic tissue of patients with inflammatory bowel disease (IBD).
Density of extrafollicular HEVs in colonic tissue (A), determined in the inflamed colonic tissue of patients 
with Crohn’s disease (CD) and ulcerative colitis (UC) as well as in healthy controls. The density is higher in 
UC patients when compared to controls (P =0.033) and there is a trend for higher densities in CD patients 
compared to controls (P =0.092). 
Immunohistochemical staining (B1-B5). Representative photomicrographs, with a magnification of 200x, 
of an immunostained colonic biopsy sample from a Crohn’s disease patient with MECA-79 staining (B1), 
CD20 staining showing B lymphocytes (B2) and CD3 staining showing T lymphocytes (B3). HEVs are shown 
in closer detail in B4 (extrafollicular) and B5 (inside a follicle). Arrows in figure B1, B4 and B5 indicate 
HEVs. Red arrows indicate HEVs inside a lymphoid follicle and black arrows indicate extrafollicular HEVs.
HEV density is not associated with neovascularization
To examine whether the difference in density of PNAd-expressing HEV-like vessels in 
patients could be attributed to neovascularization, we quantified the number of HEVs/mm2 
and correlated this with the total number of CD31+ vessels in patients and controls. We also 
compared colonic UC with colonic CD biopsy specimens. We did not find a correlation and 
no statistical difference was found between UC and CD patients (P=0.198), indicating that the 
differences in HEV density was not related to or associated with neovascularization.
To assess a potential correlation with several confounders, as listed in table 1, we found that 
HEV density in inflamed colon was negatively correlated with smoking (Spearman’s rho= -0.543, 
P=0.002) when analysing all IBD patients. However, when subdivided into CD and UC, it was 
only significantly correlated in CD (Spearman’s rho -0.683, P=0.001) and not in UC (Spearman’s 
rho -0.139, P=0.721). Smoking was not correlated with HEV density of inflamed ileum in CD 
patients. We did not find any correlations with other baseline characteristics (data not shown).
HEVhigh IBD patients have increased colonic lymphoid follicles and infiltration of TN+TCM cells
The immunohistochemical findings were correlated to the maturation state of T cell infiltrates, 
assessed by flowcytometric immunophenotyping of biopsied specimens taken from the same 
area of inflamed tissue and harvested during the same ileocolonoscopy. The extrafollicular HEV 
density in inflamed colon of IBD patients (n=30, 10 UC patients, 20 CD patients) was positively 
correlated with the percentage of mucosal TN+TCM lymphocytes (Spearman’s rho= +0.544, 
P=0.002) and negatively correlated with the percentage of mucosal TEM+TEMRA lymphocytes 
(Spearman’s rho= -0.545, P=0.002). Comparable percentages of lymphocyte subsets were found 
for UC and CD patients (TN+TCM lymphocytes (P=0.406), TEM+TEMRA lymphocytes (P=0.451)).
In malignancy, a cut-off point for increased density of HEVs has been described in patients with 
breast cancer 20. However, in chronic inflammation, no such approach has yet been undertaken. 
We discriminated patients with a high and a low density of HEVs using a cut-off point set at the 
median density of extrafollicular HEVs/mm2 in the inflamed colon of UC patients. According 
to this cut off value, we identified 10 HEVhigh patients and 20 HEVlow patients (table 3). HEVhigh 
patients displayed less cytotoxic T cells (P=0.00008), a higher CD4:CD8 ratio (P=0.0008), less 
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mucosal T cells (P=0.015), more TCM cells (P=0.0009), more TN+TCM cells (P=0.003), less TEM 
cells (P=0.022), less TEMRA cells (P=0.008) and less TEM+TEMRA cells (P=0.004) in the inflamed 
colonic mucosa than HEVlow patients (table 3 and figure 2).
The number of colonic follicles was higher in HEVhigh IBD patients (median 0.54/mm2, (IQR 
0.28-0.84)) compared to HEVlow patients (median 0.25/mm2, (IQR 0.08-0.45) P=0.031) and to 
healthy controls (0.31/mm2, (IQR 0.23-0.45), P=0.043). The number of colonic follicles in the 
inflamed colon of patients was comparable between CD and UC (P=0.348).
In a subgroup of the current patient cohort we analysed a series of serum cytokines and 
chemokines of which CXCL-13 and CCL-19 (both associated with lymphoid organogenesis 22) 
were present at higher concentrations in the HEVhigh patient group. Patients in this group (n=4) 
had higher baseline levels of CXCL-13 (median 67 pg/ml (IQR 52-742 pg/ml)) compared to 
patients in the HEVlow group (n=8, median 36 pg/ml (IQR 27-47 pg/ml) P=0.008) and to healthy 
controls (n=4, median 24 pg/ml (IQR 18-28 pg/ml) P=0.029, figure 3). Furthermore, there was a 
trend towards higher CCL-19 levels in HEVhigh patients (median 176 pg/ml, IQR 126-199 pg/ml) 
compared to HEVlow patients (median 125 pg/ml, IQR 90-141 pg/ml, P=0.073).
Table 3. Characteristics and FACS results of HEVhigh and HEVlow IBD patients.
HEVhigh (n=10) HEVlow (n=20) P-value
CD/UC 5/5 15/5 0.169
Age at diagnosis in years, median (IQR) 21 (20-36) 28 (19-33) NS
Female, n (%) 9 (90%) 14 (70%) NS
Symptoms before diagnosis in months
0-3
3-6
>6
4 (40%)
5 (50%)
1 (10%)
12 (60%)
3 (15%)
5 (25%)
NS
Follow-up period in months, median (IQR) 34 (22-56) 50 (28-65) NS
Family with IBD, n (%) 3 (30%) 5 (25%) NS
Smoking status 
• Never
• Current
• Ceased
• Unknown
9 (90%)
-
-
1 (10%)
11 (55%)
8 (40%)
1 (5%)
-
0.029
HBI score, median (IQR) 7 (5-14) (n=5) 10 (7-13) (n=15) NS
CD disease location (Montreal)
• Ileal, n (%)
• Colonic, n (%)
• Ileocolonic, n (%)
• + Upper GI involved, n (%)
• + Perianal disease, n (%)
-
2 (40%)
3 (60%)
1 (10%)
2 (20%)
-
3 (20%
12 (80%)
7 (44%)
3 (17%)
NS
HEVS AND T CELL SUBSETS IN EARLY IBD
51
3
Table 3. continued
HEVhigh (n=10) HEVlow (n=20) P-value
CD disease behaviour (Montreal)
• Inflammatory, n (%)
• Stricturing, n (%)
• Penetrating, n (%)
5 (100%)
-
-
11 (73%)
3 (20%)
1 (7%)
NS
SES-CD score, median (IQR) 14 (9-19) (n=5) 20 (12-34) (n=15) NS
SES-CD severity
• Mild (4-10), n (%)
• Moderate (11-19), n (%)
• Severe (>19), n (%)
2 (40%)
3 (60%)
0 (0%)
2 (13%)
5 (33%)
8 (53%
NS
UC clinical score (Montreal)
• Remission, n (%)
• Mild, n (%)
• Moderate, n (%)
• Severe, n (%)
-
1 (20%)
2 (40%)
2 (40%)
-
-
2 (40%)
3 (60%)
NS
UC disease location (Montreal)
• Proctitis, n (%)
• Left-sided, n (%)
• Pancolitis, n (%)
-
-
5 (100%)
-
-
5 (100%)
NS
UC endoscopic severity (Mayo)
• Normal, n (%)
• Mild, n (%)
• Moderate, n (%)
• Severe, n (%)
-
2 (40%)
1 (20%)
2 (40%)
-
-
3 (60%)
2 (40%)
NS
FACS analysis of inflamed colon*
• CD3, median (IQR)
• CD19, median (IQR)
• CD4, median (IQR)
• CD8, median (IQR)
• CD4/CD8 ratio, median (IQR)
• CD103, median (IQR)
• TN, median (IQR)
• TCM, median (IQR)
• TEM, median (IQR)
• TEMRA, median (IQR)
• Treg, median (IQR)
50 (45-63)
39 (29-49)
74 (38-83)
15 (11-19)
4.3 (3.0-6.1)
7 (4-12)
23 (20-40)
58 (41-72)
12 (6-18)
2 (1-3)
12 (8-18)
59 (52-72)
23 (18-42)
61 (36-75)
29 (22-37)
2.2 (1.2-3.2)
15 (8-43)
23 (9-54)
33 (20-45)
26 (12-46)
6 (2-12)
14 (12-17)
0.267
0.108
0.169
0.00008
0.0008
0.015
0.779
0.001
0.024
0.010
0.379
CD = Crohn’s disease, UC = ulcerative colitis, HEV = high endothelial venule, IQR = interquartile range, 
IBD = inflammatory bowel disease, HBI= Harvey-Bradshaw Index, SES-CD = simple endoscopic score for 
Crohn’s disease, TN = naïve T lymphocyte, TCM = central memory T lymphocyte, TEM = effector memory T 
lymphocyte, TEMRA = effector memory T lymphocyte re-expressing RA, Treg= regulatory T lymphocyte
*Expressed as percentage of the whole lymphocyte population
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Figure 2. Correlation between high endothelial venules (HEVs) and T cell subpopulations.
Lymphocyte subsets as well as maturation state of T lymphocytes was assessed with flowcytometric 
immunophenotyping of biopsied specimens taken from the same inflamed colonic tissues during the same 
ileocolonoscopy. Patients are divided in HEVhigh (n=10) or HEVlow (n=20) group using the median density of 
extrafollicular PNAd expressing HEV like vessels in inflamed colon of ulcerative colitis (UC) patients as cut 
off value. Statistical significant results are indicated with an asterisk (*). 
A. Shows more central memory T cells (TCM, CD45RA
-CD27+, p=0.0009), less effector memory T cells 
(TEM, CD45RA
-CD27-, p=0.022) and less effector memory T cells re-expressing RA (TEMRA, CD45RA
+CD27-, 
p=0.008) in HEVhigh patients when compared with HEVlow patients. There was no statistical significant 
difference for naive T cells (TN CD45RA
+CD27+). 
B. Shows less cytotoxic T cells (CD3+CD8+, p=0.00008), a higher CD4:CD8 ratio (p=0.0008) and less mucosal 
T cells (CD3+CD103+, p=0.015) in HEVhigh patients. There was no statistical significant difference for B cells 
(CD19+), T cells (CD3+), T-helper cells (CD3+CD4+) and regulatory T cells (CD3+CD25highFoxP3+). 
C. Representative flow cytometric dot plots from inflamed colonic biopsy specimens of IBD patients which 
show the distribution of the maturation of (CD3+) T lymphocytes. C1 shows a HEVhigh patient with mainly TN 
(CD45RA+CD27+, 54%) and TCM (CD45RA
-CD27+, 38%) lymphocytes. C2 shows a HEVlow patient with mainly 
(91%) TEM (CD45RA
-CD27-) lymphocytes.
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Figure 3 Serum CXCL-13 concentrations in IBD patients and healthy controls.
Serum of a subgroup of patients and healthy controls was analysed by multiplex immunoassay for several 
cytokines and chemokines. Patients are divided in HEVhigh or HEVlow group using the median density of 
extrafollicular HEVs in inflamed colon of ulcerative colitis patients as cut off value. HEVhigh patients had 
higher CXCL-13 concentrations compared to HEVlow patients (P=0.008) and compared to healthy controls 
(P=0.029). 
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DISCUSSION
In the present study, increased percentages of extrafollicular HEVs were observed in inflamed 
colon and ileum of newly diagnosed IBD patients compared to healthy controls. In controls, 
these HEVs were restricted to lymphoid follicles (SLOs). A high heterogeneity was observed 
in the number of extrafollicular HEVs in IBD patients. We identified two subgroups of patients 
according to the density of the extrafollicular HEVs in the inflamed colonic mucosa: HEVhigh 
and HEVlow. In HEVhigh patients, a higher percentage of TN+TCM lymphocytes was observed 
in the inflamed colonic mucosa compared to HEVlow patients. Patients in the HEVhigh group 
also displayed a higher number of lymphoid follicles (TLOs) in the inflamed colonic mucosa 
compared to patients in the HEVlow group and controls. Furthermore, chemokines associated 
with TLO formation (CXCL-13 and CCL-19) were upregulated in the serum of HEVhigh patients
In physiologic conditions, HEVs are known to be exclusively present within SLOs, whereas in the 
present study we demonstrated their presence outside follicles in the inflamed intestine of IBD 
patients. It is our interpretation that extrafollicular HEVs represent an early phase of lymphoid 
neogenesis (TLO formation), as these vessels were virtually absent in healthy controls. In 
addition to Peyer’s patches, GALT also contains other forms of SLOs, such as isolated lymphoid 
follicles and submucosal lymphocyte aggregations. Isolated lymphoid follicles are mostly seen 
within the mucosa, while submucosal lymphocyte aggregations lie deeper within the muscularis 
mucosa and submucosa 23,24. Peyer’s patches are mostly present in jejunum and ileum while 
isolated lymphoid follicles have also been found in the human colon 24. In accordance with this, 
we found HEVs within lymphoid follicles of the normal gut mucosa of both ileum and colon of 
healthy controls; however, they did not display such vessels outside these follicles.
In IBD, HEVs were previously investigated in one study using MECA-79 immunostaining of 
biopsy specimens from UC patients and surgical specimens of CD patients, presumably with 
longstanding disease and under immunomodulatory treatment 5. Increased HEVs were found 
in inflamed colonic mucosa of UC patients and (to a lesser extent) in CD patients, compared 
to non-inflamed colonic mucosa of other IBD patients. However, no healthy controls were 
included, T cell maturation in the gut mucosa was not analysed and no serial biopsy samples at 
different time points and phases of disease within the same patients were analysed. Numbers 
of HEVs in patients with non-inflamed colonic mucosa have not been investigated during active 
disease and therefore it might concern a subgroup of patients without ectopic HEV formation 
similar to our HEVlow group. Our results expand upon this previous study, as we demonstrated 
differences in HEV density and TLOs in newly diagnosed, untreated IBD patients with active 
disease in correlation with different T cell subsets in the gut. Direct comparison with our 
presented results is difficult, as we included healthy controls and studied mucosal T cell 
maturation status and the presence of HEVs in relation to lymphoid follicles. We demonstrated 
increased extrafollicular HEVs formation in a subgroup of patients (HEVhigh) in the early phase 
of disease. The lack of extrafollicular HEVs in the other subgroup (HEVlow) might be explained 
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by a different disease mechanism in these patients or the early phase of disease, assuming that 
formation of HEVs in inflamed mucosa is a characteristic of chronicity. Increased percentages 
of TEM cells in HEV
low patients suggest predominant recruitment of TEM cells into the inflamed 
gut. These TEM cells, known to be α4β7
+, might enter the inflamed gut by binding to MAdCAM-1 
present on endothelial cell, in the absence of extrafollicular HEVs.
Lymphoid follicles in the gut were previously studied in established CD patients. In line with 
our findings in colonic samples of early IBD patients, they demonstrated the presence of 
submucosal de-novo lymphoid follicles in surgical ileal resection specimen of CD patients 17. 
The authors interpreted these lymphoid follicles as being TLOs, based mainly on their location 
in the submucosa, muscularis propria and subserosa, but theoretically these follicles might 
still represent SLOs. However, no MECA-79 immunostaining with HEV quantification was 
performed 17. Furthermore, the use of ileal resection specimen suggests a highly refractory 
patient group with longstanding disease. Potential differences between patients and associated 
mucosal T cell subsets were not investigated. 
The mechanism of TLO development has not yet been clarified. Nevertheless, chemokines such 
as CXCL-13, CCL-19 and CCL-21 together with lymphotoxin α1β2 (LTα1β2, TNF family member) 
expressed on lymphoid tissue inducer cells (LTi) were shown to be required for lymphoid 
organogenesis 22. LTα1β2 is implicated in generation of follicular dendritic cells and HEVs out 
of stromal cells, while CCL-19, CCL-21 and CXCL-13 control the organization of the T- and 
B-cell follicular regions 12,22,25. Previously, increased CXCL-13 expression has been observed 
in inflamed gut of UC patients 26, while research in transgenic mice demonstrated that CXCL-
13 expression promotes B-cell recruitment and formation of lymphoid follicles 27. Remarkably, 
we found increased serum CCL-19 and CXCL-13 in HEVhigh patients. This suggests a systemic 
reflection of gut-localized formation of TLOs in these patients.
Recently, research in mice lacking LTi, it was demonstrated that lymphoid organogenesis 
was linked to the activation of stromal cells by TNF-α. This suggests that increased TNF-α 
expression during chronic inflammation might play an important role in TLO development in 
IBD 28. Development of TLOs containing HEVs has been reported in other diseases with chronic 
inflammation and in patients with solid tumours. In patients with rheumatoid arthritis, TLOs 
were associated with an inferior therapeutic response to anti-TNF treatment and reversal of 
TLOs was a good marker of beneficial therapeutic response 29.
In our study, the higher number of colonic follicles found in the HEVhigh group indicated that 
in this subgroup of IBD patients, de novo lymphoid follicles were being formed, representing 
TLOs. The patients in the HEVhigh group not only had more follicles, they also exhibited more 
HEVs outside these follicles and this was correlated with a higher percentage of mucosal 
TN+TCM lymphocytes (known to be L-selectin
+ 18,19) and a lower percentage of mucosal 
TEM+TEMRA lymphocytes (known to be L-selectin
- 18,19). Remarkably, the patients in HEVlow 
group were comparable to healthy controls regarding these findings. HEVs express different 
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functional ligands (PNAd, MAdCAM-1) for L-selectin, facilitating extravasation and entry of 
TN+TCM lymphocytes into lymphoid organs 
30. Our findings suggest differences between IBD 
patients, both UC and CD, regarding TLO formation and recruitment of different lymphocyte 
subsets to the inflamed gut mucosa. These results further expand on our previous paper in 
newly diagnosed IBD patients with increased numbers of TN and TCM cells in the inflamed gut of 
a subgroup of patients 7. Taken together, our results point out that increased homing of TN and 
TCM lymphocytes to non-lymphoid gut tissue in a subgroup of IBD patients might be facilitated 
by de-novo formation of extrafollicular HEVs and TLOs.
A limitation of the present study was that mucosal biopsy specimens precluded full examination 
of the deeper layers of the intestine wall (submucosa, muscularis propria and subserosa), which 
potentially contain HEVs and TLOs in IBD patients, particularly in CD. However, the strengths of 
our study were the prospective design, the sampling of untreated patients early in the course of 
IBD and the use of a standardized description of TLOs and HEVs in inflamed mucosa of patients.
The clinical and therapeutic relevance of these findings in IBD patients remain to be elucidated; 
the presence of lymphoid follicles in initial biopsy specimens may, however, be predictive for 
colectomy due to drug refractory UC 31. Furthermore, novel treatment strategies targeting T 
cell migration to the inflamed gut mucosa of IBD patients, such as anti-α4β7 (vedolizumab 
(Entyvio®)) and anti-MAdCAM-1 monoclonal antibodies (PF-00547659) are emerging 32,33. 
HEVlow patients with higher percentage of TEM lymphocytes, suggesting increased recruitment of 
α4β7+ T cells, might theoretically benefit more and thus respond better to Vedolizumab treatment 
than HEVhigh patients. Moreover, these findings may lead to further development of new treatment 
targets in IBD, designed to influence HEV and TLO formation by targeting the lymphotoxin pathway 34.
CONCLUSION
In conclusion, higher numbers of extrafollicular HEVs were demonstrated in IBD patients 
compared to healthy controls. An increased density of extrafollicular HEVs and TLOs in IBD 
patients was associated strongly with mucosal infiltration of TN+TCM lymphocytes, while a 
low density of HEVs correlated with higher numbers of mucosal TEM cells. This suggests that 
the homing of TN and TCM lymphocytes to non-lymphoid gut tissue in IBD patients might be 
facilitated by extrafollicular HEVs and de-novo TLO formation within inflamed mucosa. Different 
‘T cell migration phenotypes’ based on TLO formation in the early phase of IBD may allow for 
risk-stratification of patients and enable individualized treatment. 
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ABSTRACT
Introduction
A dysregulated intestinal T-cell response is presumed in patients with inflammatory bowel 
disease (IBD). In this longitudinal study, we investigated the changes in intestinal T lymphocyte 
subsets in IBD at first presentation and over time during endoscopic active or inactive disease 
and relate them to disease activity and outcome. 
Methods
We included 129 newly diagnosed patients (87 Crohn´s disease (CD), 42 ulcerative colitis (UC)) 
and 19 healthy controls (HC). Follow-up biopsy specimens were analysed from 70 IBD patients. 
Immunophenotyping of specimens was performed by flow cytometry identifying lymphocyte 
subpopulations.
Results
IBD patients at diagnosis displayed higher percentages of CD4 T cells, Tregs and central 
memory T cells (TCM) and with lower percentages of CD8 and CD103 T lymphocytes than 
HC. Follow-up specimens of patients with endoscopic inactive disease showed T-cell subset 
recovery comparable to HC. Endoscopic active disease at follow-up coincided with T-cell 
subsets similar to those at diagnosis. 
In UC, lower baseline percentages of CD3 cells was associated with milder disease course 
without the need of an immunomodulator, whereas in CD, higher baseline percentages of CD4 
and Tregs were associated with complicated disease course.
Conclusions
The intestinal T-cell infiltrate in IBD patients with active endoscopic disease is composed of 
increased percentages of CD4+ T cells, Tregs, and TCM, with lower percentages of CD8
+ T cells 
and CD103+ T cells compared with HC and endoscopic inactive IBD. Baseline percentages of 
CD3, CD4 and Tregs were associated with disease outcome. Further research is needed to 
demonstrate the predictive value of these lymphocyte subsets. 
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INTRODUCTION
Ulcerative colitis (UC) and Crohn’s disease (CD) are immune-mediated, inflammatory bowel 
diseases (IBD), with a chronic and relapsing character. Diagnosis is based on a combination of 
internationally accepted clinical, endoscopic, histological and radiological findings 1,2. Incidence 
is increasing and disease burden is substantial due to the chronic nature and generally young age 
at onset of disease 3. Disease presentation and course are heterogeneous and unpredictable. 
Approximately 50% of CD patients are expected to develop disease complications over time 
requiring aggressive medical therapy such as (biologic) immunomodulators or surgery 4,5. In 
CD patients, clinical determinants associated with a complicated disease course are younger 
age (<40), perianal or stricturing disease, involvement of the upper gastrointestinal tract, 
penetrating disease, and smoking 6,7. Colectomy is considered a solid endpoint for disease 
severity in UC, and is required in approximately 10% of patients in the first 10 years of disease. 
Extensive colitis, as well as severe systemic symptoms were shown to be predictors of 
colectomy 8 9,10. 
Guidelines for the choice of treatment modality in IBD are still generic and historically based 
without much focus on the individual patient. Biomarkers that can predict disease course or 
response to therapy would help in focusing on the individual patient. Until now, results have 
been somewhat disappointing. Some efforts have been made in a study describing CD8+ T 
cell transcriptional signatures associated with frequently relapsing disease in IBD patients 11. 
Recently, a list of key research priorities regarding IBD treatment was compiled, including 
selection of patients for optimal treatment strategies 12. Identifying biomarkers that relate to 
disease behaviour and response to therapy would help in this process. The first step in this 
process would be to identify potential biomarkers in IBD patients and to analyse the behaviour 
of these candidate biomarkers in patients over time. A dysregulated T lymphocyte response is 
often implicated as key mediator of chronic inflammation in IBD 13,14. This is supported by the 
growing number of successful therapeutic approaches targeting T cells in IBD patients such 
as: thiopurines, inducing T cell apoptosis; anti-α4β7, targeting the traffic of gut homing T cells 
and anti-IL12/23 p40, interfering with T-helper 1 (Th1) and Th17 lymphocytes 15. 
Most research on T lymphocytes in IBD has focused on activated CD4+ T effector lymphocytes 
(Th1, Th2, Th17 and regulatory T cells (Tregs)) 13. The research on T lymphocytes in IBD was 
mainly based on cytokines detected in the mucosa of longstanding IBD patients and animal 
models. Instead of an overwhelming increase of effector memory T cells (TEM), we previously 
identified newly diagnosed patients with increased percentages of naïve T lymphocytes (TN) 
and central memory T lymphocytes (TCM) in their inflamed gut mucosa
16. Furthermore, it was 
shown that patients had higher percentages of Tregs and lower percentages of CD103+ T cells 
at diagnosis, when compared with healthy controls. Differences in mucosal T cell subsets 
between IBD patients at diagnosis might have predictive value for response to different 
therapeutic agents. Our hypothesis is that intestinal mucosal T lymphocyte subsets may be 
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potential biomarkers for disease course in IBD. Therefore, the primary aim of this longitudinal 
study was to investigate the changes of intestinal mucosal T lymphocyte subsets in IBD patients 
at diagnosis and during follow-up in both presence and absence of endoscopic inflammation. A 
secondary aim was to study these subsets in relation to disease course over time. 
MATERIAL AND METHODS
Study population
Patients suspected of IBD were prospectively enrolled at the outpatient clinic of the Crohn 
and Colitis Centre of Rijnstate Hospital Arnhem, The Netherlands. After standardised work-up 
including clinical, endoscopic, histopathological and, when applicable, radiological evaluation, 
all patients met the accepted international diagnostic criteria of CD or UC1,2. Patients were 
recruited before initial diagnostic ileocolonoscopy, enrolled after IBD was diagnosed, and 
subsequently followed in their clinical course. During the initial ileocolonoscopy, multiple 
biopsy specimens were taken for histopathological analysis and immunophenotyping by flow 
cytometry analysis. Lymphocyte subsets at baseline, for part of the IBD patients included in 
this study and healthy controls (HC) were previously described 16. These groups were expanded 
with newly diagnosed patients and HC. Follow-up endoscopy was performed as part of standard 
care, taking additional biopsy specimens for immunophenotyping. 
Healthy controls underwent ileocolonoscopy for polyp-surveillance and did not present 
endoscopic pathology. None of the healthy controls had any signs of IBD or other immune 
mediated diseases. 
Classification and definitions
Endoscopic severity of the disease at baseline and follow-up was assessed in CD by the simple 
endoscopy score for CD (SES-CD; ranging from <4 to>19) and in UC by the Mayo score (ranging 
from 0 to 3) 17. Inactive disease was defined as endoscopic remission (Mayo=0/ SES-CD<4). 
Active disease was defined as endoscopic disease activity (Mayo >0/ SES-CD>3). Active disease 
was further subdivided in mild (Mayo 1 or SES-CD 4-10), moderate (Mayo 2 or SES-CD 11-19) 
or severe (MAYO 3 or SES-CD>19). At baseline, all IBD patients were classified with active 
disease (Mayo >0/ SES-CD>3). At follow-up endoscopy, 36% of patients were classified as 
active and 56% as inactive disease. 
Disease phenotype (location and behaviour) at baseline and at latest follow-up was assessed 
according to the Montreal classification 18. Clinical disease activity at baseline and follow-up 
was assessed using the Harvey-Bradshaw index for CD and the Montreal classification for 
UC 18,19.
Overall use of and response to medication was recorded. In general, therapeutic management 
of IBD after diagnosis was done according to the step-up approach, as recommended by the 
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Dutch guidelines 20. In UC patients, topical and/or oral 5-aminosalicylate (5-ASA) was initiated 
as induction therapy. In case of a severe pancolitis or when induction with 5-ASA treatment 
failed, patients were treated with topical or systemic steroids. When UC patients were steroid 
refractory, anti-tumour necrosis factor (TNF) therapy was started. When patients were steroid 
dependent, or had relapsing disease, a thiopurine was initiated and, in case of therapy failure or 
relapsing disease, anti-TNF treatment was initiated. Failure in either induction or maintenance 
of remission could lead to surgical escape therapy, i.e. colectomy. In CD patients, steroids 
were started as induction therapy. This was usually followed by the initiation of maintenance 
treatment (thiopurine derivates or methotrexate), especially in case of steroid-dependent 
disease. Anti-TNF therapy was initiated in case of steroid-refractory or steroid-dependent 
disease, or in case of extended perianal fistulising disease, usually in combination with a 
thiopurine derivate. If the disease did not respond to conventional treatment, resective surgery 
was considered. During relapse, escalation of maintenance treatment was considered. 
We determined the highest treatment step in each patient, comparing 5-ASA, steroids, 
immunomodulator, anti-TNF and resective surgery as measures of severity of the disease. 
UC patients only needing 5-ASA treatment, and/or a short initial treatment with steroids, were 
classified as mild disease. Moderate UC was defined as the use of thiopurines after 5-ASA 
failure, and severe UC as the need for anti-TNF, vedolizumab or colectomy. CD patients with a 
mild disease course only needed 5-ASA, steroids, and/or an immunomodulator. Moderate CD 
was defined as the need for step up treatment above an immunomodulator (for instance anti-
TNF therapy) without meeting the criteria of severe disease. Severe disease in CD was defined 
as the occurrence of penetrating or stricturing disease, perianal fistulizing disease with the 
need for anti-TNF initiation and/or surgical intervention, and CD-related resective surgery. 
Tissue samples and cell preparation
Six intestinal biopsy specimens from IBD patients at baseline were obtained from the 
macroscopically most inflamed areas at primary diagnosis, before the initiation of any 
medical treatment. At follow-up endoscopy, six biopsy specimens were obtained from the 
macroscopically most inflamed areas or, when there was no inflammation, from the areas of 
inflammation at baseline. Regular histopathological analysis was performed at baseline and 
follow-up, as well as immunophenotyping of the mucosal lymphocyte populations. 
In healthy controls, six biopsy specimens were randomly obtained from ileal and colonic 
areas. Regular histopathological examination confirmed the absence of inflammation, and 
immunophenotyping of the mucosal lymphocyte populations was performed.
Biopsy specimens meant for flow cytometry analysis were kept in phosphate-buffered 
saline solution at 2-8°C and processed within 8 h. Specimens were pooled and finely minced 
in Hanks’/1% bovine serum albumin using a 70-mm gaze and spatula followed by Ficoll 
density gradient centrifugation. The homogenate was resuspended, after washing, in 0.5 mL 
Hanks’/1% bovine serum albumin. The cell concentration of the mononuclear cell suspension 
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was estimated by microscopic counting with a KOVA glasstic slide (Hycor Biomedical, Penicuik, 
UK). 
Flow cytometry
For flow cytometric analysis, 200 µL of the total cell suspension was used, irrespectively of 
the absolute cell numbers. Single cell suspensions of the biopsies were analysed using a 
FACS Canto (BD Biosciences). Intestinal lymphocyte subpopulations were defined as T cells 
(CD3+) expressed as percentages of the whole lymphocyte population (CD45+/low side scatter). 
Mucosal T cells (CD3+CD103+), T-helper cells (CD3+CD4+) and cytotoxic T cells (CD3+CD8+) 
were expressed as percentages of the T cell population (CD3+/light scatter characteristics). 
Regulatory T cells (Tregs, CD3+CD4+CD25highFoxP3+) were expressed as percentages of the 
CD3+CD4+ population. The maturation state of T cells was assessed by using CD45RA and 
CD27 21, defining naive T cells (TN: CD45RA
+CD27+), central memory T cells (TCM: CD45RA
-
CD27+), effector memory T cells (TEM: CD45RA
-CD27-) and T effector memory cells re-
expressing CD45RA (TEMRA: CD45RA
+CD27-) and expressed as percentages of the T cell (CD3+) 
population. 
Statistical analysis
All variables were tested for normality using the Shapiro-Wilk test. Categorical variables were 
expressed as numbers of patients and percentages and compared with chi-square or Fisher’s 
exact test when necessary. Continuous variables were described as median and interquartile 
range (IQR) and compared with the Mann-Whitney U test. When more than two groups were 
compared, we used the Kruskal-Wallis test followed by the Dunn test when applicable. Paired 
data (baseline and follow-up percentages of lymphocyte subsets) were compared using the 
Wilcoxon matched-pairs signed-rank test. We performed hierarchical clustering analysis 
to discriminate the potential signature of inactive and active disease at follow-up using 
the software R22. Multivariate analyses were performed using binary logistic regression to 
identify independent predictors of disease course. Comparison of the initiation of thiopurine 
treatment in UC patients was performed using univariate and multivariate Cox-regression 
analysis, graphically represented by a Kaplan-Meier plot, resulting in a relative risk (RR) with 
corresponding confidence interval (CI). SPSS statistics for Windows (version 22.0; IBM Corp, 
Armonk, NY, USA) and GraphPad Prism (GraphPad Software version 7.0, La Jolla, CA, USA) 
were used to analyse data. Statistical significance was defined as a P-value lower than 0.05. 
Ethical considerations
Written informed consent was obtained from each participating patient before any study-
related procedure was performed. The procedures were performed in accordance with the 
Declaration of Helsinki. The regional medical ethics committee approved the study protocol 
(NL28761.091.09).
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RESULTS
Patient characteristics
This study included 87 CD patients, 42 UC patients and 19 HC. Baseline characteristics can be 
found in table 1. IBD patients were significantly younger than HC (median 28 years (IQR=21-40) 
vs. 40 years (IQR=32-57), P=0.0001). There were more females in the HC group (89% vs. 66%, 
P=0.03). The median follow-up duration after initial diagnosis was 32 months (IQR 18-66) for 
CD patients and was significantly longer compared with UC patients (23 months (IQR 13-38), 
P=0.004). Endoscopic disease severity, categorised as mild, moderate, or severe disease, was 
evenly distributed in both CD and UC. CD patients had longer symptom duration before the 
establishment of primary diagnosis (P=0.002), and a larger proportion were smokers (P=0.002) 
and had a higher baseline C- reactive protein (CRP) (P=0.0001) than UC patients.
Table 1. Baseline patient characteristics.
CD (n= 87) UC (n=42) P-value CD 
vs UC
HC (n=19)
Patient characteristics
Median age at diagnosis in years (IQR) 26 (21-41) 28 (22-38) 0.61 40 (32-57)
Female/male 58/29 27/15 0.47 17/2
Duration of symptoms before 
diagnosis, n (%)
- 0-3 months
- 3-6 months
- >6 months
- 27 (31%)
- 20 (23%)
- 40 (46%)
- 23 (55%)
- 13 (31%)
- 6 (14%)
0.002
First degree relative with IBD, n (%) 12 (14%) 11 (26%) 0.12 0 (0%)
Smoking at diagnosis, n (%)
- Current
- Former
- Never
- 38 (44%)
- 8 (9%)
- 41 (47%)
- 5 (12%)
- 6 (14%)
- 31 (74%)
0.002
- 6 (32%)
- 2 (11%)
- 11 (58%)
Laboratory values at diagnosis, n, 
median, (IQR)
CRP 
Faecal calprotectin 
N=78, 19 (9-56)
N=41, 488 (251-
1237)
N=35, 5 (1-17)
N=25, 396 (239-
825)
0.0001
0.54
N=14, 3 (1-8)
N=5, 2 (0-7)
Median follow-up in months (IQR) 32 (18-66) 23 (13-38) 0.004
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Table 1. continued
CD (n= 87) UC (n=42) P-value CD 
vs UC
HC (n=19)
Disease characteristics
Harvey Bradshaw Index, median (IQR)
- Remission (<5)
- Mild (5-7)
- Moderate (8-16)
- Severe (>16)
8 (6-12)
8 (9%)
30 (34%)
39 (45%)
10 (12%)
SES-CD (0-56), median (IQR)
- Remission (<4)
- Mild (4-10)
- Moderate (11-19)
- Severe (>19)
12 (8-22)
- 0 (0%)
- 34 (39%)
- 27 (31%)
- 26 (30%)
Disease location (CD) at diagnosis, 
n (%)
- L1 (ileal)
- L2 (colonic)
- L3 (ileocolonic)
- L4 (proximal of ileum)
Disease behaviour (CD) at diagnosis, 
n (%)
- B1 (non-stricturing, non-penetrating)
- B2 (stricturing)
- B3 (penetrating)
- P (Perianal disease)
- 30 (34%)
- 17 (20%)
- 40 (46%)
- 23 (26%)
- 68 (78%)
- 15 (17%)
- 4 (5%)
- 12 (14%)
Montreal classification of clinical 
severity at diagnosis, n (%)
- S0 (remission)
- S1 (mild)
- S2 (moderate)
- S3 (severe)
- 0 (0%)
- 13 (31%)
- 16 (38%)
- 13 (31%)
Endoscopic MAYO-score at diagnosis, 
n (%)
- Mayo 0
- Mayo 1
- Mayo 2
- Mayo 3
- 0 (0%)
- 9 (21%)
- 24 (58%)
- 9 (21%)
INTESTINAL T CELL SUBSET PROFILING IN IBD
69
4
Table 1. continued
CD (n= 87) UC (n=42) P-value CD 
vs UC
HC (n=19)
Highest treatment to reach initial 
remission
- No treatment
- 5ASA
- Steroids
- Immunomodulator
- Biological
- Surgery
- 2 (2%)
- 4 (5%)
- 17 (19%)
- 46 (53%)
- 12 (14%)
- 6 (7%)
- 0 (0%)
- 23 (55%)
- 10 (24%)
- 6 (14%)
- 1 (2%)
- 2 (5%)
0.0001
Lymphocyte distribution at baseline in IBD patients compared with healthy controls
To determine if lymphocyte subsets’ distribution in the inflamed gut was influenced by 
biopsy location, we compared lymphocyte subset percentages from CD patients with ileal 
location (n=30), biopsy specimens being taken only from the inflamed ileum, with those with 
colonic location (n=17), biopsy specimens being taken only from the inflamed colon. There 
were no statistical differences for any of the analysed lymphocyte subsets between ileal and 
colonic location in CD (supplementary table 1). Therefore, we analysed the ileal and colonic 
lymphocyte subsets from CD patients together. IBD patients showed a distinctive composition 
of T lymphocyte subsets in their inflamed intestine when compared with HC (table 2). They 
had higher percentages of CD4+ T cells with lower percentages of CD8+ T cells whereas HC 
had higher percentages of mucosal CD103+ T cells and lower percentages of Tregs. When 
examining T cell maturation in patients and controls, IBD patients had higher percentages of 
TCM cells. The difference in relative amounts of T lymphocyte subsets compared with HC was 
most pronounced in UC patients. They had higher percentages of CD4+ T cells and percentages 
of TCM cells as well as lower percentages of CD8
+ T cells and percentages of CD103+ T cells, 
than CD patients. 
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Table 2. Baseline intestinal lymphocyte populations in healthy controls (HC), Crohn’s disease (CD) and 
ulcerative colitis (UC). Medians (interquartile range) are reported.
HC (n=19) CD (n=87) UC (n=42) P-valueab P-valueac P-valued
CD3+ as % of lymphocytes 66 (56-69) 53 (45-64) 58 (48-69) 0.021 0.28 0.17
CD3+CD4+ as % of T cells 48 (31-76) 67 (53-75) 73 (64-82) 0.005 0.0001 0.004
CD3+CD8+ as % of T cells 45 (24-58) 28 (22-36) 22 (16-29) 0.003 0.0001 0.003
CD3+CD103+ as % of T cells 43 (23-66) 17 (9-34) 12 (6-21) 0.001 0.0001 0.009
TN* as % of T cells
9 (3-25) 17 (9-35) 19 (11-30) 0.33 0.27 0.97
TCM*as % of T cells
21 (11-27) 33 (24-45) 50 (38-57) 0.032 0.002 0.0001
TEM* as % of T cells
41 (24-52) 26 (10-45) 20 (12-29) 0.30 0.008 0.23
Treg* as % of T cells 4 (2-5) 11 (8-16) 10 (8-16) 0.001 0.004 0.80
*Subsets were defined as described in methods: TN by CD3
+CD27+CD45RA+, TCM by CD3
+CD27+ CD45RA-, 
TEM by CD3
+CD27-CD45RA- and Treg by CD3+CD4+CD25+Foxp3+
a. corrected for age
b. comparing CD and HC
c. comparing UC and HC
d. comparing CD and UC
Development of lymphocyte subsets during follow-up in IBD patients
Seventy patients (54% of all IBD patients) underwent follow-up endoscopy with consecutive 
lymphocyte subsets analysis. From these patients, 25 had active endoscopic disease at the time 
of the follow-up endoscopy (36%), and 39 had inactive endoscopic disease (56%). Discrepancy 
of endoscopic disease activity between ileum and colon was observed in six CD patients (8%), 
with active disease in one bowel segment and inactive disease in the other segment, although 
these patients had ileocolonic disease at baseline. These patients were left out of the analysis 
on the change of the lymphocyte subsets between baseline and follow-up. 
When compared with baseline, patients with inactive endoscopic disease at follow-up had decreased 
percentages of CD4+ T cells (fold change (FC) =0.78, P=0.001) and increased percentages of CD8+ 
T cells (FC=1.46, P=0.0001,) (figure 1 and supplementary table 2). They also presented increased 
percentages of CD103+ T cells (FC=2.43, P=0.0001), decreased percentages of Tregs (FC=0.38, 
p=0.004), and a shift towards more TEM (FC 1.48, P=0.0001) leading to lower percentages of TN and 
percentages of TCM (FC=0.45 and FC=0.55; P=0.002 and P=0.0001, respectively). 
Patients with active endoscopic disease at follow-up showed an even further decrease of 
percentages of CD8+ cells compared with their baseline percentages (FC=0.76, P=0.016). All 
other T lymphocyte subsets did not differ statistically from baseline in patients with active 
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endoscopic disease. Subdividing UC and CD patients gave similar results to those among the 
whole group (figure 1, supplementary table 2).
For baseline intestinal lymphocyte populations of the endoscopic inactive and active disease 
group at follow-up see supplementary tables 5-7, percentages at baseline were comparable 
among both groups.
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disease at follow-up endoscopy
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Baseline : follow-up
Figure 1. Fold change of different lymphocyte subsets in inflammatory bowel disease (IBD) patients 
at follow-up endoscopy with either endoscopic active or inactive disease when compared to their 
baseline values (all with active disease) by Wilcoxon matched-pairs signed-rank test. 
IBD patients with inactive endoscopic disease at follow-up endoscopy had a statistical significant decrease 
compared to baseline percentages of CD4 T cells, naïve T cells (TN), central memory T cells (TCM) and 
regulatory T cells (Treg) with a significant increase of %CD8 T cells, CD103 T cells and effector memory 
T cells (TEM). In patients with active endoscopic disease at follow-up, T lymphocyte subsets did not differ 
significantly from baseline percentages, except for an even further decrease of the CD8%. When subdividing 
ulcerative colitis (UC) and Crohn’s disease (CD) patients the same patterns were found.
*inactive (MAYO=0/SES-CD<4) or active (MAYO>0/SES-CD>3) disease at follow-up endoscopy
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We additionally performed a hierarchical cluster analysis to compare the lymphocyte subsets 
signature of patients with active endoscopic disease with those with inactive endoscopic 
disease at follow-up (figure 2). We found that patients with active endoscopic disease had higher 
percentages of CD4+ T cells, lower percentages of CD8+ T cells, lower percentages of CD103+ 
T cells, higher percentages of Tregs, higher percentages of TCM and lower percentages of TEM 
(all: P=0.0001) and higher percentages of TN (P=0.001) than patients with inactive endoscopic 
disease (figure 3 and 4, table 3). Comparing the different grades (mild vs moderate vs severe) of 
endoscopic disease severity in active disease did not show mutual significant differences. The 
same results were found when subdividing UC and CD (supplementary tables 3 and 4).
The percentages of T lymphocyte subsets in patients without endoscopic disease activity 
recovered to levels comparable to HC (figure 3 and 4, table 3). Medical treatment at the moment 
of the follow-up endoscopy was very different between patients. No statistical differences were 
found for lymphocyte subsets percentages when adjusting for the different regimens. However, 
no definite conclusions can be drawn about the effect of treatment modality on lymphocyte 
subsets due to the small sample size per treatment regimen.
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Figure 2. Hierarchical clustering analysis comparing IBD patients at follow-up with active endoscopic 
(green) and inactive endoscopic disease (yellow).
TN = naïve T cells, TCM = central memory T cells, TEM = effector memory T cells, Treg = regulatory T cells.
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Figure 3. Intestinal lymphocyte subsets at follow-up endoscopy in inflammatory bowel disease (IBD) 
patients with endoscopic active and -inactive disease and healthy controls. 
The T cell subsets from patients with active endoscopic disease showed a distinct pattern from healthy 
controls and patients with inactive endoscopic disease, while T cell subsets from patients with inactive 
endoscopic disease approached those of healthy controls. 
TN= naïve T cells, TCM= central memory T cells, TEM = effector memory T cells, Treg = regulatory T cells.
* inactive (MAYO=0/SES-CD<4) or active (MAYO>0/SES-CD>3) disease at follow-up endoscopy
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Figure 4. Representative flow cytometric dot plots showing (from left to right) a patient with 
ulcerative colitis at diagnosis with active endoscopic disease and the same patient at follow-up 
endoscopy with inactive endoscopic disease next to a healthy control. 
A. shows CD4/CD8 gated in the CD3+ population, B. shows CD103+ cells within the CD3+ population, 
C. shows T cell maturation based on CD27 and CD45RA within the CD3+ population with naïve T cells 
(CD27+CD45RA+), central memory T cells (CD27+CD45RA-), effector memory T cells (CD27-CD45RA-) and 
effector memory T cells re-expressing CD45RA (CD27-CD45RA+), D. shows regulatory T cells (CD25+FoxP3+) 
within the CD3+CD4+ population.
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Table 3. Intestinal lymphocyte populations at follow-up endoscopy from IBD patients with either 
endoscopic active (MAYO>0/ SES-CD>3) or inactive (MAYO=0/ SES-CD<4) disease and healthy controls 
(HC). Medians (interquartile range) are reported.
IBD: endoscopic 
inactive disease 
(n=39)
IBD: endoscopic 
active disease 
(n=25)
P-
valuea 
HC 
(n=19)
P-
valuebc
P-
valuecd
FU duration from diagnosis 
until follow-up endoscopy 
in months, median (IQR)
24 (13-47) 22 (11-39) 0.27 - - -
CD3+ as % of lymphocytes 59 (46-74) 53 (42-63) 0.09 66 (56-69) 0.41 0.013
CD3+CD4+ as % of T cells 50 (40-61) 77 (70-83) 0.0001 48 (31-76) 0.86 0.002
CD3+CD8+ as % of T cells 41 (31-54) 19 (11-26) 0.0001 45 (24-58) 0.71 0.002
CD3+CD103+ as % of T cells 47 (26-70) 10 (4-24) 0.0001 43 (23-66) 0.62 0.004
TN* as % of T cells
6 (4-18) 17 (11-35) 0.001 9 (3-25) 0.23 0.34
TCM*as % of T cells
19 (9-35) 47 (32-57) 0.0001 21 (11-27) 0.86 0.006
TEM* as % of T cells
48 (24-78) 14 (6-34) 0.0001 41 (24-52) 0.11 0.043
Treg* as % of T cells 5 (3-8) 10 (6-15) 0.0001 4 (2-5) 0.19 0.004
*Subsets were defined as described in methods: TN by CD3
+CD27+CD45RA+, TCM by CD3
+CD27+ CD45RA-, 
TEM by CD3
+CD27-CD45RA- and Treg by CD3+CD4+CD25+Foxp3+
a. Comparing endoscopic active and inactive IBD
b. Comparing endoscopic inactive IBD and HC 
c. Corrected for age
d. Comparing endoscopic active IBD and HC 
T cell maturation profiles at baseline and during follow-up
Previously, we distinguished four T-cell maturation profiles in the intestinal mucosa of IBD 
patients (figure 5) 16. At baseline, 71% of UC patients had a B profile with predominantly TCM, 
whereas CD patients were more heterogeneous (B in 34%, C in 30%, A in 17% and D in 16%) 
and HC had mainly a C or D profile (47% and 37% respectively, figure 5). T cell maturation 
profiles were not associated with disease phenotypes or course.
In patients with IBD with active endoscopic disease at follow-up endoscopy, 89% of patients 
with a B profile at baseline retained this profile at follow-up. Among patients with a C or D 
profile at baseline, 50% changed to an A or B profile when there was disease activity at follow-
up endoscopy. 
On the other hand, in IBD patients with inactive endoscopic disease at follow-up endoscopy, 
the A and B profile changed to C or D in 79% of patients. The change of profile from baseline to 
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follow up in patients with inactive disease at follow-up endoscopy was statistically significant 
(P=0.014). Patients with C or D profile at baseline maintained this profile largely when there 
was inactive endoscopic disease at follow-up (86%). 
CD (n=85)*
UC (n=41)*
Healthy 
controls (n=19)
A (TN › 40%) B (TCM › 40%) C (TEM › 40%) D (equally divided TN, TCM, TEM) 
0 10 20 30 40 50 60 70 80 90 100%
Figure 5. Different intestinal T cell maturation profiles at baseline in healthy controls and IBD 
patients.
*in two IBD patients (1 UC and 1 CD) the maturation profiles were not determined (technical reasons)
Predicting disease course in UC 
We determined the association between baseline lymphocyte subsets and disease course in 
UC patients with a follow-up duration of longer than one year (n=33, 79% of all UC patients). 
Of these patients, 27 had a disease exacerbation during follow-up and six patients retained 
remission. Their follow-up duration was comparable (respectively a median of 26 months 
(IQR 19-54) and 38 months (20-56), P=0.80). During their follow-up, 13 UC patients used 
5-ASA as highest treatment strategy (39%), three patients needed steroids as highest step 
(9%), 12 patients needed an immunomodulator (36%), two patients used anti-TNF as highest 
treatment step (6%), and three UC patients ultimately needed resective surgery (9%). Follow-
up duration of these groups was not different (P=0.10). UC patients with 5-ASA as highest 
treatment strategy (n=13) had lower baseline percentages of CD3+ cells (median 48% (43-63), 
P=0.03) than patients in need of step-up treatment (n=20, median 62% (50-71)). Patients with 
an immunomodulator as highest treatment strategy (n=12) had higher baseline percentages of 
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CD3+ cells (median 65% (57-78), P=0.005) than patients who only needed 5-ASA and/or steroids 
(n=16, 49% (44-66)). 
There were no associations between the percentages of lymphocyte subsets at baseline and the 
following disease outcomes: surgery, biologics, relapsing disease, or future disease severity.
Predicting disease course in CD 
We determined the association between lymphocyte subsets at baseline and disease course 
in CD patients with a follow-up duration of longer than one year (n=77, 90% of all CD patients). 
Disease exacerbation occurred in 43 CD patients (56%) and 34 patients (44%) retained remission, 
with comparable follow-up duration between these groups (P=0.10). From this group, three 
CD patients (4%) only used 5-ASA during follow-up, nine patients (12%) only needed steroids, 
34 patients (44%) used an immunomodulator as highest treatment step, 22 patients (29%) 
used anti-TNF as highest treatment strategy and nine CD patients (12%) ultimately needed 
resective surgery. Follow-up duration of the groups was generally comparable, except between 
the surgery and steroid groups (P=0.03). Compared with uncomplicated inflammatory disease 
(B1, n=60), future stricturing or penetrating disease (B2/B3, n=17) was associated with higher 
baseline percentages of CD4+ cells (median 74% (IQR=65-79) vs. 65% (IQR=52-73), P=0.02) and 
higher baseline percentages of Tregs (median 15% (IQR=9-23) vs. 11% (IQR=7-15) P=0.04). 
Follow-up duration was comparable between these two groups (P=0.49). 
Abdominal surgery was associated with higher baseline percentages of Tregs compared with 
patients who did not need surgery (median percentages of Tregs 15% (IQR=14-19) vs. 10% 
(IQR=7-15), P=0.014). However, after correction for follow-up duration this was not significant 
anymore (P=0.051). Steroids as highest treatment modality (n=9) were associated with lower 
baseline percentages of Tregs (median 8% (IQR=5-10), P=0.014) compared with patients 
needing for step-up treatment (n=65, median 11% (IQR=8-16)). This remained significant after 
correction for follow-up duration (P=0.033).
DISCUSSION
In the present study, marked differences were demonstrated in intestinal T lymphocyte subset 
composition of IBD patients with active endoscopic disease when compared with HC and patients 
in with inactive endoscopic disease. IBD patients at diagnosis displayed higher percentages of 
CD4, Tregs and TCM with lower percentages of CD8 and CD103 T lymphocytes. Patients with 
active endoscopic disease at follow-up analysis maintained the same compositions of T cell 
subsets as at the moment of diagnosis with even lower percentages of CD8 T lymphocytes. This 
confirms consistency of T cell subset composition in time. Follow-up biopsy specimens of IBD 
patients with inactive endoscopic disease showed recovery of these subsets to a T lymphocyte 
composition, comparable to HC. Lymphocyte subset percentages were associated with 
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endoscopic disease activity. Furthermore, in UC lower baseline percentages of CD3 cells were 
associated with a milder disease course without the need of step-up to an immunomodulator, 
whereas in CD higher baseline percentages of CD4 and higher percentages of Tregs were 
associated with a more complicated disease course.
There were no differences found between ileum and colon regarding lymphocyte subsets: the 
composition of subsets seems more disease related than location related. This is endorsed 
by the association of the different lymphocyte subsets with endoscopic disease activity. 
Differences in lymphocyte subsets were more pronounced in UC than in CD patients. This 
might be explained by the fact that UC is characterised by more continuous inflammation 
conveyed to the mucosa and submucosa with high chances that biopsy specimens from these 
patients are abundantly inflamed, whereas in CD biopsy samples might have been taken from 
the edge of an ulcer with partly uninflamed tissue. 
Intestinal inflammation in IBD has been attributed to CD4 subsets based on animal models 
and cytokine expression in the gut mucosa 23. However, auto-reactive CD8 cells have also been 
suggested as instigators of the disease by destruction of epithelial cells after which exposure 
to luminal antigens may attract and expand the CD4 lineage exacerbating inflammation 24. The 
imbalance that we found of increased CD4 with decreased CD8 frequencies in active endoscopic 
IBD at baseline and follow-up seems to represent a CD4 expansion over CD8, but cannot 
provide further information on the real instigators of disease. The imbalance was normalised 
in the endoscopically inactive mucosa of IBD patients in remission, approaching comparable 
frequencies to HC. The percentages CD8 and CD4 T cells that we found in the intestines of 
controls was consistent with a previous study in organ donors 25. In our study in CD patients, 
higher baseline percentages of CD4 were associated with the development of strictures or 
penetrating disease. This could represent increased expansion of (proinflammatory) CD4 
lymphocytes accompanied by Treg expansion, in an (unsuccessful) attempt to diminish 
inflammation, leading to disease complications by unknown mechanisms that need to be 
investigated further. 
Tregs are involved in the maintenance of intestinal homeostasis by suppressing abnormal 
responses to enteric antigens by direct interaction with other cells and through secretion of anti-
inflammatory cytokines like TGF-beta and IL-10 26. In this study, we showed that IBD patients 
have increased percentages of Tregs at diagnosis (always with active endoscopic disease) and 
when there is active endoscopic disease during follow-up, whereas percentages decrease 
significantly in the same patients at times of inactive endoscopic disease. Furthermore, in 
CD patients, higher baseline percentages of Tregs were associated with a more complicated 
disease course with strictures or penetration and a trend was observed towards more abdominal 
surgeries. Lower baseline percentages of Tregs in CD patients was associated with a milder 
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course with steroids as highest treatment step. It is tempting to speculate about a hampered 
function of Tregs in CD to be compensated by numbers. Increased mucosal Treg frequencies 
have been shown in active IBD before 27. This could represent active recruitment and local 
expansion of these cells, attempting to suppress inflammation. However, this expansion is 
apparently not sufficient to control inflammation, possible due to the still too small number of 
cells. Another explanation might be that their function is impaired by upregulation of Smad7 
in IBD patients, which inhibits TGF-beta signalling, thereby impairing the suppression of T cell 
activation and proliferation but possibly also the differentiation of naïve T cells into Tregs 28,29. 
Finally, there is evidence that transformation of Tregs into proinflammatory Th17 cells could 
also contribute to uncontrolled inflammation 26.
We demonstrated that IBD patients with active endoscopic disease had lower percentages of 
CD103+ T lymphocytes compared to HC, and a significant increase of percentages of CD103+ T 
lymphocytes in patients with endoscopic inactive disease at follow-up endoscopy. CD103 is the 
integrin αE of αEβ7 expressed on several immune cell subsets and its expression is thought 
to contribute to the retention of T lymphocytes within the mucosa. Our findings suggest a less 
prominent role for CD103+ T cells as pathogenic factor in IBD patients than previously assumed, 
as it was thought to be upregulated in active endoscopic disease 30-32. Therefore, it would be 
very interesting to study the CD103+ cell subpopulations in more detail with the upcoming 
development of anti-β7 treatment. The function of the αEβ7+ T lymphocytes needs to be further 
investigated. αEβ7 is present on tissue-resident-memory T cells (TRM, mainly on CD8
+ T cells) 
with an immunosurveillance and protective function33. Recently, lung-derived CD103+TRM 
cells were shown to possess a gene-expression programme associated with the inhibition of 
T cell activation, which might play a role in preventing excessive immunoreactivity 34. αEβ7+ 
T lymphocytes might even be necessary to achieve or maintain remission in patients and a 
definitive pathogenic role of these cells in IBD has not yet been shown. Thus, from a mechanistic 
point of view, its blockade remains questionable 35.
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CONCLUSION
The intestinal T cell infiltrate in IBD patients with active endoscopic disease is composed of 
increased CD4+ T cells, Tregs and TCM, with lower percentages of CD8
+ T cells and CD103+ T 
cells compared with HC and endoscopically inactive IBD. After patients entered endoscopic 
remission, the lymphocyte subset composition of the gut recovered to percentages comparable 
with HC. Baseline percentages of CD3, CD4 and Tregs were associated with disease outcome in 
this study. Further research is needed to demonstrate the predictive value of these lymphocyte 
subsets. Knowledge of intestinal immune subsets at baseline and during follow-up could guide 
the use of new drugs and should be incorporated in the early phases of drug development to 
identify predictors of response. 
CHAPTER 4
82
REFERENCES
1. Van Assche G, Dignass A, Panes J, et al. The second european evidence-based consensus 
on the diagnosis and management of crohn’s disease: Definitions and diagnosis. J Crohns 
Colitis 2010;4:7-27.
2. Dignass A, Eliakim R, Magro F, et al. Second european evidence-based consensus on the 
diagnosis and management of ulcerative colitis part 1: Definitions and diagnosis. J Crohns 
Colitis 2012;6:965-90.
3. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the 
inflammatory bowel diseases with time, based on systematic review. Gastroenterology 
2012;142:46-54 e42; quiz e30.
4. Louis E, Collard A, Oger AF, et al. Behaviour of crohn’s disease according to the vienna 
classification: Changing pattern over the course of the disease. Gut 2001;49:777-82.
5. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV, Jr. Risk factors associated 
with progression to intestinal complications of crohn’s disease in a population-based 
cohort. Gastroenterology 2010;139:1147-55.
6. Yarur AJ, Strobel SG, Deshpande AR, Abreu MT. Predictors of aggressive inflammatory 
bowel disease. Gastroenterol Hepatol (N Y) 2011;7:652-9.
7. Billiet T, Ferrante M, Van Assche G. The use of prognostic factors in inflammatory bowel 
diseases. Curr Gastroenterol Rep 2014;16:416.
8. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected 
european cohort followed for 10 years. Gastroenterology 2007;132:507-15.
9. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of 
ulcerative colitis: Results from a population-based inception cohort (ibsen study). Scand J 
Gastroenterol 2009;44:431-40.
10. Moum B, Ekbom A, Vatn MH, et al. Clinical course during the 1st year after diagnosis in 
ulcerative colitis and crohn’s disease. Results of a large, prospective population-based 
study in southeastern norway, 1990-93. Scand J Gastroenterol 1997;32:1005-12.
11. Lee JC, Lyons PA, McKinney EF, et al. Gene expression profiling of cd8+ t cells predicts 
prognosis in patients with crohn disease and ulcerative colitis. The Journal of clinical 
investigation 2011;121:4170-9.
12. Hart AL, Lomer M, Verjee A, et al. What are the top 10 research questions in the treatment 
of inflammatory bowel disease? A priority setting partnership with the james lind alliance. 
J Crohns Colitis 2017;11:204-11.
13. Maynard CL, Weaver CT. Intestinal effector t cells in health and disease. Immunity 
2009;31:389-400.
14. Marsal J, Agace WW. Targeting t-cell migration in inflammatory bowel disease. Journal of 
internal medicine 2012;272:411-29.
INTESTINAL T CELL SUBSET PROFILING IN IBD
83
4
15. Monteleone G, Caprioli F. T-cell-directed therapies in inflammatory bowel diseases. Clin 
Sci (Lond) 2010;118:707-15.
16. Horjus Talabur Horje CS, Middendorp S, van Koolwijk E, et al. Naive t cells in the gut 
of newly diagnosed, untreated adult patients with inflammatory bowel disease. Inflamm 
Bowel Dis 2014;20:1902-9.
17. Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, 
simplified endoscopic activity score for crohn’s disease: The ses-cd. Gastrointest Endosc 
2004;60:505-12.
18. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and 
serological classification of inflammatory bowel disease: Report of a working party of the 
2005 montreal world congress of gastroenterology. Can J Gastroenterol 2005;19 Suppl 
A:5A-36A.
19. Harvey RF, Bradshaw JM. A simple index of crohn’s-disease activity. Lancet 1980;1:514.
20. Maag-Darm-Leverartsen NVv. Richtlijn diagnostiek en behandeling van inflammatoire 
darmziekten bij volwassenen. Haarlem: Kwaliteitsinstituut voor de Gezondheidszorg CBO 
2008: 1-299.
21. Larbi A, Fulop T. From “truly naive” to “exhausted senescent” t cells: When markers predict 
functionality. Cytometry Part A : the journal of the International Society for Analytical 
Cytology 2014;85:25-35.
22. Team RC. R: A language and environment for statistical computing. 2016.
23. Shale M, Schiering C, Powrie F. Cd4(+) t-cell subsets in intestinal inflammation. 
Immunological reviews 2013;252:164-82.
24. Cheroutre H. In ibd eight can come before four. Gastroenterology 2006;131:667-70.
25. Sathaliyawala T, Kubota M, Yudanin N, et al. Distribution and compartmentalization of 
human circulating and tissue-resident memory t cell subsets. Immunity 2013;38:187-97.
26. Sun M, He C, Cong Y, Liu Z. Regulatory immune cells in regulation of intestinal inflammatory 
response to microbiota. Mucosal immunology 2015;8:969-78.
27. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory cd4+ 
cd25(high) t cells in inflammatory bowel disease. Gastroenterology 2005;128:1868-78.
28. Chen W, Konkel JE. Tgf-beta and ‘adaptive’ foxp3(+) regulatory t cells. J Mol Cell Biol 
2010;2:30-6.
29. Boschetti G, Kanjarawi R, Bardel E, et al. Gut inflammation in mice triggers proliferation 
and function of mucosal foxp3+ regulatory t cells but impairs their conversion from cd4+ t 
cells. J Crohns Colitis 2017;11:105-17.
30. Stefanich EG, Danilenko DM, Wang H, et al. A humanized monoclonal antibody targeting 
the beta7 integrin selectively blocks intestinal homing of t lymphocytes. Br J Pharmacol 
2011;162:1855-70.
31. Vermeire S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: 
A randomised, controlled, phase 2 trial. Lancet 2014;384:309-18.
CHAPTER 4
84
32. Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase i study of etrolizumab 
(rhumab beta7) in moderate to severe ulcerative colitis. Gut 2013;62:1122-30.
33. Mueller SN, Mackay LK. Tissue-resident memory t cells: Local specialists in immune 
defence. Nat Rev Immunol 2016;16:79-89.
34. Hombrink P, Helbig C, Backer RA, et al. Programs for the persistence, vigilance and 
control of human cd8+ lung-resident memory t cells. Nat Immunol 2016;17:1467-78.
35. Smids C, Horjus Talabur Horje CS, van Wijk F, van Lochem EG. The complexity of alpha e 
beta 7 blockade in inflammatory bowel diseases. J Crohns Colitis 2017;11:500-8.
INTESTINAL T CELL SUBSET PROFILING IN IBD
85
4
SUPPLEMENTARY TABLES
Supplementary table 1. Baseline lymphocyte subsets in Crohn’s disease (CD) patients with solitary 
ileal and colonic disease. Median (interquartile range IQR) are reported.
CD solitary ileal disease CD solitary colonic disease P-value 
Number of patients 30 17
CD3+ as % of lymphocytes 51 (39-66) 62 (48-68) 0.14
CD3+CD4+ as % of T cells 70 (52-78) 67 (58-72) 0.63
CD3+CD8+ as % of T cells 26 (20-36) 28 (23-32) 0.62
CD3+CD103+ as % of T cells 15 (8-36) 15 (9-34) 0.56
TN* as % of T cells
20 (9-33) 26 (12-44) 0.44
TCM*as % of T cells
41 (25-48) 38 (25-44) 0.37
TEM* as % of T cells
27 (10-43) 25 (7-47) 0.94
Treg* as % of T cells 12 (6-17) 11 (9-13) 0.67
*Subsets were defined as described in methods: TN by CD3
+CD27+CD45RA+, TCM by CD3
+CD27+CD45RA-, 
TEM by CD3
+CD27-CD45RA- and Treg by CD3+CD4+CD25+Foxp3+
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Supplementary table 2. Fold change (FC) of different lymphocyte populations at follow-up endoscopy 
with active or inactive endoscopic disease when compared to their baseline values (all active disease), 
looking at al IBD patients (n=64) and subdividing CD (n=43) and UC (n=21).
%CD3 %CD4 %CD8 %CD103 %TN %TCM %TEM %Treg
IBD 
inactive 
(n=39) 
1.12 
(0.84-1.46)
0.78 
(0.58-0.99)
1.46 
(1.11-2.43)
2.43 
(1.40-6.15)
0.45 
(0.13-1.12)
0.55 
(0.25-0.96)
1.48 
(1.05-3.72)
0.52 
(0.29-0.78)
P-value* 0.047 0.001 0.0001 0.0001 0.002 0.0001 0.0001 0.0001
IBD 
active 
(n=25)
0.92 
(0.75-1.15)
1.05 
(0.98-1.13)
0.76 
(0.56-0.95)
0.78 
(0.26-1.63)
1.28 
(0.60-1.73)
0.97 
(0.68-1.22)
0.84 
(0.37-1.20)
0.87 
(0.63-1.23)
P-value* 0.367 0.050 0.016 0.618 0.426 0.648 0.236 0.126
CD inactive 
(n=32) 
1.18 
(0.84-1.50)
0.78 
(0.58-0.96)
1.43 
(1.07-2.07)
2.03 
(1.40-6.87)
0.50 
(0.13-1.23)
0.55 
(0.30-0.98)
1.34 
(1.00-2.96)
0.52 
(0.30-0.67)
P-value* 0.071 0.003 0.001 0.0001 0.020 0.001 0.003 0.0001
CD active 
(n=11) 
0.94 
(0.84-1.13)
1.05 
(1.03-1.12)
0.80 
(0.63-0.90)
0.83 
(0.18-1.60)
1.30 
(0.42-1.62)
0.90 
(0.49-1.20)
0.95 
(0.30-1.15)
0.80 
(0.57-0.98)
P-value* 0.859 0.056 0.041 0.824 0.789 0.423 0.508 0.012
UC inactive 
(n=7) 
1.09 
(0.76-1.31)
0.71 
(0.61-1.08)
2.40 
(1.12-2.84)
5.20 
(1.40-5.58)
0.20 
(0.05-0.91)
0.40 
(0.12-0.73)
3.50 
(1.27-4.76)
0.58 
(0.14-1.63)
P-value* 0.398 0.236 0.128 0.028 0.043 0.237 0.028 0.293
UC active 
(n=14) 
0.88 
(0.64-1.19)
1.04 
(0.95-1.25)
0.71 
(0.55-1.15)
0.77 
(0.29-2.21)
1.26 
(0.91-2.17)
1.00 
(0.76-1.34)
0.64 
(0.38-1.47)
0.94 
(0.71-1.65)
P-value* 0.220 0.209 0.133 0.396 0.099 0.969 0.346 0.834
* Wilcoxon matched-pairs signed-rank test, comparing follow-up lymphocyte subsets to baseline 
lymphocyte subsets
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Supplementary table 3. Intestinal lymphocyte populations at follow-up endoscopy from CD patients 
with endoscopic inactive CD (SES-CD<4) or endoscopic active CD (SES-CD>3). Medians (interquartile 
range) are reported.
Inactive CD (n=32) Active CD (n=11) P-value IBD patients
FU duration in months 36 (13-53) 24 (5-40) 0.138
CD3+ as % of lymphocytes 63 (46-73) 59 (49-66) 0.651
CD3+CD4+ as % of T cells 49 (40-61) 73 (55-82) 0.015
CD3+CD8+ as % of T cells 41 (31-53) 22 (16-32) 0.009
CD3+CD103+ as % of T cells 48 (27-72) 23 (6-32) 0.004
TN* as % of T cells
7 (4-19) 16 (7-43) 0.180
TCM*as % of T cells
19 (9-35) 39 (19-47) 0.064
TEM* as % of T cells
45 (25-77) 29 (3-43) 0.056
Treg* as % of T cells 4 (3-7) 8 (6-13) 0.003
*Subsets were defined as described in methods: TN by CD3
+CD27+CD45RA+, TCM by CD3
+CD27+CD45RA-, 
TEM by CD3
+CD27-CD45RA- and Treg by CD3+CD4+CD25+Foxp3+
Supplementary table 4 Intestinal lymphocyte populations at follow-up endoscopy from UC patients 
with endoscopic inactive UC (MAYO=0) or endoscopic active UC (MAYO>0). Medians (interquartile 
range) are reported.
Inactive UC (n=7) Active UC (n=14) P-value UC patients
FU duration in months 14 (12-23) 21 (15-39) 0.149
CD3+ as % of lymphocytes 55 (46-85)  50 (40-55) 0.224
CD3+CD4+ as % of T cells 51 (39-66) 78 (74-86) 0.0001
CD3+CD8+ as % of T cells 41 (25-54) 16 (11-23) 0.0001
CD3+CD103+ as % of T cells 46 (22-58) 8 (3-16) 0.0001
TN* as % of T cells
5 (1-10) 24 (13-34) 0.0001
TCM*as % of T cells
12 (7-40) 53 (45-66) 0.006
TEM* as % of T cells
62 (17-81) 11 (6-24) 0.031
Treg* as % of T cells 6 (3-11) 10 (8-15) 0.056
*Subsets were defined as described in methods: TN by CD3
+CD27+CD45RA+, TCM by CD3
+CD27+CD45RA-, 
TEM by CD3
+CD27-CD45RA- and Treg by CD3+CD4+CD25+Foxp3+
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Supplementary table 5. Baseline intestinal lymphocyte populations in patients with follow-up 
endoscopy classified as endoscopic inactive IBD (MAYO=0/ SES-CD<4) or endoscopic active IBD 
(MAYO>0/ SES-CD>3). Medians (interquartile range) are reported.
Baseline % of lymphocyte 
subsets from patients with 
inactive IBD at follow-up 
endoscopy (n=39)
Baseline % of lymphocyte 
subsets from patients with 
active IBD at follow-up 
endoscopy (n=25)
P-value
CD3+ as % of 
lymphocytes
52 (43-65) 57 (48-68) 0.487
CD3+CD4+ as % of 
T cells
69 (48-78) 74 (59-81) 0.339
CD3+CD8+ as % of 
T cells
25 (19-32) 23 (18-34) 0.773
CD3+CD103+ as % 
of T cells
14 (9-29) 13 (7-26) 0.644
TN* as % of T cells
15 (9-34) 18 (9-27) 0.879
TCM*as % of T cells
37 (26-52) 47 (38-56) 0.211
TEM* as % of T cells
24 (11-47) 25 (12-32 0.784
Treg as % of T cells 10 (8-17) 12 (9-17) 0.552
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Supplementary table 6. Baseline intestinal lymphocyte populations in CD patients with follow-up 
endoscopy classified as endoscopic inactive CD (SES-CD<4) or endoscopic active CD (SES-CD>3). 
Medians (interquartile range) are reported.
Baseline % of lymphocyte 
subsets from patients with 
inactive CD at follow-up 
endoscopy (n=32) 
Baseline % of lymphocyte 
subsets from patients with 
active CD at follow-up 
endoscopy (n=11)
P-value 
CD3+ as % of 
lymphocytes
52 (43-64) 57 (49-68) 0.371
CD3+CD4+ as %
of T cells
67 (49-78) 65 (50-78) 0.880
CD3+CD8+ as % 
of T cells
25 (21-32) 29 (21-37) 0.315
CD3+CD103+ as 
% of T cells
19 (9-28) 15 (12-39) 0.573
TN* as % of T cells
14 (8-36) 26 (15-30) 0.652
TCM*as % of T cells
37 (26-50) 44 (32-50) 0.535
TEM* as % of T cells
29 (11-53) 27 (20-53) 0.888
Treg as % of T cells 11 (8-17) 14 (11-18) 0.255
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Supplementary table 7. Baseline intestinal lymphocyte populations in UC patients with follow-up 
endoscopy classified as endoscopic inactive UC (MAYO=0) or endoscopic active UC (MAYO>0). Medians 
(interquartile range) are reported.
Baseline % of lymphocyte 
subsets from patients with 
inactive UC at follow-up 
endoscopy (n=7)
Baseline % of lymphocyte 
subsets from patients with 
active UC at follow-up 
endoscopy (n=14) 
P-value
CD3+ as % of 
lymphocytes
58 (44-70) 55 (48-65) 1.000
CD3+CD4+ as %
of T cells
72 (36-87) 78 (62-83) 0.535
CD3+CD8+ as % of 
T cells
19 (12-48) 21 (13-29) 0.971
CD3+CD103+ as % of T 
cells
12 (5-30) 11 (6-17) 0.913
TN* as % of T cells
22 (11-34) 14 (8-24) 0.393
TCM*as % of T cells
33 (26-56) 53 (45-60) 0.211
TEM* as % of T cells
17 (4-25) 16 (10-30) 0.643
Treg as % of T cells 9 (6-16) 10 (8-15) 0.659
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Integrin alphaEbeta7 in IBD: friend or foe?
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Dear editor:
We read with great interest the article of Tew et al. on the association between increased 
gene expression of integrin αE and granzyme A (GZMA) and clinical remission to etrolizumab 
treatment in patients with ulcerative colitis (UC) 1. This report follows the recent publication of 
the phase two trial on etrolizumab, describing its moderate potential as induction therapy for 
UC 2. Etrolizumab is a humanized monoclonal IgG1 antibody that targets integrin subunit β7 
and therefore both αEβ7 and α4β7. It does not target GZMA expression. Baseline characteristics 
of the study by Tew et al. showed statistically significant lower endoscopy, and histology score 
in patients with αEhigh gene expression compared with patients with αElow gene expression. 
Moreover, a significant histological improvement after etrolizumab was only found in the αElow 
gene expression group and not in the αEhigh gene expression group. The clinical relevance of 
these observations is denoted as unclear, but αEhigh expression might in fact reflect an intrinsic 
protective immunological mechanism in these patients. This opposes the emerging pathogenic 
role attributed to αEβ7 in UC by Tew et al, based on, inter alia, an unpublished paper from 2014. 
The role of αEβ7 in physiological conditions as well as in inflammatory bowel disease (IBD) is 
less distinct than that of the gut homing α4β7. In murine colitis anti-β7 has shown contradictory 
results 3,4. We recently showed that newly diagnosed, untreated IBD patients had statistically 
significant lower percentages of αE+ T cells in their actively inflamed intestinal biopsy specimen 
(Crohn’s disease: 15% and UC: 11%) compared to healthy controls (30%, P=0.02), challenging 
the pathogenic role in IBD 5. Furthermore, in contrast to the present study of Tew et al, which 
showed a higher gene expression of αE in anti-TNF-naïve clinical remitters, Arijs et al found 
no increased gene expression of αE nor β7 in IBD patients when compared to healthy controls 
or Infliximab responders 6. The gene expression of the principal ligand of αEβ7, E-cadherin, 
was decreased in active colonic IBD when compared with healthy controls, and the use of this 
pathway as treatment target was seriously challenged in this paper. E-cadherin was also down 
regulated in active UC in the phase two etrolizumab trial, where E-cadherin expression even 
increased in clinical remission after treatment 2. 
The authors describe increased GZMA gene expression in CD4+αE+ mucosal T cells compared 
to CD4+αE- cells, with strikingly only 2.86% of all CD4+ cells being αE+β7+. On the other hand, 
in CD8+αE+ T cells, with 48.9% of all CD8+ cells expressing αEβ7, no difference is found for 
GZMA expression. Recently, a regulatory CD8+αE+ T cell subset was found that could inhibit 
CD4+ proliferation in vitro and attenuated adoptively transferred ileitis in mice 7. In humans, 
alloantigen induced CD8+αE+ T cells also showed functional regulatory characteristics 8. 
Amongst others, etrolizumab might also affect this subset, which could explain why higher 
doses led to worse results with respect to clinical remission (41% in 100 mg group vs. 18% in 
300 mg+LD group of GZMA high patients).
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In conclusion we believe there is currently insufficient evidence to argument that αEβ7 is a 
“foe” in IBD. One should keep in mind that beneficial effects of etrolizumab may also rely on its 
effect on the α4β7 integrin. We greatly support the effort of the authors to define biomarkers/
subgroups in IBD to reach personalized medicine. However, first consistent therapeutic benefit 
from etrolizumab treatment in UC patients’ needs to be proven in the current phase three trial.
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ABSTRACT
Monoclonal antibodies targeting integrins are emerging as new treatment option in Inflammatory 
Bowel Diseases. Integrins are molecules involved in cell adhesion and signalling. After the 
successful introduction of anti-α4β7, currently anti-β7 is under evaluation in a phase three 
trial. Anti-β7 blocks both α4β7/MAdCAM-1 and αEβ7/E-cadherin interaction, targeting both the 
homing to and the retention in the gut of potential pathological T cells. Since the physiological 
and potential pathological role of immune cells expressing αEβ7 is less distinct than of those 
expressing α4β7. An overview of the current state of knowledge on αEβ7 in mice and human in 
both health and Inflammatory Bowel Diseases is presented here, also addressing the potential 
consequences of anti-β7 treatment. 
KEYWORDS
Integrin, anti-β7, inflammatory bowel diseases, CD103, immunity
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INTRODUCTION
Anti-integrin therapy targeting T-cell trafficking to the gut is evolving for patients with 
Inflammatory Bowel Diseases (IBD) 1. Integrins are transmembrane molecules that mediate 
cell-to-cell and cell-to-extracellular-matrix interactions. They are obligate heterodimers 
composed of an α and β subunit, each penetrating the plasma membrane. Subunit β7 can 
form a heterodimeric integrin with α4 (α4β7), which can bind to Mucosal Addressin Cell 
Adhesion Moleclule-1 (MAdCAM-1) expressed on gut endothelial cells (figure 1). α4β7 can 
also bind vascular cell adhesion molecule-1 and the extracellular matrix protein fibronectin 2. 
Subunit β7 can also form a heterodimeric integrin with αE (CD103) to form αEβ7. In turn, αE 
can only form a heterodimeric integrin with β7. For clarity, here we refer to CD103 expression 
when a monoclonal antibody (mAb) recognizes the αE subunit on the cell surface (by flow 
cytometric or immunohistochemical analysis). Since the expression of integrins on cell surface 
is constrained to the amount of α subunits inside the cell (as there is an excess of β subunits 
in the cell), and free subunits are not found on the cell surface, CD103 expression represents 
αEβ7 expression 3. The only known ligand for αEβ7 is E-cadherin, an adhesion molecule on 
epithelial cells that is not found on endothelial cells 4. αEβ7 expression on T lymphocytes 
is thought to contribute to their retention within the gut, whereas α4β7 is proposed as the 
major gut homing receptor on circulating lymphocytes. Anti-α4β7 blocks the gut specific α4β7/
MAdCAM-1 interaction and it has been approved for the treatment of moderate to severe 
ulcerative colitis (UC) and Crohn’s disease (CD). The mechanism of action of anti-β7 is aiming 
to block the binding of α4β7 and αEβ7 to MAdCAM-1 and E-cadherin respectively, rather than 
depleting the β7 expressing cells. Anti-β7 is mechanistically expected to have a broader, and 
potentially stronger, effect than anti-α4β7, given the dual approach mechanism of action 5. 
By intervening with the α4β7/MAdCAM-1 interaction the anti-β7 should block the homing of 
α4β7+ lymphocytes to the gut, while blocking the αEβ7/E-cadherin interaction should disrupt 
the retention of αEβ7+ lymphocytes inside the gut epithelium. However, since αEβ7 is also 
expressed on other immune cells and not exclusively in the gut (see below), anti-β7 treatment 
may have implications beyond T lymphocyte blockade. Here we present an overview of the 
current knowledge on αEβ7 expression and blockade in health and IBD. 
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Figure 1 Integrin expression in the gut and anti-integrin treatment. 
α4β7 expressing T lymphocytes enter the gut through high endothelial venules expressing MAdCAM-1. This 
interaction is prohibited by anti-α4β7. In a Transforming Growth Factor-β (TGF-β) dependent manner, α4β7 
can be downregulated on lamina propria lymphocytes (LPL), while αEβ7 is upregulated. TGF-β is secreted 
by intestinal epithelial cells and αEβ7 expressing dendritic cells (DCs). Some of the αEβ7 LPLs are destined 
to reside in the intestinal epithelium as intraepithelial lymphocytes. They interact with E-cadherin on the 
epithelial cells. Anti-β7 blocks both α4β7/ MAdCAM-1 and αEβ7/E-cadherin interaction. Other immune 
cells like DCs and regulatory T cells can also express αEβ7 and are therefore likely to be inhibited by 
anti-β7.
HUMAN β7 EXPRESSING IMMUNE CELLS
Immune cells expressing α4β7 can be found in the gastrointestinal tract (oesophagus, stomach, 
small intestine, colon), but also in the cervix, prostate, urinary bladder, salivary gland, tonsils, 
thymus, lymph nodes, spleen and peripheral blood 6. α4β7 is expressed on B and T lymphocytes 
(more abundantly on CD4+ than on CD8+ cells), natural killer cells, basophils and eosinophils, 
but also on innate lymphoid cells and bone marrow precursors required for the induction of 
tolerogenic gut-associated dendritic cells (DCs) 7-11. The proportion of CD4+ T lymphocytes in 
healthy human blood co-expressing CD45RO (memory phenotype) and α4β7 was shown to be 
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36% 12. By blocking α4β7, one could expect a reduced recruitment of T lymphocytes into the 
intestine, given its high specificity for gut homing. However, it would also effect other immune 
subsets expressing α4β7 (as discussed in 13,14). After anti-α4β7 treatment in IBD patients, 
saturation of peripheral CD45RO+CD4+α4β7+ T lymphocytes was 90-95%15,16. There were no 
data presented on the examination of other cell subsets expressing α4β7 or of T lymphocyte 
subsets in biopsy specimens 15,16. Effects of anti-β7 treatment on T lymphocytes are discussed 
below. B cells were shown to accumulate in the periphery after β7 blockade (absolute numbers), 
but neither intestinal effects nor effects on other α4β7+ immune subsets were examined 17. 
Diverse immune cell subsets can induce CD103 (and therefore αEβ7) expression on their 
surface. These cells can be found in the spleen, thymus, skeletal muscle, heart, liver, kidney, 
skin, brain, gastrointestinal tract, urogenital tract and lungs 18-25. In the intestinal mucosa, the 
CD103+ immune cell subsets include intraepithelial T lymphocytes (IELs, CD103 expressed on 
the vast majority of IELs, mainly on CD8+ IELs) 24-26, lamina propria T lymphocytes (LPLs, CD103 
expressed on about half of LPLs, mainly on CD8+ LPLs) 24-26, subsets of DCs 27-30, intraepithelial 
innate lymphoid cells type 1 31, and regulatory T lymphocytes 32,33 (see figure 1). CD103 
expression has been described on colonic CD4+CD25+FoxP3+CD127lowCTLA-4+ regulatory T 
cells (phenotypic Tregs) 32. In addition, a regulatory alloantigen-induced CD8+CD103+ T-cell 
subset has been described in humans 34. Furthermore, intestinal epithelial cells were shown 
to induce suppressive CD8+CD103+ cells 33, suggestive of a regulatory CD103+ subset in the 
intestinal mucosa 33,34. The same research group underlined the relevance of these cells in 
maintaining mucosal tolerance, when they demonstrated the absence of this CD8+ regulatory 
activity in both UC and CD 35. Next to migratory subsets of T lymphocytes (central memory 
and effector memory) expressing α4β7 to grant them access to the gut, it has become clear 
that another, non-migratory, subset of T lymphocytes exists: tissue-resident memory T cells 
(TRM) 
36. These TRM cells reside in epithelial barrier tissues and deliver a prompt response 
to former encountered pathogens, independent of recruitment of migratory T cells from the 
blood. Therefore, TRM mediate the rapid protective immunity to infectious agents, which is a 
hallmark of adaptive immune memory. Migratory T cells can, when necessary, replenish the 
TRM compartment. CD103 has been described on a subset of TRM cells, more predominant 
on CD8+TRM than on CD4
+TRM cells (approximately 88% of CD8
+ LPL and 38% of CD4+ LPL 
in one human study 25 and 80% of CD8+ cells versus 15% of CD4+ cells in healthy human 
ileum and colon in another study 37). Around 40% of CD103+ cells in the gut were shown to 
express TRM marker CD69 
30. CD103 (αEβ7) expression on peripheral blood T lymphocytes is 
virtually absent (<2%) 37. Expression of CD103 on CD4+ and CD8+ T lymphocytes is mediated 
by the anti-inflammatory cytokine Transforming Growth Factor-β (TGF-β) 30,38,39 (figure 1). By 
blocking CD103, one could expect a reduced retention of T lymphocytes within the intestine, 
in particular the CD8+ subset, but also the TRM and Treg subpopulation. However the role and 
function of CD103 positivity of T cells, including TRM and Treg, in chronic inflammation has not 
yet been elucidated. Effects of specific α4β7 and αEβ7 blockade on the migration and retention 
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of different cell subsets would therefore be an interesting topic of investigation. Furthermore, 
since αEβ7 is not as gut-specific as α4β7, retention of αEβ7 expressing cells in other barrier 
tissues such as the lung and skin would also be affected. Even though the implications of β7 
blockade for other organs are still unclear, this might lead to unwanted side effects of anti-β7 
treatment in IBD patients. 
REGIONAL DIFFERENCES IN β7 EXPRESSION ALONG THE INTESTINE
Intestinal disease location differs greatly between different clinical phenotypes of UC and CD. 
Therefore, potential differences in the number of CD103 expressing immune cells in different 
bowel segments are relevant, and should be addressed when considering anti-β7 treatment 
(see figure 2). A regional difference of CD103 expressing cells was found in the gut of rhesus 
macaques with more CD103+ cells in the small intestine (±35% CD103+ cells/mm epithelium) 
than in the colon (±25%) 40. This correlated well with CD3 positivity, implying a decline of IEL 
numbers along the macaques’ intestine. The same results were found in healthy humans, 
with higher percentages of CD103 expressing IEL and LPL in ileum (median 84% CD103+IEL 
and 42% CD103+LPL) versus colon (median 56% CD103+IEL and 22% CD103+ LPL) 41. These 
findings are in line with another study describing a linear decrease of the number of cells 
expressing CD103 from ascending colon to rectum in healthy humans, which was contrarily to 
what the authors expected 42. Therefore, a direct relation between the number of CD103+ cells 
and the disease distribution in UC (increasing severity from distal to proximal colon) seems 
unlikely. Moreover, β7 blockade might show less effect in patients with disease limited to the 
rectum (proctitis) compared with involvement of the entire colon (pancolitis). 
In contrast with the decreasing presence of CD103+ T lymphocytes along the intestine, a 
reversed presence of CD103 expressing DCs was recently reported in humans, with lower 
proportions of CD103+ DCs in the proximal compared with distal colon 43. These authors also 
showed that healthy human colonic CD103+ DCs co-express β7 43. 
In healthy human ileum, α4 was expressed on 32% of IELs and 35% of LPLs whilst in left colon 
it was expressed on 48% of IELs and 58% of LPLs 41. In another study, the proportion colonic T 
lymphocytes in healthy humans expressing α4β7 was 72% 12.
It remains to be determined how different β7+ immune cell subsets are distributed along the 
intestine, but it would be important to assess their location and function profile in order to fully 
understand the consequences of their blockade.
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Figure 2. Healthy human expression of β7 immune subsets along the intestinal wall and in peripheral 
blood.
The number of T lymphocytes expressing αEβ7 is highest in ileum, with a descending gradient along the 
intestine showing lower numbers in de descending colon. On the other hand, frequencies of dendritic cells 
expressing αEβ7 are lower in the ascending colon than in the descending colon, with unknown expression 
in ileum. T lymphocytes expressing α4β7 are lower in ileum and higher in descending colon. αEβ7+ T 
lymphocytes are virtually absent in the peripheral blood compartment, with a more substantial presence 
of α4β7+ T lymphocytes. 
DENDRITIC CELLS EXPRESSING CD103
Dendritic cells are strategically positioned in the intestinal mucosa to capture antigen 
and play a key role in initiating and modulating immunogenic and tolerogenic responses. 
Different subsets can be discriminated by expression of surface markers and their functional 
characteristics. The subset of myeloid DCs (CD11c+CD123–HLADR+) co-expressing CD103 is 
specialized in generating regulatory T cell responses via TGF-β and retinoic acid 44,45. In mice, 
specific subsets of DCs were identified, with different capacity of peripheral Treg induction 46. 
Both subsets of DCs (CD103+ and CD103-) induced expression of the gut homing integrin 
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α4β7 on CD4+ T cells, but only CD103+ DCs were able to induce expression of C-C chemokine 
receptor 9 (CCR-9) on T cells 47. CCR-9 is a homing marker for the small bowel, as it binds 
to C-C motif ligand 25 on epithelial cells of the small intestine. Further investigation showed 
only CD103- DCs to be able to induce effector T lymphocytes that secreted proinflammatory 
cytokines (interleukin-6 and tumour necrosis factor-α (TNF-α)), whereas CD103+ DCs were 
responsible for inducing functionally suppressive FoxP3+Tregs 44. In mice, CD103 expression 
on DCs was found to be mandatory for the induction of Tregs that suppressed colitis and 
attenuated ileitis 47,48. The presence of a tolerogenic CD103+ DC population, able to drive Treg 
development, was also identified in the human gut 29. The literature regarding effects of DCs 
in CD103 knockout mice is discussed below. Lack of β7 expression in the innate immune 
compartment resulted in accelerated T cell-mediated colitis in β7-/-RAG2-/- mice, correlating 
with lower numbers of retinoic acid producing DCs 9. Furthermore, lack of β7+ DCs impaired 
induction of Foxp3+ and IL-10 producing Tregs 9. In a T cell-mediated model of colitis, a subset 
of CD103- DCs accumulating in the inflamed intestine, were shown to express E-cadherin and 
to produce colitogenic cytokines upon activation 49. After Fms-related tyrosine kinase 3 ligand 
administration this DC subset decreased in the lamina propria, whilst CD103+ DCs increased, 
resulting in the induction of CD4+CD25+FoxP3+ Tregs and attenuation of murine ileitis 48. We 
hypothesize that the decrease of proinflammatory CD103-E-cadherin+ DCs might be mediated 
by regulatory interaction of CD103 (DCs and Tregs) with E-cadherin resulting in immune 
suppression. 
Of note, Foxp3 is known to be a specific marker for functionally suppressive CD4+ Tregs in 
mice 50. The role of this marker for Tregs in human remains controversial, as activation of non-
Tregs can lead to transient Foxp3 expression without inducing a suppressive function 51. This 
does not concern the interpretation of the data presented here, as it mostly regards Tregs in 
mice, but caution should be taken when interpreting human data on this subject.
A dramatic loss of CD103+ intestinal DCs was observed during experimental colitis (CD4+CD62L+ 
transfer model and chronic Dextran sulphate sodium-colitis) in the lamina propria and 
mesenteric lymph nodes (MLN) compared with healthy mice 52. Recently, this was reaffirmed 
in Dextran sulphate sodium-colitis mice, with decreased frequencies of CD103+ DC subsets 
associated with a reduced ability to promote Treg generation 53. CD103+ DCs with similar 
phenotype and functions as in mice were also found in human MLN 30,44. Reduced numbers 
of CD103+ DCs were also described in the colonic biopsy specimen of patients with active UC 
compared with healthy controls 54. Similarly, statistically significant lower numbers of CD103+ 
DCs were reported in inflamed compared with non-inflamed gut mucosa of CD patients 55. The 
CD103+ DC population increased statistically significant after anti-TNF-α treatment 55. 
Taken together, these findings support a role for CD103+ DCs in the intestinal maintenance of 
immune homeostasis, as they are involved in Tregs induction in the gut. Therefore, blocking β7 
would not exclusively block αEβ7+ on T lymphocytes, but might also affect the CD103+ subset of 
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DCs and β7+ innate immune cells, thereby exercising a potentially negative influence on long-
term immune homeostasis. 
The process of Tregs induction by CD103+ DCs is dependent on TGF-β and potentiated by vitamin 
A metabolite retinoic acid. On the other hand, TGF-β can also induce formation of Th-17 cells in 
the presence of the pro-inflammatory cytokine IL-6 56 (see figure 3). Furthermore, as described 
earlier, TGF-β induces CD103 expression on both CD4+ and CD8+ T lymphocytes 30,38,39. TGF-β 
signalling is regulated through the SMAD-pathway. Overexpression of SMAD7 in transgenic 
mice completely impaired the TGF-β mediated up-regulation of CD103 expression on CD4+ 
T cells and reduced the number of intestinal IEL in these mice by 46%, compared with 
their wild-type littermates 57. To our knowledge, this has not yet been studied in humans. 
However, overexpression of SMAD7 was reported in the inflamed intestine of IBD patients, 
concomitantly to abnormally decreased TGF-β1 activity 58. An oral antisense therapy inhibiting 
SMAD7 was remarkably effective in inducing remission and clinical response in a phase two 
trial in CD patients 59. It is tempting to speculate that the inhibition of SMAD7 could ensure an 
increased functional TGF-β activity and might result in up-regulation of CD103 expression on 
T lymphocytes 57,60.
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Figure 3. Transforming Growth Factor- β (TGF-β) dependent immune balance between pro- and 
anti-inflammatory responses in the gut. 
CD4+CD25+FoxP3+ regulatory T lymphocytes (Tregs) can emerge when CD103+ dendritic cells (DCs) present 
antigen to naïve T lymphocytes (TN). This process is dependent on the presence of TGF-β and retinoic acid 
(RA). On the other hand, Th-17 lymphocytes are formed when CD103- DCs present antigen to TN in the 
presence of TGF-β and the proinflammatory cytokine interleukin-6 (IL-6). Additionally, IL-6 reduces Treg 
induction and RA reduces Th-17 lymphocyte induction.
CD103 AND E-CADHERIN EXPRESSION IN IBD PATIENTS
A detailed overview of different papers studying CD103 expression in IBD patients can be 
found in table 1. One study examined CD103 expression on IELs and LPLs in surgical colonic 
resection specimen of patients with CD (disease activity and location unclear), UC (both active 
and inactive disease, disease location unclear) and controls (colectomy due to colorectal 
carcinoma) 61. No difference in CD103 expression on IELs was observed between IBD patients 
and controls. Higher numbers of CD103+ LPLs were found in CD patients compared with UC 
patients and controls. In this study no difference regarding E-cadherin expression was found 
between patients and controls. Another study was performed on CD103 expression on IEL 
and LPL in the ileum and colon of CD patients (active and inactive disease taken together) 
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and healthy controls 41. In contrast with the aforementioned study, no difference was found 
for CD103 expression on LPL between CD and controls. Furthermore, decreased expression 
of CD103 was found on IEL in the ileum of CD patients compared to controls. The only cell 
subset with a statistically significant overexpression of CD103 was the CD3+CD25+ LPL of the 
left hemicolon, which also include Tregs. The same research group performed a pilot study 
in patients with CD, UC (partly under treatment with mesalazine and/or corticosteroids) 
and healthy controls 62. IL-2 expanded T cells were generated from inflamed colonic biopsy 
specimens. After expansion, increased CD103 expression was observed on CD3+ and CD8+ 
cells, but not on CD4+ cells, in CD patients compared to controls. In UC patients this was only 
demonstrated on the CD8+ subset and not CD4+ or overall CD3+ cells.
We previously described lower percentages of CD103+ T lymphocytes in actively inflamed 
intestinal biopsy specimens of newly diagnosed, untreated IBD patients (CD and UC), compared 
with biopsy specimens of healthy controls (P=0.02) 63. Recently, immunohistochemical analysis 
of CD103 expression in gut samples of unknown location demonstrated higher percentage of 
CD4+CD103+ cells in treated IBD patients compared to controls 30. However, the percentage of 
CD103+CD8+ cells did not differ between patients and controls. Altogether, there is no strong 
evidence for increased CD103 expression on T cells in the gut of IBD patients. At the level of 
gene expression of cell adhesion molecules, no statistically significant difference was found 
for gene expression of αE and β7 in the (inflamed) mucosa between active IBD patients and 
healthy controls or post-Infliximab treatment 64. Gene expression of E-cadherin in inflamed 
colonic samples of IBD was statistically significant decreased compared to healthy controls. 
The authors seriously challenged the use of this pathway as treatment target, as they observed 
no upregulation of αE or β7 in the inflamed IBD mucosa next to down-regulation of its principal 
ligand E-cadherin. On the other hand, support for the use of anti-α4β7 in patients with IBD was 
found in this study, as α4 and MAdCAM-1 gene expression was significantly increased in active 
inflammation and both decreased in Infliximab responders after therapy. 
Results on intestinal E-cadherin expression in IBD are also inconsistent, but most studies 
advocate a decreased expression. As mentioned, E-cadherin gene-expression was 
downregulated in active colonic IBD when compared with healthy controls 64. In line with 
this, immunohistochemical staining of colonic specimen of IBD patients showed decreased 
staining of E-cadherin at the mucosal edges of ulcerations in all active UC patients and in half 
of active CD patients. Non-ulcerated and non-inflamed mucosa showed normal E-cadherin 
expression 65. E-cadherin was downregulated in another study performed in UC patients 66. 
On the other hand, E-cadherin was upregulated (immunohistochemistry and mRNA) at sites 
adjacent to ulcerations, with absence inside the ulceration of ileal and colonic biopsy specimen 
of IBD patients with active disease 67. E-cadherin expression is likely to be adjusted to local 
CD103 expression. It is conceivable that decreased E-cadherin expression in gut mucosa of IBD 
patients might diminish the effect of anti-β7 treatment on retention of CD103+ T lymphocytes 
within the epithelium.
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Overall, the knowledge on CD103 and E-cadherin expression in IBD patients is most likely 
blurred by inhomogeneous patient cohorts including both active and inactive disease and under 
various types of anti-inflammatory treatment. Examining CD103 and E-cadherin together 
might provide more clarity on their expression and interaction. Furthermore, studies have only 
addressed CD103 expression on the total T cell population, while subpopulations may differ in 
expression levels and may also be affected differently by anti- β7 treatment. So far there is no 
convincing evidence of increased CD103 or β7-expression on T cell (subsets) in the inflamed 
gut mucosa of IBD patients.
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LESSONS FROM αEβ7 IN MOUSE MODELS
Most of the current knowledge on αEβ7 blockade is derived from animal models. Anti-β7 
treatment was shown to reduce (but not heal) colitic lesions in a CD45RBhighCD4+ T cell transfer 
model of murine colitis 68. In a study on anti-β7 treatment in SCID mouse after T cell transfer, 
mice were sacrificed 1.5 hours after anti-β7 administration 5. In this model, lower numbers 
of lymphocytes were found in the inflamed colon of treated mice and there was no apparent 
effect on the spleen. However, the observational period was too short to determine long-term 
effects. Contrarily, another study showed that the transfer of naïve T cells from β7 knockout 
mice into SCID mice only delayed the development of murine colitis (symptoms started after 
20 weeks instead of within 3-4 weeks) and did not alter the course of disease 69. β7 expression 
was not even a strict requirement for the localization of T lymphocytes to the mouse intestine 
(β7 knockout mice) and it was suggested that alternate pathways might compensate a lack 
of β7. Another study on β7 knockout mice demonstrated less pronounced colitis compared to 
wild-type mice, coinciding with decreased numbers of mucosal proinflammatory monocytes 70. 
Progenitors of these monocytes were shown to express β7, but expression of α4β7 and/or αEβ7 
was not studied individually. Anti-β7 treatment and β7 knockout models affect α4β7 and αEβ7 
expressing cells simultaneously. This impairs differentiation between the specific effects of 
anti-β7 treatment on homing (α4β7) or retention (αEβ7) of immune cells. 
Anti-CD103 treatment was able to prevent the development of colitis and ameliorated existing 
colitis in a TNP-OVA-immunized IL-2 knock-out mouse model 71. When mice were sacrificed 7 
days after the first anti-CD103 injection a reduction of CD4+ LPLs was seen, but, surprisingly, 
there was little effect on CD8+ T lymphocytes. Moreover, the treatment led to inflammation 
of the spleen. Another study failed to confirm any role of CD103 expressing T lymphocytes in 
the development of colitis and showed that accumulation of CD4+ T cells in the intestine did 
not require CD103 expressing T lymphocytes 47. Colitis developed normally in the absence of 
CD103 expressing T lymphocytes in a T cell transfer mouse model and regulatory CD103- T 
cells were still able to suppress colitis 47.
Overall, there is a broad range of effects in mice treated with anti-β7 or anti-CD103 and 
retention of T lymphocytes in the gut seemed to be compensated by influx of migratory T cells, 
in the absence of CD103 and β7. 
With respect to DC subsets, similar composition was found in Rag2-/- mice and CD103-/-
Rag2-/- mice, but the function of these DCs was not analysed. In another study, CD103-/- mice 
with a helminth infection displayed comparable frequencies of DCs with wild type mice 72. 
Unfortunately, the ability of these DCs to generate retinoic acid, Tregs and α4β7/CCR9 
expressing T lymphocytes was not analysed. On the other hand, in mice with induced diabetes, 
anti-CD103 immunotoxin (with a depleting effect on CD103+ cells) resulted in a dramatic loss 
of DCs and Tregs in the mesenteric lymph nodes 73. Therefore, even though the number of DCs 
present after CD103 knockout induction in mice, does not seem to differ, it is conceivable that 
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these DCs might have a more proinflammatory function. Another explanation could be, that 
DCs need β7 to exert their function of inducing suppressive Tregs or to block the function of 
CD103-E-cadherin+ DC subsets 11.
A regulatory CD8+CD103+ T cell subset that could inhibit CD4+ proliferation in vitro and attenuate 
adoptively transferred ileitis has also been described in mice 74. This was confirmed in another 
study, in which is shown that only the CD8+CD103+, not the CD8+CD103-, T lymphocyte subset 
could suppress T-cell mediated colitis in Rag2-/- mice 75. Remarkably, numbers of regulatory 
CD8+CD103+ blood T lymphocytes increased gradually during a year of anti-α4 treatment in 
patients with multiple sclerosis, more significantly in patients with clinical response 76. These 
data show evidence of a regulatory CD8+CD103+ T cell subset. The effects of anti-β7 treatment 
on these subsets have not yet been evaluated. 
ANTI-β7 TREATMENT IN IBD PATIENTS
The rationale behind anti-β7 treatment is based on mice studies and some of the studies 
described in table 1, under the assumption of an upregulated CD103 expression in the inflamed 
intestine of IBD patients 41,61,62. The phase one trial of anti-β7 in IBD included 48 patients with 
UC in order to assess safety and tolerability 77. Overall, it was well tolerated with headache as 
most common adverse event. Clinical response was observed in 12/18 anti-β7 treated patients 
(4/5 in placebo group), with clinical remission in 3/18 anti-β7 treated patients (1/5 placebo 
group). The phase two trial tested anti-β7 in 119 UC patients in two dosages: 100mg and 300mg 
compared with placebo 17. Administration of anti-β7 led to maximal occupation of β7 receptors 
on circulating T lymphocytes (CD4+ and CD8+) with a subsequent increase of CD4+β7+ numbers 
in the peripheral blood in line with the hypothesis that anti-β7 interferes with recruitment 
of effector T cells to the intestine. Peripheral CD8+β7+ frequencies remain the same. In the 
inflamed colonic mucosa the β7 receptors on CD8+ T lymphocytes were maximally occupied 
(both αEβ7 and α4β7). However, frequencies of these lymphocytes remained comparable with 
placebo treated patients. Unfortunately, CD4+β7+ T lymphocytes were not analysed in the colonic 
biopsy specimens. Intestinal biopsy mRNA levels of αE, β1 and β7 were unchanged. Therefore 
the mechanism of action of anti-β7 seems more blocking than depleting. Clinical remission 
at week 10 was observed in 8/39 patients with 100mg, 4/39 patients with 300mg and 0/41 
patients with placebo. A simultaneous endoscopic and rectal bleeding subscore of 0 at week 
10 was found in 4/39 patients with 100mg, 3/39 with 300mg and 0/41 with placebo. An indirect 
comparison, posed in the discussion of this phase two trial, of anti-β7 with the phase two 
trial of anti-α4β7 15 indicated a higher placebo-corrected clinical remission in patients treated 
with anti-β7 (21% compared with 18.5%). However, this was an unequal comparison, since the 
endpoint after 6 weeks of treatment in the anti-α4β7 trial was compared to the endpoint after 
10 weeks in the anti-β7 trial. The placebo-corrected clinical remission in the 100mg anti-β7 
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group after 6 weeks of treatment was much lower (5%) than in the anti-α4β7 trial (18,5%). The 
same trend was seen when making an indirect comparison for endoscopic remission: at week 
6 the placebo-corrected endoscopic remission was 20% in the anti-α4β7 trial as opposed to 5% 
in the anti-β7 trial. Of note, patient cohorts studied were different regarding disease severity, 
refractoriness to previous medication and both studies allowed co-medication during the study 
period. Obviously, final comparison can only be made in a head-to-head trial studying both 
mAbs.
In a recent post-hoc study on the potency of biomarkers in IBD patients treated with anti-β7, 
gene expression of integrin alpha E (ITGAE) and granzyme A were studied as potential predictive 
markers of response 78. Baseline characteristics showed lower endoscopy- and histology 
scores in patients with ITGAEhigh compared with ITGAElow patients. The clinical relevance of this 
observation was denoted as unclear, but we wonder if the ITGAEhigh expression could in fact 
reflect a predominant anti-inflammatory pathway in these patients? Histological improvement 
was only found in the ITGAElow group and not in the ITGAEhigh group. 
Considering the earlier mentioned gradual decline of CD103+ T lymphocytes along the 
intestine, it might be possible that there are other identifiable subgroups of patients who might 
benefit from anti-β7 treatment (e.g. ileal disease when compared with distal colonic disease). 
On the other hand, in view of αEβ7 expression on specific regulatory immune cell subsets, 
comprehensive evaluation of these subsets might also uncover markers to stratify patients for 
personalised medicine. It would be of interest to determine the actual integrin expression on 
the surface of all different subsets of immune cells in the gut by, for example, FACS analysis 
before and after anti-β7 treatment. 
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CONCLUSION
Intervening in the gut specific infiltration of T lymphocytes (α4β7+) is a very effective approach 
to directly address the site of inflammation in IBD. On the other hand, the effect of blocking 
retention of T lymphocytes (αEβ7+), which already populate the inflamed intestinal mucosa, 
is less clear. In addition, the effect of anti-β7 treatment on the diverse immune subsets 
expressing αEβ7 in the peripheral blood as well as the different epithelial compartments has 
not yet received sufficient attention.
We believe that, given the current knowledge, there is no evidence for an exclusively pathogenic 
role of αEβ7 positive intestinal immune cells in IBD, as there is no consistent evidence for 
increased αEβ7 expression on lymphocytes in patients. Moreover, αEβ7 integrin blockade 
might interfere with the action of different regulatory immune cell subsets. Conflicting results 
have been reported in different mouse models regarding treatment with anti-CD103 and 
anti-β7 mAb, therefore the results of the phase three anti-β7 trial are eagerly awaited. In the 
meantime, more comprehensive studies on αEβ7 expression in IBD are needed to elucidate 
its true nature and eventually define specific subgroups of patients that might benefit from 
anti-β7 treatment. Furthermore, it is essential to take into account the possible effects of αEβ7 
blockade on long-term immune homeostasis, as well as side effects on other organs and the 
response to intestinal infections.
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ABSTRACT
Background
Data on serum antibodies in untreated adult inflammatory bowel disease (IBD) patients at 
diagnosis are scarcely available, and results on the stability of antibody presence over time are 
inconsistent. Our aim was to investigate antibodies in newly diagnosed, untreated IBD patients 
in relation to disease phenotype and course. Furthermore, we analyzed antibody presence over 
time.
Methods
Baseline anti-Saccharomyces cerevisiae antibodies (ASCA), anti-chitobioside carbohydrate 
antibodies (ACCA), anti-laminaribioside carbohydrate antibodies (ALCA) and anti-mannobioside 
carbohydrate antibodies (AMCA) were measured with enzyme-linked immunosorbent assays 
and perinuclear anti-neutrophilic cytoplasmic antibodies (pANCA) was measured by indirect 
immunofluorescence in serum of 120 untreated IBD patients at diagnosis and 19 healthy 
controls. Antibodies were related to disease outcomes. Serial measurements were available 
in 71 patients. 
Results
The combination of pANCA and ASCA enabled good discrimination between UC and CD 
(P=0.004). Antibody presence was relatively stable over time, even though there were significant 
changes in concentrations. There was a trend towards larger fluctuations in concentration with 
immunosuppressive medication. Baseline pANCA in UC patients correlated with calprotectin 
values (rho=0.545, P=0.019) and change in pANCA status over time was associated with disease 
activity at that moment. No associations were found with antibodies at diagnosis and disease 
outcomes. 
Conclusion
Antibody profiles at diagnosis support the distinction between CD and UC. Anti-glycan 
antibodies are reasonably stable over time, but may fluctuate under the influence over 
immunosuppressive treatment which may explain the inconsistency in findings hitherto. The 
appearance or disappearance of pANCA antibodies during follow-up correlated with disease 
activity in UC and may be used in disease monitoring. 
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INTRODUCTION
Inflammatory bowel diseases (IBD) covers a heterogeneous group of chronic, relapsing-
remitting diseases of the gastrointestinal tract, classified as Crohn’s disease (CD), ulcerative 
colitis (UC) and IBD type unclassified (IBDU). CD and UC diagnosis are based on a combination 
of clinical, endoscopic, histological and radiological criteria 1,2. IBDU is diagnosed in 10-15% 
of patients, in whom there is diagnostic uncertainty and in the absence of resection material of 
ileum or colon, which may influence clinical decision making 3,4. In IBD patients, it is difficult 
to predict disease course or response to treatment at initial diagnosis and during follow-up. 
Early identification of IBD patients at risk for a severe disabling disease course could allocate 
those in need for early top-down treatment. Easily accessible, objective, markers for disease 
activity or that predict future disease course would substantially contribute to early patient 
stratification in IBD. 
Serological antibodies have been investigated extensively in IBD patients for many years 5,6. 
Simultaneous measurement of anti-Saccharomyces cerevisiae antibodies (ASCA) and 
perinuclear anti-neutrophilic cytoplasmic antibodies (pANCA) was shown to carry high 
specificity, but low sensitivity, in differentiating CD (ASCA+, pANCA-) from UC (ASCA-, pANCA+) 7. 
These antibodies might be helpful in further classification of IBDU patients, but their routine 
use in IBD patients and their role as biomarker for disease activity is still not clear 8,9. 
Recently, it was found that patients with higher number and titers of antimicrobial markers 
before diagnosis were at highest risk of presenting with complicated disease 10. New anti-
glycan antibodies like anti-chitobioside carbohydrate antibodies (ACCA), anti-laminaribioside 
carbohydrate antibodies (ALCA) and anti-mannobioside carbohydrate antibodies (AMCA) have 
been identified in IBD patients 11-13. Anti-glycan antibodies were shown to be predominantly 
present in CD patients with ileal disease and in patients with a complicated disease phenotype 
(stricturing and/or penetrating disease behavior). However, in previous papers on adult IBD 
patients, these antibodies were mainly analyzed in cross-sectional, single time point studies, 
when complications had already occurred and treatment was already commenced 12-17. Results 
on baseline concentrations at primary diagnosis are scarcely available and mainly derived 
from pediatric cohorts 18,19. Therefore the value of serological autoantibodies in IBD patients 
can merely be considered to reflect, rather than predict, complicated disease phenotype 20. 
Only a few studies have evaluated the evolution of antibodies over time (longitudinally), but no 
definite statement on their stability of antibody presence over time can be made, as serum 
samples were not assessed at diagnosis 21. Although some papers claim stability over time, 
mixed associations with disease duration, disease activity and drug therapy have been found, 
contradicting antibody stability 20. 
In other immune mediated diseases, serological antibody evaluation is used during disease 
follow-up 22-27. In IBD patients no definite conclusions can be drawn on the use of serological 
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antibodies, neither as marker for disease activity during follow-up, nor as predictive biomarker 
at diagnosis for disease progression. 
We aimed to investigate a panel of candidate serological antibodies in newly diagnosed, 
untreated, adult IBD patients at diagnosis and during the course of disease, by assessing 
their presence and serum concentration over time in relation to disease activity, severity and 
response to therapy. 
MATERIAL AND METHODS
Study population
IBD patients were prospectively enrolled and longitudinally followed-up at the outpatient 
clinic of the Department of Gastroenterology and Hepatology at Rijnstate Hospital Arnhem, a 
secondary care hospital in the Netherlands. Patients were recruited prior to the initial diagnostic 
ileocolonoscopy. After standardized work-up with clinical, endoscopic, histopathological and, 
when applicable, radiological evaluation, all patients met the generally accepted international 
diagnostic criteria of CD, UC or IBDU 1,2. The healthy controls consisted of an age- and gender 
matched group that also underwent ileocolonoscopy (negative for IBD). This group did not show 
evidence or familial history of IBD or any other immune mediated disorders. Venous blood 
samples were drawn from all patients and healthy controls. Sera were immediately frozen at 
-20oC. In patients, the first sample was obtained at baseline, immediately after endoscopic 
evaluation (before treatment was initiated). Thereafter a second sample was collected at an 
arbitrary visit to our hospital, with an interval of at least three months from the first sample.
Classification and definitions
Disease phenotype (location and behavior), at presentation and at latest follow-up, was 
assessed according to the Montreal classification 28. Endoscopic severity of the disease in 
CD was assessed by the simple endoscopy score for CD (SES-CD) and for UC by the Mayo 
score 29. Clinical disease activity was assessed using the Harvey Bradshaw index (HBI) for CD 
and Montreal classification for UC 28,30.
Overall use- and response to medication was recorded. In general, therapeutic management 
of IBD after diagnosis was done according to the step-up approach, as recommended by 
the Dutch guidelines 31. In UC patients, topical and/or oral 5-ASA was initiated as induction 
therapy. In case of severe pancolitis or when induction with 5-ASA treatment failed, systemic 
steroids were initiated. In CD patients, systemic steroids were started as induction therapy. In 
CD patients this was usually followed by the initiation of maintenance treatment (thiopurine 
derivates or methotrexate), especially in case of steroid-dependent disease. Anti-TNF therapy 
was initiated in both UC and CD in case of steroid refractory or steroid-dependent disease, 
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usually in combination with a thiopurine derivate. When disease did not respond to conventional 
treatment, resective surgery was considered. During relapse, escalation of maintenance 
treatment was considered. Surgery was defined as the resection of part of the bowel (resective) 
or abscess drainage or fistula operations (other).
At first serum sampling all IBD patients presented with active disease. At second serum 
sampling patients were grouped according to disease exacerbation or remission. Remission 
was defined as the disappearance of clinical symptoms after induction treatment (HBI<5/
Montreal=S0) at general physician’s assessment in combination with endoscopic remission 
(SES-CD<4/Mayo=0) and/or normalization of radiological examination and/or decreasing 
parameters of inflammation like CRP or fecal calprotectin. Disease exacerbation was defined 
as occurrence of symptoms (HBI>4/Montreal>S0) combined with either increased fecal 
calprotectin levels and/or abnormalities on imaging and/or endoscopic activity (SES-CD>3/
Mayo>0), resulting in escalation of medical treatment or surgical intervention.
For the purpose of the study, severe disease outcome in CD was defined as the occurrence of 
penetrating or stricturing disease, perianal disease with the need for anti-TNF initiation and/
or surgical intervention and CD related resective surgery. In UC, severe disease was defined as 
step-up of treatment when 5-ASA and/or steroids failed in achieving and/or maintain remission, 
thus initiation of thiopurines or anti-TNF or Vedolizumab therapy or the need for a colectomy. 
These conditions were compared to the presence of serological antibodies.
Serological assays
Serum was separated from blood by centrifugation and kept frozen at -20 °C until analysis 
was performed. PANCA was determined by indirect immunofluorescence (EUROIMMUN 
Granulocyte Mosaic 13 slides) according to the manufacturers’ protocol using a 1:10 serum 
dilution. PANCA was classified as positive or negative. Commercially available kits of enzyme-
linked immunosorbent assays (ELISA) were used to measure the expression of the following 
antibodies in all sera: gASCA IgA, ACCA IgA, ALCA IgG and AMCA IgG (Glycominds LTD, Lod, 
Israel). The laboratory technician was blinded for clinical phenotype and disease course; the 
clinical investigators had no access to antibody results at the time of clinical data acquisition. 
The assays were tested according to the manufacturers’ protocol. Results were expressed 
as arbitrary ELISA units/milliliter (EU/mL), a concentration relative to a calibration serum 
sample. Manufacturers’ cutoff levels were used: gASCA IgA (positive>50EU/mL), ACCA IgA 
(positive>90EU/mL), ALCA IgG (positive>60EU/mL), AMCA IgG (positive>100EU/mL). 
Inter- and intra-assay precision errors were controlled by 8 sera with different antibody profiles 
that were repeatedly tested in every run (n=3). The relative deviation from the mean for gASCA 
IgA, ACCA IgA, ALCA IgG and AMCA IgG were 11%, 17%, 23% and 26%respectively.
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Statistical analysis
Antibody results were displayed as serum concentration (anti-glycan antibodies; quantitative) 
and positive/negative (anti-glycan antibodies and pANCA; qualitative). The Shapiro-Wilk test 
was used to test normality. Categorical variables were expressed as numbers of patients and 
percentages and compared with Fisher’s exact test. Continuous variables were expressed as 
median with its interquartile range (IQR) and compared with Mann-Whitney U test. Kruskal-
Wallis analysis was used followed by the Dunn test. Multivariate analyses were performed 
using binary logistic regression to identify independent predictors of seropositivity for each 
individual marker and disease outcome corrected for age at diagnosis, gender, disease 
location and disease phenotype. Spearman’s correlation coefficients were used to assess the 
correlation of baseline antibody concentration and status with disease activity scores and with 
serial measurements. Paired data over time were compared using the Wilcoxon matched-
pairs signed-rank test for antibody concentration and McNemar’s test for antibody status. 
We computed receiver operating characteristic (ROC) curves, which yielded an area under 
the curve (AUC), and defined the optimal cutoff value using the Youden’s index. Sensitivity, 
specificity, positive and negative predictive values were calculated to assess the predictive 
power of anti-glycan antibodies and pANCA to differentiate between CD and UC and between 
CD and healthy controls (HC). SPSS statistics for Windows (version 22.0; IBM Corp, Armonk, 
NY, USA) and GraphPad Prism (GraphPad Software version 7.0, La Jolla, CA, USA) were used to 
analyze the data. Statistical significance was defined as a P-value less than 0.05. 
Ethical considerations
Written informed consent was obtained from each participating patient before any study-
related procedure was performed. The procedures were performed in accordance with the 
Declaration of Helsinki. The regional medical ethics committee approved the study protocol.
RESULTS
Patient characteristics
A total of 120 newly diagnosed IBD patients were included for baseline serologic measurement, 
of which 86 were classified as CD, 29 as UC and five as IBDU. The median follow-up duration 
was 27 months (IQR 14-59). Demographic and baseline characteristics can be found in table 1. 
Nineteen healthy controls were included. There were no statistical significant differences 
between the different patient groups and healthy controls for age or gender. CD patients had 
higher baseline CRP levels compared to healthy controls and to UC patients (both P=0.0001). 
IBD patients had higher baseline calprotectin levels compared to healthy controls (P=0.0001 
for CD and UC, P=0.017 for IBDU).
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Table 1. Baseline characteristics.
CD (n=86) UC (n=29) IBDU (n=5) HC (n=19)
Median age at diagnosis in years (IQR) 27 (22-41) 30 (24-39) 23 (22-45) 35 (26-47)
Female, n (%) 58 (67%) 18 (62%) 2 (40% 15 (79%)
Symptoms before diagnosis in months
0-3
3-6
>6
26 (30%)
18 (21%)
42 (49%)
13 (45%)
14 (48%)
2 (7%)
3 (60%)
1 (20%)
1 (20%)
-
Median follow-up period in months (IQR) 30 (16-64) 20 (12-51) 20 (10-65) -
Median time in months between first 
and second sample (IQR)
30 (12-50) 17 (12-29) 25 (9-49) -
Family with IBD, n (%) 12 (14%) 9 (31%) 0 (0%) 0 (0%)
Smoking status at diagnosis
• Never
• Current
• Ceased
41 (48%)
38 (44%)
7 (8%)
24 (83%)
2 (7%)
3 (10%)
3 (60%)
1 (20%)
1 (20%)
12 (63%)
4 (21%)
3 (16%)
CRP 19 (9-58) 5 (1-15) 2 (1-22) 4 (1-6)
Calprotectin 476 (238-1120) 381 (194-676) 1352 (525-1692 6 (0-15)
Median HBI score (IQR) 8 (6-13) - 15 (9-22) -
CD disease location (Montreal)
• Ileal (L1), n (%)
• Colonic (L2), n (%)
• Ileocolonic (L3), n (%)
• + Upper GI (+L4), n (%)
• + Perianal disease (+P), n (%)
32 (37%)
19 (22%)
35 (41%)
22 (39%)
13 (15%)
-
-
5 (100%)
-
2 (50%)
-
-
CD disease behaviour (Montreal)
• Inflammatory, n (%)
• Stricturing, n (%)
• Penetrating, n (%)
67 (78%)
15 (17%)
4 (5%)
-
5 (100%)
-
-
-
Median SES-CD score (IQR) 12 (8-21) - 18 (10-21) -
SES-CD severity
• Mild (4-10), n (%)
• Moderate (11-19), n (%)
• Severe (>19), n (%)
33 (38%)
29 (34%)
24 (28%)
-
1 (20%)
2 (40%)
2 (40%)
-
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Table 1. continued
CD (n=86) UC (n=29) IBDU (n=5) HC (n=19)
UC clinical score (Mayo)
• Remission, n (%)
• Mild, n (%)
• Moderate, n (%)
• Severe, n (%)
-
0 (0%)
12 (41%)
10 (34%)
7 (24%)
0 (0%)
1 (20%)
2 (40%)
2 (40%)
-
UC disease location (Montreal)
• Proctitis (E1), n (%)
• Left-sided (E2), n (%)
• Pancolitis (E3), n (%)
-
6 (21%)
8 (28%)
15 (52%)
1 (20%)
1 (20%)
3 (60%)
-
UC endoscopic severity (Montreal)
• Normal, n (%)
• Mild, n (%)
• Moderate, n (%)
• Severe, n (%)
-
0 (0%)
7 (24%)
16 (55%)
6 (21%)
0 (0%)
1 (20%)
3 (60%)
1 (20%)
19 (100%)
Recurrence after first period of 
remission, n (%)
38 (46%) 21 (72%) 4 (80%)
Highest treatment step during follow-up
• 5-ASA
• Oral steroids
• Immunosuppressants
• Anti-TNF
• Resective surgery
3 (3%)
10 (12%)
41 (48%)
23 (27%)
9 (10%)
13 (45%)
5 (17%)
7 (24%
1 (3%)
3 (10%)
0 (0%)
1 (20%)
3 (60%)
1 (20%)
0 (0%)
-
IBD=inflammatory bowel disease, CD = Crohn’s disease, UC = ulcerative colitis, IBDU = IBD unclassified, 
HC = healthy controls, n = number, IQR = interquartile range, HBI = Harvey-Bradshaw Index, SES-CD= 
simple endoscopic score for Crohn’s disease
Antibodies at diagnosis for differentiating IBD
Seropositivity of any antibody at diagnosis was detected in 43% of CD patients, 48% of UC 
patients, 20% of IBDU patients and 5% of healthy controls (table 2). In CD patients this was 
mainly attributed to the presence of ASCA (23%), followed by positive ALCA (13%), AMCA (9%), 
ACCA (6%) and pANCA (5%). Patients with UC were mainly positive for pANCA (45%), followed 
by ASCA (3%) and AMCA (3%) with no ALCA or ACCA present in the serum. One IBDU patient 
was seropositive for pANCA, with no detectable anti-glycan antibodies. One healthy control was 
positive for ACCA, all other antibodies tested negative in controls.
Differentiating IBD patients from healthy controls by the use of antibody status could be 
done with pANCA in UC patients (P=0.0001) and with ASCA in CD patients (P=0.012). ASCA 
seropositivity could differentiate CD from UC (P=0.011), ALCA positivity was also associated 
with CD (P=0.034), while pANCA was associated with UC (P=0.0001) (see table 2). Any positive 
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anti-glycan with negative pANCA could differentiate CD patients (33/86) from UC patients, 
who were mainly anti-glycan negative/pANCA positive (13/29 patients, P=0.0001). We analyzed 
the predictive power of the different antibodies, with the previously defined cutoff levels, in 
differentiating CD from UC patients and CD patients from healthy controls (table 3 and 
4, respectively). Predefined cutoff levels showed low accuracy, with high specificity but low 
sensitivity. Therefore, we constructed ROC curves and used the Youden’s index to define the 
optimal cutoff values and their accuracy in our patient group (figure 1, table 3 and 4). Optimal 
cutoff levels differed considerably from the predefined cutoff levels. The most accurate single 
marker in differentiating CD from UC was ASCA (AUC = 0.820) and the combination of ASCA and 
pANCA added only slightly to this accuracy (AUC = 0.891). Using all anti-glycans and pANCA 
did not improve accuracy more (AUC=0.887). ASCA and ALCA were the most accurate single 
markers for the differentiation of CD patients from HC (AUC 0.790 and 0.773, respectively) and 
a combination of all anti-glycans improved accuracy to an AUC of 0.851. 
After multivariate analysis, with correction for age, gender, smoking habit and other antibodies, 
pANCA status (P=0.003) and the combination of ASCA and pANCA status (P=0.004), were able to 
discriminate between UC and CD, whilst other antibodies were not independently associated. 
Serological status did not correlate with clinical (HBI/Montreal) and endoscopic (SES-CD/Mayo) 
disease activity scores at diagnosis. A negative correlation was found for CRP with pANCA 
status (rho=-0.285, P=0.003). In UC patients, calprotectin levels at diagnosis correlated strongly 
with pANCA status (rho=0.545, P=0.019). No such correlations were found in CD patients.
Table 2. Serological results at diagnosis.
CD (n=86) UC (n=29) IBDU (n=5) HC (n=19) P-value
Markers, any positive, 
n (%)
gASCA positive, n (%)
AMCA positive, n (%)
ALCA positive, n (%)
ACCA positive, n (%)
pANCA positive, n (%)
37 (43)
20 (23)
8 (9)
11 (13)
5 (6)
4 (5)
14 (48)
1 (3)
1 (3)
0 (0)
0 (0)
13 (45)
1 (20)
0 (0)
0 (0)
0 (0)
0 (0)
1 (20)
1 (5)
0 (0)
0 (0)
0 (0)
1 (5)
0 (0)
CD-UC 0.527, UC-HC 0.005, 
CD-HC 0.001, IBDU-HC 0.380
CD-UC 0.011, UC-HC 0.604, 
CD-HC 0.012
CD-UC 0.284, UC-HC 0.604, 
CD-HC 0.190
CD-UC 0.034, CD-HC 0.098, 
CD-UC 0.227, UC-HC 0.396, 
CD-HC 0.703
CD-UC 0.0001, UC-HC 0.0001, 
CD-HC = 0.444
IBD = inflammatory bowel disease, CD = Crohn’s disease, UC = ulcerative colitis, IBDU = IBD unclassified, 
HC = healthy control, n= number, IQR = interquartile range, statistically significant P-values are shown in 
bold
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Table 3. Predictive power of antibodies in differentiating between CD and UC.
Cut-off level 
CD vs UC
Youden’s 
index
Sensitivity Specificity Positive 
Predictive 
Value 
Negative 
Predictive 
Value
ASCA predefined
ASCA optimal
50 EU
10 EU
0.198
0.606
23%
71%
97%
90%
95%
95%
30%
51%
ALCA predefined
ALCA optimal
60 EU
20 EU
0.128
0.340
13%
62%
100%
72%
100%
87%
28%
39%
ACCA predefined
ACCA optimal
90 EU
53 EU
0.058
0.210
6%
28%
100%
93%
100%
92%
26%
30%
AMCA predefined
AMCA optimal
100 EU
36 EU
0.047
0.353
10%
70%
97%
65%
90%
86%
27%
42%
pANCA - 0.402 45% 95% 76% 84%
Combination all anti-
glycans and pANCA1
0.2923933 -0.642 85% 79% 92% 64%
Combination of ASCA 
and pANCA2
0.2815950 -0.666 91% 76% 92% 73%
1y=1.094 + ASCA*-0.038 + ALCA*-0.019 + ACCA*-0.013 + AMCA*-0.026 + pANCA*3.053
2y=-0.595 + ASCA*-0.056+ pANCA*2.460
Table 4. Predictive power of antibodies in differentiating Crohn’s disease (CD) and healthy controls 
(HC).
Cut-off level
CD vs HC
Youden’s 
index
Sensitivity Specificity Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
ASCA predefined
ASCA optimal
50 EU
20 EU
0.233
0.512
23%
51%
100%
100%
100%
100%
22%
31%
ALCA predefined
ALCA optimal
60 EU
17 EU
0.128
0.551
13%
71%
100%
84%
100%
95%
20%
39%
ACCA predefined
ACCA optimal
90 EU
23 EU
0.006
0.206
6%
84%
95%
37%
83%
86%
19%
33%
AMCA predefined
AMCA optimal
100 EU
40 EU
0.081
0.277
9%
59%
100%
68%
100%
89%
20%
27%
Combination of  
anti-glycans1
0.8464560 0.654 70% 95% 98% 41%
1^y=-1.784 + ASCA*0.090 + ALCA*0.069 + ACCA*0.006 + AMCA*0.007
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A. Crohn’s disease vs ulcerative colitis
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B. Crohn’s disease vs healthy controls
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Figure 1. (a) Discrimination between CD and UC patients based on anti-glycan antibodies and 
pANCA. (b) Discrimination between CD patients and HC based on anti-glycan antibodies, combi = the 
combination of ASCA, ALCA, AMCA and ACCA.
Association of antibody status at diagnosis with disease phenotype and outcome in CD 
patients
At univariate analysis, no association was found for any of the antibodies with disease phenotype 
or -course. In CD patients with a follow-up duration of at least one year (n=70), severe disease 
developed in 22 patients (31%). Classification of severe disease was based on resective CD 
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related surgery (7/22), perianal disease with the need of anti-TNF initiation and/or surgical 
intervention (10/22) and penetrating or stricturing disease at last follow-up (5/22). There was 
no association between the baseline presence of antibodies and the development of severe 
disease. In this group 36 patients (51%) had at least one exacerbation after initial remission 
(relapsing disease), while 34 patients (49%) maintained remission. There was no association 
between the presence of antibodies at baseline and relapsing disease.
Association of antibody status at diagnosis with disease phenotype and outcome in UC 
patients
In UC patients there was no association of antibody status with any of the patient characteristics 
described in table 1, including disease location and endoscopic severity. In patients with a 
follow-up duration of at least one year (n=22), severe disease developed in nine UC patients 
(41%). This classification was based on colectomy (2/9), anti-TNF therapy (1/9) or thiopurine 
therapy after 5-ASA failure (6/9). Relapsing disease (at least one exacerbation after initial 
remission) occurred in 18 patients (81%) while 4 patients (18%) maintained remission. There 
were no associations with antibody status and severe disease outcome or relapsing disease in 
UC patients.
Serologic change over time
Serial serologic assessment was available in 71 IBD patients (49 CD, 18 UC and four IBDU, 
see table 5 and table 6), after a median follow-up duration of 26 months (IQR 13-47). A change 
of serum antibody status compared to initial assessment was observed for pANCA in 15% of 
IBD patients, for ASCA in 10%, for ALCA in 10%, for AMCA in 9% and for ACCA in 6% (table 6). 
Antibody concentrations were stable over time in most cases. 
In 86-94% (antibody dependent) of CD patients anti-glycan antibodies and pANCA presence 
remained unchanged at serial measurement compared to diagnosis. However, AMCA, ACCA 
and ALCA concentrations did show a statistical significant change from baseline (P<0.05, 
table 5). There was a trend towards a stronger decrease of AMCA concentrations in CD patients 
using anti-TNF treatment at serial measurement (P=0.092) while other types of treatment did 
not affect the change in antibody concentrations.
At the moment of follow-up blood collection 33 CD patients were in remission while 16 patients 
experienced an exacerbation. There was a comparable follow-up duration for these two groups 
(P=0.424). Changes in the presence of antibodies were comparable between the two groups 
(antibodies P>0.05). ACCA and AMCA concentrations decreased from baseline values in both 
groups (ACCA: inactive P=0.002 and active P=0.005; AMCA: inactive P=0.006 and active P=0.007 
respectively). However, there were some differences in the change of antibody concentration 
between the two groups. A trend towards a higher increase in ALCA concentrations from 
baseline to follow-up was observed in patients with inactive disease when compared to active 
disease (P=0.055 and P=0.352 respectively). ASCA concentrations decreased more in patients 
with inactive disease (P=0.085) than in patients with active disease (P=0.642). 
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Table 5. Serologic results at serial measurement, during follow-up
FU CD (n=49) FU UC (n=18) FU IBDU (n=4)
Markers, any positive, n (%)
gASCA positive, n (%)
Change in gASCA level, median EU/ml (IQR)
AMCA positive, n (%)
Change in AMCA level, median EU/ml (IQR)
ALCA positive, n (%)
Change in ALCA, median EU/ml (IQR)
ACCA positive, n (%)
Change in ACCA level, median EU/ml (IQR)
pANCA positive, n (%)
19 (39%)
7 (14%)
-1 (-5;+2)
2 (4%)
-11 (-30;-2)*
10 (20%)
+3 (-3;+12)*
2 (4%)
-7 (-17;-1)*
3 (6%)
7 (39%)
0 (0%)
0 (-1;+1)
0 (0%)
-1 (-15;+6)
0 (0%)
+4 (0;+9)*
1 (6%)
-5 (-9;+3)
6 (33%)
2 (50%)
0 (0%)
-1 (-3;0)
0 (0%)
+12 (-5;+27)
0 (0%)
+3 (+2;+4)
0 (0%)
-4 (-8;+16)
2 (50%)
FU = follow-up, CD = Crohn’s disease, UC = ulcerative colitis, IBDU = IBD unclassified, n= number, IQR = 
interquartile range
*change in level has a P<0.05 when compared to baseline
In UC patients, anti-glycan antibody status remained unchanged at follow-up, except for ACCA, 
which became positive in 6% of patients. PANCA remained stable in 67% of UC patients, while 
17% became negative and 17% became positive at serial measurement. This change in pANCA 
presence correlated with disease activity at follow-up (rho= 1.000, P=0.01), as the three patients 
that became negative all achieved remission while the three patients that became positive all 
had an exacerbation at serial measurement. However, in patients with stable pANCA status 
(n=12) no correlation was found with disease activity at serial measurement.
In UC patients there was a trend towards a stronger decrease from baseline of ASCA 
concentrations when patients were using thiopurine medication at serial measurement 
(P=0.053). Other treatments did not affect the change in antibody concentrations in UC.
At the moment of follow-up blood collection ten UC patients were in remission while eight 
patients experienced an exacerbation. There was a comparable follow-up duration for these 
two groups (P=0.726). Antibody presence did not change in a different manner between the two 
groups (all P>0.05). Change in AMCA (P=0.799 and P=0.123) and ASCA (P=0.959 and P=1.000) 
concentrations was comparable between the two groups. However, ACCA concentrations 
decreased more from baseline to follow-up in patients with inactive disease (P=0.037) 
compared to patients with active disease (P=0.575), whereas ALCA concentrations increased 
from baseline to follow-up in patients with inactive disease compared to active disease (P=0.037 
and P=0.401 respectively). 
In IBDU no changes were observed for the anti-glycan antibodies, while 50% of pANCA status 
changed from negative to positive at follow-up. 
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Table 6. Changes in serological results from baseline to follow-up.
Marker IBD (n=71) CD (n=49) UC (n=18) IBDU (n=4)
ASCA
No change
+ to –
- to +
McNemar P-value
64 (90%)
5 (7%)
2 (3%)
42 (86%)
5 (10%)
2 (4%)
0.453
18 (100%)
-
-
4 (100%)
-
-
AMCA
No change
+ to –
- to +
McNemar P-value
65 (91%)
4 (6%)
2 (3%)
43 (88%)
4 (8%)
2 (4%)
0.688
18 (100%)
-
-
4 (100%)
-
-
ALCA
No change
+ to –
- to +
McNemar P-value
64 (90%)
2 (3%)
5 (7%)
42 (86%)
2 (4%)
5 (10%)
0.453
18 (100%)
-
-
4 (100%)
-
-
ACCA
No change
+ to –
- to + 
McNemar P-value
67 (94%)
2 (3%)
2 (3%)
46 (94%)
2 (4%)
1 (2%)
1.000
17 (94%)
-
1 (6%)
4 (100%)
-
-
pANCA
No change
+ to –
- to +
McNemar P-value
60 (84%)
5 (7%)
6 (8%)
46 (94%)
2 (4%)
1 (2%)
1.000
12 (67%)
3 (17%)
3 (17%)
2 (50%)
-
2 (50%)
DISCUSSION
In this cohort of newly diagnosed untreated IBD patients 43% of CD and 48% of UC patients 
were seropositive for any antibody at baseline. This was mainly attributed to ASCA positivity in 
CD patients and pANCA positivity in UC, while newer anti-glycan antibodies (ACCA, ALCA and 
AMCA) were less prevalent and mostly found in CD. Anti-glycan antibodies and pANCA had a 
good accuracy for differentiating IBD from healthy controls and differentiating CD from UC. 
Overall, there was a good correlation between baseline and serial measurement of antibody 
presence, although concentration of antibodies did show some significant changes from 
baseline to follow-up, sometimes related to specific immunosuppressive therapy. A change in 
the presence of pANCA occurred in up to 34% of pANCA change in UC patients. This change 
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in pANCA presence in UC patients correlated with disease activity at serial measurement. No 
associations were found with disease phenotype, severity of disease activity or disease course. 
The antibody prevalence in this study was relatively low compared to previous studies, where 
a prevalence of positive antibodies in IBD patients was described as followed: of 42-69% ASCA 
positivity in CD (23% in our study), 19-27% ALCA positivity in CD (here 13%), 12-28% AMCA 
positivity in CD (here 9%), 8-25% ACCA positivity in CD (here 6%) and pANCA positivity in 
UC patients of 41-73% (45% here) 9,20. An explanation for these differences could be that we 
included patients at the time of initial diagnosis in a secondary care hospital, representing 
the real-world IBD population and not a referral-based population, probably including more 
complex patients. Supporting this explanation, the ASCA and pANCA prevalence in the present 
study are in line with a Norwegian population-based cohort study 32. Cutoff values of anti-
glycan antibodies have been established previously with ROC curve analysis to differentiate 
CD from UC 11. This was done in a referral-based population of IBD patients with longstanding 
disease (mean duration of eight years for UC and nine years for CD) all under medication 
and up to 39% of patients with bowel surgery. This could also be an explanation for the lower 
prevalence found in our cohort.
A predictive role for serological antibodies in UC patients at diagnosis or during follow-up cannot 
be supported by our results, as few patients were positive for other antibodies than pANCA 
and no associations were found with disease course. Similarly, in CD patients no associations 
were found between antibody presence at baseline and disease course. Previously described 
associations with age, disease location (ileal), perianal disease and future surgery could not be 
confirmed in our patient cohort 20. In other immune mediated diseases, serum autoantibodies 
can be used to monitor disease activity, where the autoantibody level can be associated to 
disease remission and treatment response 22-27. In autoimmune hepatitis autoantibodies are 
known to fluctuate before and after immunosuppressive therapy and persisting high titers 
are associated with disease activity 22. Recently, it was shown in early rheumatoid arthritis 
that anti-citrullinated protein antibodies (ACPAs) could disappear from the circulation upon 
antirheumatic therapy 23. ACPA and rheumatoid factor levels also decrease after anti-TNF 
therapy, significantly more in responders 24. ANCA titers are routinely checked in diagnosis 
and follow-up of vasculitis 25. In systemic lupus erythematosus, elevated anti-double-stranded 
DNA antibody concentrations precede disease flares 33,34. In celiac disease disappearance of 
autoantibodies indicates treatment adherence 26,27. 
In our study, disease activity scores (both clinical and endoscopic) in IBD patients at diagnosis 
did not correlate with presence or concentration any of the antibodies in serum. However, all 
patients had some degree of disease activity at diagnosis and therefore our patient cohort at 
baseline is more homogeneous than when comparing patients with active and inactive disease. 
During follow up the anti-glycan antibody concentration showed clear variety between active 
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and inactive disease, while the presence of antibodies at follow up did not differentiate between 
active or inactive disease. Anti-glycan antibodies are antibodies to cell wall carbohydrate 
epitopes found in bacteria and fungi 20. Their presence therefore reflects increased intestinal 
permeability but might also reflect a loss of tolerance towards microbiota 20. Their involvement 
in the IBD pathogenesis is disputable by their low prevalence in patients and their largely 
unaffected status by inflammatory burden (disease activity). However, the heterogeneous 
prevalence of anti-glycan antibodies in CD patients underlines the heterogeneity of this group 
of patients and supports the idea of a multifactorial pathogenesis in CD.
On the other hand, in 34% of UC patients, change in pANCA status correlated with disease 
activity at follow-up measurement, as patients that became positive all had an exacerbation and 
patients that became negative all achieved remission at that moment. Therefore, there might 
be a role for monitoring pANCA in UC patients for assessment of disease activity. This was also 
underlined by the strong correlation of baseline pANCA status with calprotectin values. Recently 
it has been shown in UC patients that pANCA positivity declined after treatment compared to 
baseline 18. PANCA is directed against a protein of the nuclear envelope of neutrophils 35. In 
line with the fact that UC has a more homogeneous disease presentation than CD, until now 
only one antibody (pANCA) seems relevant in this disease. Even though pANCA positivity in UC 
is not 100%, it might still play a role in the pathogenesis or it might represent a bystander effect 
of chronic inflammation. 
PANCA and anti-glycan antibodies in serum could be helpful to categorize IBDU patients as 
being CD or UC. Three of five IBDU patients in our cohort were pANCA positive (one at diagnosis, 
two at serial measurement), without any anti-glycan antibodies present. It was previously found 
that ASCA-/pANCA+ predicted UC in 64% of IBDU patients, whereas ASCA+/pANCA- was more 
helpful as it predicted CD in 80% of cases 8. At present, with a median follow-up of 20 months 
after diagnosis (IQR 10-65), none of the three pANCA positive IBDU patients could (yet) be 
diagnosed as having UC nor as having CD. 
We showed that, even though there was an overall stable presence of anti-glycan antibodies, 
there is inter-individual variation of antibody concentration and status over time. These 
findings are in line with previous studies, in patients with longstanding IBD, showing marked 
concentration changes over time with status change to a lesser extent 21,36,37. It depends on 
which percentage of status change would be generally acceptable, to clearly state (in)stability 
over time. ALCA concentrations increased more in IBD patients in remission at follow-up 
blood collection, while AMCA and ACCA concentrations decreased over time, irrespective of 
disease activity at the moment of follow-up blood collection. Furthermore, there was a trend 
for an association between thiopurine use and anti-TNF treatment at second blood collection 
with change in antibody concentration. Thiopurine medication induced a stronger decrease of 
ASCA in UC patients while anti-TNF treatment in CD patients induced a stronger decrease of 
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AMCA concentrations. These findings imply the possibility of confounding factors by specific 
immunomodulatory treatment on antibody status. This should be taken into account when 
studying antibodies in IBD patients under treatment. Furthermore, it would be interesting to 
study these antibodies into more detail in a larger patient cohort prior to initiation of medication 
and evaluating response to treatment.
We identified several limitations of this study. As longer follow-up duration (>10 year) is generally 
accepted as ideal to determine disease outcome in IBD patients, we were limited by a shorter 
follow-up duration and therefore definite conclusions on the relation between antibodies and 
development of complications cannot be drawn. The low number of IBDU patients precludes 
us from drawing robust conclusions about the utility of serological antibodies in this patient 
group. However, given the high AUC (0.891) of the combination between ASCA and p-ANCA 
in discriminating between CD and UC, these two antibodies can have an added value to the 
primary diagnostic work-up in newly diagnosed IBDU patients. 
Strengths of this study were that it was performed in a secondary care center with access 
to the full range of IBD phenotypes (no selection bias) and prospective inclusion of solely 
newly diagnosed IBD patients. All patients had endoscopic confirmed inflammation and were 
untreated at baseline, followed by serial measurements that were performed to determine 
stability over time. 
CONCLUSION 
In conclusion, this population-based study confirms diagnostic value of analyzing ASCA and 
pANCA for differentiating IBD. Other anti-glycan antibodies were found in low prevalence, 
almost exclusively in CD patients. The anti-glycan antibody profile remains unchanged during 
follow up, with a status change in only 6-14% of CD patients, irrespective of their disease activity. 
The pANCA status change which occurred in 34% of UC patients, correlated with disease 
activity at serial measurement and could be added as a biomarker to assess disease activity. 
Although antibody presence was quite stable over time, antibody concentrations did fluctuate 
significantly, sometimes related to specific immunosuppressive therapy. In the present study, 
there is no evidence found for a predictive or prognostic role of serological antibodies in adult 
IBD patients.
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ABSTRACT
Background and Aims
More than half of patients with Crohn’s disease (CD) develop disease complications requiring 
aggressive medical therapy or surgery over time. However, predicting disease course and 
treatment response remains difficult. We therefore identified distinctive serum analytes 
associated with disease activity and course in newly diagnosed, untreated patients at 
presentation and during their follow-up.
Methods
In a pilot study, a multiplex immunoassay analysis on 36 markers was performed on serum 
from 20 CD patients at the time of primary diagnosis following endoscopic evaluation. The 12 
most potent markers associated with disease activity, phenotype and course were analysed 
in a consecutive cohort of 66 CD patients at diagnosis and follow-up (n=39). A healthy control 
group (n=20) was included as a reference.
Results
CD patients had higher baseline levels of sTNF-R2 (P=0.001), sIL-2R (P=0.0001) and MMP-
1 (P=0.001) compared with healthy controls. Serial measurements revealed that these three 
analytes dropped statistically significantly from baseline level during remission and were high 
during exacerbation. Great decline of sTNF-R1 levels was found during remission with 6.7 
fold lower levels than in healthy controls (P=0.015). Patients who did not respond to initial 
prednisone treatment had higher baseline levels of sTNF-R2 (P=0.001). Patients experiencing 
relapses during follow-up had lower baseline sTNF-R2 and VCAM levels compared with 
patients with long-lasting remission.
Conclusions
In a large cohort of newly diagnosed untreated CD patients we identified candidate serum 
markers (sTNF-R1, sTNF-R2, sIL-2R and MMP-1) associated with disease activity. Furthermore, 
sTNF-R2 was associated with prednisone response and, together with VCAM, with long-lasting 
remission.
SERUM MARKERS IN EARLY CD
149
7
INTRODUCTION
Crohn’s disease (CD) is an idiopathic chronic inflammatory disease, primarily affecting the 
gastrointestinal tract and belonging to the group of inflammatory bowel diseases (IBD). CD is 
characterised by lifelong episodes of relapsing-remitting disease and covers a wide spectrum 
of disease phenotypes. Disease behaviour at diagnosis consists of uncomplicated mucosal 
inflammation in 70-80% of patients, whereas 20-30% have already developed complications 
with stricturing or penetrating disease 1,2. At presentation of the disease, younger age (<40), 
perianal or stricturing disease, involvement of the upper gastrointestinal tract, penetrating 
disease and smoking are clinical determinants associated with a complicated disease 
course 3,4. Approximately 50% of CD patients are expected to develop disease complications 
over time requiring aggressive medical therapy such as biologics, immunomodulators or 
surgery. Disease monitoring, on which clinical decisions depend, include clinical scores (often 
inaccurate 5), radiological techniques, endoscopy (including histological analysis) and faecal 
calprotectin. Despite clinical determinants and disease monitoring, it is difficult to predict 
disease course and response to therapy in clinical practice. Therefore, treatment is based on 
generic principles, without much focus on the individual patient. Reliable predicting indicators 
(biomarkers) on disease course and response to therapy would help in focusing on fast and 
accurate therapy in the individual patient and prevent administration of potentially toxic and 
expensive medication to nonresponsive patients 6. Some efforts in this respect, have been 
made in a study that identified CD8+ T cell transcriptional signatures associated with frequently 
relapsing disease in IBD and in a study on serological antibodies in IBD 7,8.
The involvement of a disrupted immune system in initiation and progression of CD has been 
established, but the driving immune regulatory factors involved in the early stages of CD are 
still poorly understood. It has been suggested that CD originates as a result of a dysregulated 
immune response to gut bacteria, characterised by the infiltration of inflammatory cells 
derived from the circulation into the gut mucosa of a genetically susceptible host 9. In a previous 
study, we focused on the characterisation of the lymphocytic infiltrate in colonic biopsies and 
identified a subpopulation of naive T-cells that was associated with the clinical phenotype at 
presentation 10. In addition, the local production of cytokines upon stimulation of the mucosal 
biopsies was related to the infiltrated T cell subpopulations and the clinical presentation. This 
local release of cytokines and the expression of adhesion molecules and cytokine receptors 
are thought to contribute to recruitment of the inflammatory cells and perpetuation of local 
inflammation 11. The localised immunological process in the gut most likely has systemic 
reflections, as CD is known to be a systemic disease with extra-intestinal manifestations. 
Therefore, the primary aim of this study was to identify distinctive serum analytes associated 
with disease activity in newly diagnosed, untreated CD patients at presentation and during 
follow-up. Our secondary aim was to study the correlation of these serum analytes with disease 
phenotype and course.
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MATERIALS AND METHODS
Patient selection and sample collection
An initial analysis was performed in a pilot cohort of 20 newly diagnosed, adult CD patients. We 
selected this cohort based on clinical- and mucosal immunological phenotype as presented 
earlier 10. Subsequent analysis was performed in a consecutive cohort of CD patients (n=66) 
and an age- and sex-matched healthy control group (n=20). Patients were recruited before 
initial diagnostic ileocolonoscopy, at the outpatient clinic of the Department of Gastroenterology 
and Hepatology at Rijnstate Hospital, Arnhem, The Netherlands. After clinical, endoscopic, 
histopathological and, when indicated, radiographic evaluation, all patients met the accepted 
international diagnostic criteria of CD 12.
Disease phenotype (location and behaviour) was assessed according to the Montreal 
classification at primary diagnosis and at latest follow-up 13. The Harvey-Bradshaw Index (HBI) 
was used to score clinical symptoms. The simple endoscopy score for CD (SES-CD) was used 
to assess endoscopic disease severity 14. Mild endoscopic disease activity was defined as a 
score of 4-10, moderate activity as 11-19 and severe activity as ≥20 15.
In general, therapeutic management of CD after diagnosis was done according to the step-
up approach 16. Accelerated use of antitumor necrosis factor (TNF) therapy was occasionally 
initiated, in case of complex perianal disease, in addition to surgical treatment. In accordance 
with the step-up approach, systemic steroids were started as induction therapy. This was 
usually followed by the initiation of maintenance treatment (mainly thiopurines). In case of 
steroid-dependent, -refractory or -intolerant disease, anti-TNF therapy was initiated, usually 
in combination with thiopurines or methotrexate. If disease did not respond to conventional 
treatment, surgery was considered. In case of relapse, escalation of maintenance treatment 
was considered. Remission was defined as disappearance of clinical symptoms after induction 
treatment (HBI<5): general physician’s assessment in combination with endoscopic remission 
(SES-CD<4) and/or normalization of imaging and/or decreasing parameters of inflammation 
like C-reactive protein (CRP) and/or faecal calprotectin. Relapse was defined as occurrence 
of new symptoms (HBI>4) after achieving clinical remission, combined with either increased 
faecal calprotectin levels and/or abnormalities on imaging and/or endoscopic activity (SES-
CD>3), resulting in escalation of maintenance treatment or surgical intervention. Disease 
course included any of the following parameters: initial steroid response, long-lasting remission 
(no relapses during follow-up), progression to stricturing, penetrating or perianal disease, 
initiation of anti-TNF during follow-up or surgery during follow-up. Venous blood samples were 
drawn following endoscopic evaluation at primary diagnosis, before any immunomodulating 
treatment was initiated. Serum samples were coded and stored at -20°C until analysis. Follow-
up blood samples were collected in 39 patients, either in remission or during an exacerbation.
SERUM MARKERS IN EARLY CD
151
7
Multiplex immunoassay
A total of 36 cytokines, chemokines, growth factors, soluble receptors and other mediators 
(hereafter denoted by ‘analytes’) were selected (see figure 1), based on their relevance in CD 
and other (auto)inflammatory diseases 17-21. The following panel of analytes was tested in the 
pilot cohort: IL-1RA, IL-1α, IL-1β, IL-6, IL-10, IL-12p70, IL-13, IL-17, IL-18, IL-21, IL-23p19, 
IL-33, IL-37, TNF-α, IFN-γ, CCL-2/MCP-1, CCL-3/MIP-1α, CCL-4/MIP-1β, CCL-5/RANTES, 
CCL-19/MIP-3β, CXCL-8/IL-8, CXCL-10/IP-10, CXCL-13/BLC, GM-CSF, EGF, VEGF, sICAM, 
sVCAM, sTNF-R1, sTNF-R2, sIL-2R/sCD25, sIL-6R/sCD126, MMP-1, MMP-3, MMP-9, S100A8/
MRP8. Candidate analytes that showed to be associated with clinical phenotype at diagnosis, 
endoscopic disease severity at diagnosis, and disease course (table 1; and supplementary table 
1 and 2) in the pilot cohort were selected and subsequently analysed in the consecutive CD 
patient cohort and healthy controls.
Multiplex immunoassays were performed at the MultiPlex Core Facility of the Laboratory 
of Translational Immunology (UMC Utrecht, The Netherlands) using an in-house validated 
platform (ISO9001). In brief, color-coded magnetic beads (MagPlex Microsperes, Luminex, 
Austin, Texas) were conjugated to analyte-specific antibodies and incubated with standard 
dilutions or sample for 1 h during continuous shaking in the dark. Samples were pre-treated 
with HeteroBlock (Omega biologicals, Inc., Bozeman, Montana, USA) to prevent interference by 
binding of heterophilic antibodies. Plates were washed (Bio-Plex Pro II Wash Station; Bio-Rad, 
Hercules, California, USA) and a corresponding cocktail of biotinylated detection antibodies 
was added followed by streptavidin-phycoerythrin (PE) incubation. Fluorescence intensity of 
PE was measured using a Flexmap 3D system (Luminex) and analysed using BioPlex Manager 
Software (version 6.1; Bio-Rad, USA) using five-parameter curve fitting. Undetectable analyte 
results in CD patients were replaced by the lowest measured result of the patient group divided 
in half. This surrogate value was always below the lower limit of detection.
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Table 1. Results of serum analytes associated with clinical phenotype, endoscopic severity and 
disease-course in the pilot cohort of 20 Crohn’s disease patients. Composed of results shown more 
extensively in supplementary table 1 and 2.
Analyte Clinical 
phenotype at 
diagnosis
P-value Endoscopic 
disease severity 
at diagnosis
P-value Disease course P-value
sTNF-R1 ↑ in patients with 
L2 phenotype
L2 vs. L1 
0.026
sTNF-R2 ↑ in patients with 
L2 phenotype
L2 vs. L1 
0.026
↑ when 10<SES-
CD<19
Moderate vs. 
mild 0.036
sIL-2R ↑ in patients with 
L2 phenotype
L2 vs. L1 
0.008
↑ initial steroid 
non-responder
0.032
sIL-6R ↓ in patients without 
need of anti-TNF
0.009*
S100A8 ↑ in patients with 
L2 phenotype
L2 vs. L3 
0.022
IL-37 ↑ in patients 
with +P
0.033
MMP-1 ↑ when SES-
CD>19
Severe vs. 
mild 0.039
↑ relapsing disease 0.046
MMP-9 ↓ in patients 
with +P
0.025
VCAM ↓ in patients 
with +P
0.025
CCL-5 ↑ relapsing disease 0.007
CCL-19 ↑ initial steroid  
non-responder
0.003
CXCL-13 ↓ in patients without 
need of anti-TNF
0.035*
SES-CD = Simple Endoscopy Score for Crohn’s Disease
*Follow-up duration statistically significantly different between compared groups
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Statistical analysis
The Shapiro-Wilk test was used to test the normality of variables. As most variables were 
skewed, log transformation was applied. Non-parametric tests were used for all log-
transformed variables. Continuous variables were described as median and interquartile 
range (IQR) and compared with Mann-Whitney U tests. Categorical variables were described as 
absolute frequencies and compared with Kruskal-Wallis analysis followed by Dunn test. Due to 
the exploratory nature of the pilot group, no adjustments were made to the P-value for multiple 
comparisons. In the consecutive cohort, we report P values corrected for multiple testing using 
the Holm-Bonferroni correction. We adjusted for age and gender when testing for association 
between analyses and disease phenotype as they are common confounders (although no 
association with age and gender was found in our study). Analyte values measured in blood 
samples at baseline and those collected during follow-up were compared using Wilcoxon 
matched-pairs signed-rank test. We computed receiver operating characteristic (ROC) curves, 
defined the best thresholds for the analytes using the Youden’s index and calculated the 
corresponding sensitivity, specificity, positive and negative predictive value. SPSS statistics 
for Windows (version 21.0.; IBM Corp, Armonk, NY, USA) and GraphPad Prism (GraphPad 
Software version 7.0, La Jolla, CA, USA) were used to analyse the data. Statistical significance 
was defined as a P-value lower than 0.05. 
Ethical Considerations
Written informed consent was obtained from each participating patient before any study-
related procedure was performed. The procedures were performed in accordance with the 
Declaration of Helsinki. The regional medical ethics committee approved the study protocol.
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RESULTS
Serum analytes in a pilot cohort of newly diagnosed, untreated, CD patients
The complete panel of 36 analytes (figure 1) was tested in a pilot cohort of 20 newly diagnosed 
CD patients (table 2). Many analytes (IL-1α, IL-1β, IL-10, IL-12p70, IL-13, IL-17, IL-23p19, 
IL-33, IL-37, TNF-α, IFN-γ and GM-CSF) were below the limit of detection (supplementary 
table 3). Twelve analytes were associated with disease phenotype or disease course (table 2 
and supplementary table 1&2): IL-37, CCL-5/RANTES, CCL-19/MIP-3β, CXCL-13/BLC, sVCAM, 
sTNF-R1, sTNF-R2, sIL-2R/sCD25, sIL-6R/sCD126, MMP-1, MMP-9 and S100A8/MRP8, and 
followed up in a consecutive cohort of CD patients (n=66) and age- and sex-matched healthy 
controls (n=20).
Table 2. Patient characteristics.
CD pilot 
(n=20)
CD 
(n=66)
CD FU 
(n=39)b
Controls 
(n=20)c
Median age (at diagnosis in years, IQR) 30 (21-40) 27.5 
(22.0-43.3)
29 
(22.0-44.0)
26.5 
(23.0-46.0)
Female, n (%) 14 (70%) 45 (68%) 27 (69%) 16 (80%)
Symptoms before diagnosis in months
• 0-3
• 3-6
• >6
6 (30%)
6 (30%)
8 (40%)
20 (31%)
15 (23%)
31 (47%)
13 (33%)
10 (26%)
16 (41%)
Median clinical follow-up period in months 
(IQR)
53 (27-66)a 40 (13-60)a 51 (16-61)
Median months until second serum sample 
(IQR)
- - 33 (13-54) -
Smoking status at diagnosis
• Never
• Current
• Ceased
10 (50%)
10 (50%)
-
36 (55%)
25 (38%)
5 (8%)
20 (51%))
17 (44%)
2 (5%)
Median HBI score at diagnosis (IQR) 10 (8-12) 8 (6-13) 8 (6-13)
Disease location at diagnosis (Montreal)
• Ileal (L1), n (%)
• Colonic (L2), n (%)
• Ileocolonic (L3), n (%)
• + Upper GI involved (+L4), n (%)
• + Perianal disease (+P), n (%)
4 (20%)
4 (20%)
12 (60%)
8 (40%)
5 (25%)
25 (38%)
12 (18%)
29 (44%)
16 (24%)
11 (17%)
13 (33%)
6 (15%)
20 (51%)
11 (28%)
6 (15%)
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Table 2. continued
CD pilot 
(n=20)
CD 
(n=66)
CD FU 
(n=39)b
Controls 
(n=20)c
Disease behaviour at diagnosis (Montreal)
• Inflammatory, n (%)
• Stricturing, n (%)
• Penetrating, n (%)
13 (65%)
6 (30%)
1 (5%)
48 (73%)
14 (21%)
4 (6%)
28 (72%)
10 (26%)
1 (3%)
Median SES-CD score at diagnosis (IQR) 16 (10-27) 12 (8-21) 13 (8-20)
SES-CD severity at diagnosis
• Mild (4-10), n (%)
• Moderate (11-19), n (%)
• Severe (>19), n (%)
5 (25%)
8 (40%)
7 (35%)
27 (41%)
20 (30%)
19 (29%)
15 (39%)
14 (36%)
10 (26%)
Any recurrence after first moment of 
remission, n (%)
12 (60%) 31 (47%) 23 (59%)
Treatment during blood drawl
No medication
Oral steroids
Immunosuppressants
Anti-TNF
Combination anti-TNF + immunosuppressant
Combination of steroid + immunosuppressant
20 (100%) 66 (100%) 7 (18%)
2 (5%)
19 (49%)
4 (10%)
6 (15%)
1 (3%)
Highest treatment step during follow-up
• 5-ASA
• Oral steroids
• Immunosuppressants
• Anti-TNF
•Resective surgery
-
1 (5%)
9 (45%)
7 (35%)
3 (15%)
1 (2%)
4 (6%)
35 (53%)
19 (29%)
7 (11%)
-
-
22 (56%)
12 (31%)
5 (13%)
CD = Crohn’s disease, FU = follow-up, IQR = interquartile range, HBI = Harvey-Bradshaw Index, SES-CD 
= simple endoscopic score for Crohn’s disease, GI = gastrointestinal tract, 5-ASA = 5-aminosalicylic acid.
a P<0.05 between CD pilot cohort and consecutive CD cohort, no statistical significant differences for any of 
the other characteristics between these groups. 
b no statistical significant differences for all characteristics between follow-up and baseline cohort. 
c no statistical significant differences between healthy controls and any of the CD cohorts.
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Association of analyte levels with disease phenotype at diagnosis
Baseline characteristics of the consecutive cohort are shown in table 2. All MMP-9 levels 
were above standard range and were not included for further analyses. Compared to healthy 
controls, CD patients had higher baseline levels of sTNF-R2 (fold change 1.5, P=0.001), sIL-2R 
(fold change 1.8, P=0.0001) and MMP-1 (fold change 2.0, P=0.001) as shown in table 3. 
Shorter symptom duration before diagnosis (0-3 months) was associated with higher baseline 
MMP-1 and sIL-2R levels compared with longer (>6months) symptom duration (P=0.006 and 
P=0.005 respectively). Gender, age, smoking status, disease behaviour, and the presence of 
perianal disease at diagnosis were not associated with baseline analyte levels (data not shown).
When looking at disease location, patients with ileocolonic disease had higher baseline 
values of CXCL-13 (0.036), MMP-1 (0.009) and sIL-2R (P=0.003), than patients with solitary 
ileal disease. After correction for age, gender and symptom duration, only sIL-2R remained 
significant (P=0.006, with P=0.092 for CXCL-13 and P=0.164 for MMP-1). 
When comparing severe endoscopic disease activity (SES-CD>19) at diagnosis with mild 
endoscopic disease activity (SES-CD 4-10), higher concentrations of MMP-1 were found in 
patients with severe disease activity (P=0.018, figure 2a). However, after correction for age 
and gender, SES-CD severity and symptom duration were not independent factors associated 
with MMP-1 levels. SIL-2R was higher in severe endoscopic disease compared with both mild 
(P=0.009) and moderate disease (P=0.041, figure 2b). After correction for age, gender and 
symptom duration, this remained a significant independent factor (P=0.009). STNF-R2 serum 
concentrations were higher in patients with severe endoscopic disease activity compared with 
patients with mild disease activity (P=0.038, corrected for age and gender, figure 2c). 
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Table 3. Serum analyte values of Crohn’s disease (CD) patients at baseline and during follow-up, 
compared with healthy controls.
Baseline CD 
patients (n=66)
Follow-up, CD in 
remission (n=29)
Follow-up, CD during 
exacerbation (n=10)
Healthy controls 
(n=20)
IL-37 pg/ml 5
(below detection 
limit)
5
(below detection 
limit)
5
(below detection limit)
5
(below detection limit)
CCL-19 pg/ml 116
(89-151)
101bc
(86-127)
160ac
(129-203)
88
(65-138)
CXCL-13 pg/ml 35
(26-48)
28bc
(21-39)
47ac
(34-78)
28
(21-38)
sIL-2R pg/ml 190a
(112-327)
99bc
(33-179)
232ac
(155-282)
106
(69-145)
sTNF-R1 pg/ml 4236
(1696-5909)
557abc
(313-1864)
2828bc
(1160-4172)
3742
(366-5599)
sTNF-R2 pg/ml 1923a
(1593-2320)
1388b
(1235-1587)
1661
(1294-2035)
1277
(1036-1933)
S100A8 pg/ml 4762
(3106-8784)
2137b
(1454-4916)
2361
(1860-3872)
3812
(1744-5974)
CCL-5 ng/ml* 112
(67-168)
82b
(41-12)
91
(64-134)
99
(59-148)
VCAM ng/ml* 1549
(1197-1927)
1525
(1227-1759)
1355
(1278-1972)
1356
(1152-1830)
MMP-1 ng/ml* 47a
(22-85)
24b
(18-55)
34ab
(27-50)
23
(12-32)
MMP-9 pg/ml extrapolated above 
standard range 
extrapolated above 
standard range 
extrapolated above 
standard range 
extrapolated above 
standard range 
sIL-6R ng/ml* 21
(18-26)
19b
(14-22)
22
(18-30)
22
(17-25)
a P-value <0.05 compared to healthy controls, b P-value<0.05 compared to baseline values c P-value <0.05 
inactive versus active, 
*Please note that this unit (ng/ml) differs from other analyte units in this table (pg/ml)
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Figure 2. Serum analyte values at diagnosis (baseline) in Crohn’s disease (CD) patients showing 
different groups of endoscopic disease activity based on SES-CD. 
A. values of MMP-1 in ng/ml, B values of sIL-2R in pg/ml and C values of sTNF-R2 in pg/ml. *P<0.05. SES-
CD = Simple Endoscopy Score for Crohn’s disease; MMP = matrix metalloproteinase.
Association of analyte levels with disease course
Patients who did not respond to prednisone at initial treatment (n=9, 24%) had 1.5-fold higher 
pre-treatment levels of sTNF-R2 compared with steroid responders (n=28, 76%) (P=0.001). In 
the non-responding group, more patients needed initial stepping up to anti-TNF treatment 
(P=0.002) or resective surgery (P=0.011). 
When examining patients with a follow-up longer than one year (n=51, median follow-up 51 
months (IQR 23-63)), 29 patients (57%) suffered from at least one relapse after initial remission, 
whereas 22 (43%) patients maintained remission. There was no statistical significant difference 
in follow-up duration. Patients with relapsing disease had lower baseline sTNF-R2 levels (1821 
pg/ml (IQR 1546-2044) compared with patients in long-lasting remission with 2073 pg/ml (IQR 
1834-2661), P=0.019), independently associated after correction for SES-CD, age and gender. 
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They also had lower VCAM levels with 1494 ng/ml (IQR 1252-1735) compared with 1831 ng/ml 
(IQR 1375-2475), P=0.024. Baseline analyte values were not associated with development of 
perianal disease, disease behaviour, initiation of anti-TNF medication, or surgical intervention 
(data not shown).
Differential analyte expression in CD patients in remission and with active disease
The same 11 analytes were measured during the follow-up of 39 CD patients of the consecutive 
cohort (see table 2 for patient characteristics). Patients in remission at follow-up blood 
collection (n=29) had a median follow-up duration of 35 months (IQR 13-55), which was not 
significantly different from patients with an exacerbation (n=10, median follow-up of 32 months 
(11-48), P=0.58).
Compared with baseline, many analyte levels dropped during remission (see table 3 and 
figure 3): sTNF-R1 (P=0.001), sTNF-R2 (P=0.001), sIL-2R (P=0.001), MMP-1 (P=0.001), S100A8 
(P=0.002), CXCL-13 (P=0.012), CCL-19 (P=0.021), sIL-6R (P=0.025) and CCL-5 (P=0.037). During 
remission there was no significant difference from the levels of healthy controls, except for 
sTNF-R1, which was 6.7-fold lower in remission patients than in controls (P=0.015, table 3).
In patients with an exacerbation at the time of follow-up blood collection, there was an 
overall decrease of analyte levels compared with baseline (table 3 and figure 3), but this was 
only statistically significant for sTNF-R1 (P=0.007). In the patients with an exacerbation, the 
following followed-up analyte levels were higher than in healthy controls: sIL-2R (P=0.003), 
CCL-19 (P=0.007), CXCL-13 (P=0.028) and MMP-1 (P=0.031). Levels of sIL2-R, CCL-19 and 
CXCL-13, as well as sTNF-R1, were also significantly higher in patients with an exacerbation 
than in patients in remission (sIL-2R (P=0.012), CCL-19 (P=0.001), CXCL-13 (P=0.002), sTNF-R1 
(P=0.003)). We were unable to determine the effect of treatment modality on analyte levels 
during follow-up, due to fragmentation of patient groups.
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Figure 3. Crohn’s disease patient’s serum analyte levels measured in pg/ml and transformed to ng/ml 
for MMP-1, shown as baseline- and follow-up levels. 
In blue levels of the group that was in remission at follow-up blood collection (n=29) and in red the group 
with an exacerbation at follow-up blood collection (n=10). Healthy controls are shown in green. *P-value < 
0.05. MMP = matrix metalloproteinase.
Determination of optimal analyte thresholds
Based on these results we aimed to determine the optimal thresholds of baseline and follow-
up analytes to discriminate different groups of patients. For each analyte, we constructed ROC 
curves and used Youden´s index to define the optimal threshold.
To discriminate CD and controls, baseline sTNF-R2 showed a good sensitivity (91%) but a 
relatively low specificity (60%), whereas sIL-2R and MMP-1 had good specificity (95%) but 
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relatively low sensitivity (59 and 50% respectively) (supplementary figure 1 and supplementary 
table 4). SIL-2R was the best single marker with an area under the curve (AUC) of 0.774 
(supplementary figure 1). We reached an even higher AUC by combining the three markers 
(0.845) corresponding to a sensitivity of 62% and a specificity of 95% (supplementary figure 1 
and supplementary table 4).
Baseline sTNF-R2 was the best analyte to discriminate initial steroid non-responders from 
responders with an optimal threshold at 2371.58 pg/ml corresponding to an AUC of 0.845, a 
sensitivity of 89% and a specificity of 86% (figure 4 and supplementary table 5).
Baseline VCAM and sTNF-R2 had good sensitivity and acceptable specificity to discriminate 
between CD patients with future relapsing disease and CD patients with long-lasting remission. 
The most accurate single marker was sTNF-R2 with an AUC of 0.693 and when combining both 
analytes the AUC increased to 0.738 corresponding to a sensitivity of 50%, a specificity of 97% 
and both positive and negative predictive values higher than 70% (supplementary figure 2 and 
supplementary table 6).
Follow-up analytes sIL-2R, CCL-19, CXCL-13 and sTNF-R1 were all able to discriminate 
between CD patients with a current exacerbation and patients in remission with sensitivity and 
specificity above 70% (figure 5 and table 4). The combination of these markers gave a very good 
discrimination between the two groups with an AUC of 0.914 and corresponding sensitivity of 
80%, a specificity of 93%, positive and negative predictive values of 80 and 93% respectively.
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Figure 4. Receiver operating characteristic curve of baseline sTNF-R2 in Crohn’s disease patients to 
differentiate steroid responders from non-responders. AUC = area under the curve.
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Combination^, AUC=0.914
^y=-9.153+0.001*sTNF-R1+0032*
CCL-19+0.003*CXCL-13+0.011*sIL-2R
Figure 5. Receiver operating characteristic (ROC) curves of follow-up serum analytes (alone and 
combined) in Crohn’s disease patients, for differentiation between disease exacerbation and 
remission at that moment. 
AUC = area under the curve. Combination = CXCL-13 + CCL-19 + sIL-2R + sTNF-R1.
Table 4. Thresholds of follow-up serum analytes in Crohn’s disease patients, to differentiate disease 
exacerbation from remission
Threshold in 
pg/ml
Youden’s 
index
Area 
under the 
curve
Sensitivity Specificity Positive 
Predictive 
Value
Negative 
Predictive 
Value
sTNF-R1 2035 0.493 0.810 70% 79% 54% 88%
CCL-19 135 0.628 0.833 80% 83% 62% 92%
CXCL-13 44 0.562 0.821 70% 86% 64% 89%
sIL-2R 128 0.590 0.765 90% 69% 50% 95%
Combined^ 0.3912807 0.731 0.914 80% 93% 80% 93%
^y=-9.153 + 0.001*sTNF-R1 + 0.032*CCL-19 + 0.003*CXCL-13 + 0.011*sIL-2R
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DISCUSSION
In the present study, several cytokines, chemokines, soluble receptors, growth factors, and 
other mediators were analysed in the sera of newly diagnosed, untreated CD patients. At time of 
primary diagnosis, these patients had significant higher levels of sTNF-R2, sIL-2R, and MMP-
1 compared with healthy controls. Higher sIL-2R was an independent factor associated with 
ileocolonic disease over ileal disease. Furthermore, sTNF-R2 and sIL-2R were independently 
associated with endoscopic disease severity. Serial measurements revealed that sTNF-R1, 
sTNF-R2, sIL-2R, and MMP-1 were candidate markers of disease activity, as they all dropped 
significant from baseline levels during remission and were high during exacerbation. Initial 
non-response on prednisone therapy was associated with higher baseline levels of sTNF-R2. 
Furthermore, higher baseline values of sTNF-R2 and VCAM were associated with an indolent 
disease course without relapses, whereas lower levels were associated with relapsing disease.
Remarkably, almost all pro-inflammatory cytokines, except for IL-6 and IL-18, were 
undetectable at baseline in most of the CD patients in the pilot cohort. This includes members 
of the IL-1 superfamily (IL-1a, IL-1b, IL-33), those responsible for a Th17 response (IL-12, IL-
17 and IL-23), a Th1 response (IFN-g) and a Th2 response (IL-13 and IL-33), all implicated in 
the pathogenesis of IBD 17. Particularly striking is the fact that TNF-a is undetectable in serum 
from 16 out of 20 patients. Reported series on serum TNF-a are conflicting, differing from 
raised levels 22 to normal 23 or undetectable 24. As raised TNF-a concentrations have been 
found in the inflamed mucosa of IBD patients 25, an undetectable serum TNF-a concentration 
suggests a sequestration of pro-inflammatory cytokines from the systemic circulation towards 
the inflamed gut mucosa or increased binding to soluble TNF receptors (sTNFRs). This may put 
forward an explanation of the ineffectiveness of Etanercept- an engineered human sTNF-R2, 
preferentially neutralizing soluble TNF-a 26, as opposed to the beneficial therapeutic effects of 
Infliximab and Adalimumab, which bind both soluble and membrane-bound TNF-a 27.
In the consecutive cohort of patients, baseline levels could not predict the development of 
severe disease complications like perianal disease or stricturing and penetrating disease. 
However, we still cannot rule out the value of baseline serum analytes in predicting occurrence 
of complications in CD, since longer follow-up duration (over 10 years) is needed to conclude 
on this topic. Furthermore, in accordance with the numbers in our study, it is known that 20-
30% of patients have already developed complications at time of diagnosis 1,2. We did find 
an association of lower baseline serum levels of sTNF-R2 and VCAM with relapsing disease 
behaviour, whereas higher levels raised the probability of more quiescent disease after primary 
treatment. The combination of both markers demonstrated the best predictive value (AUC 
0.738). VCAM is expressed by activated endothelium and regulates lymphocyte, monocyte, 
eosinophil and basophil adhesion, promoting their recruitment into the inflamed mucosa. 
In line with our results, positive serum VCAM levels were previously shown to be predictive 
of sustained clinical remission after infliximab cessation 28. The authors hypothesized that 
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this soluble adhesion molecule may prevent adherence of inflammatory cells to the vascular 
endothelium by competition, thereby diminishing gut inflammation.
Our serial analyte measurement in patients (a group in remission and a group during 
exacerbation at blood collection) ensured an analysis of the evolution of these different analytes 
during the course of disease. The fact that most serum analyte levels (10/11) dropped in CD 
patients in remission, is an important observation as this implies direct association of these 
serological markers with mucosal disease activity in CD. Our results therefore demonstrate that 
the value of serum analytes in CD patients should be analysed and interpreted in combination 
with disease activity. Further research with a different design needs to be initiated to study the 
effect of different treatment modalities on serum analytes in larger (sub)groups. 
Remarkably, whereas most followed-up levels in remission were comparable to those from 
healthy controls, the followed-up level of sTNF-R1 was almost 7-fold lower in patients in 
remission compared with healthy controls. In patients with an exacerbation at follow-up, 
sTNF-R1 levels also dropped compared with their baseline levels, however they were five times 
higher than in patients during remission and comparable to healthy controls. This finding on 
sTNF-R1 gives an insight into the initial immune response in CD patients. 
The evolution over time hints at a possible role for serial measurement of sTNF-R1 to monitor 
disease activity. STNFRs are able to neutralise TNF, preventing its interaction with membrane-
bound receptors and therefore functioning as physiological attenuators 29. Membrane bound 
TNF-R1 is ubiquitously expressed and binds soluble and transmembrane TNF-a, and its 
function is primarily pathogenic, inducing inflammation, tissue degeneration and apoptosis 30. 
On the other hand, membrane bound TNF-R2 preferentially binds transmembrane TNF-a and 
its function is primarily homeostatic, inducing tissue regeneration, cell proliferation and cell 
survival. 
Administration of TNF to humans was shown to induce higher sTNF-R1 and sTNF-R2, probably 
by a shedding mechanism 31,32. In our study, higher levels of sTNF-R2, but not sTNF-R1 were 
found in serum of CD patients compared to controls at baseline. As shedding of sTNF-R2 
belongs to the armoury of regulatory T lymphocytes to inhibit TNF-a mediated inflammation, 
these higher baseline levels and its decline during disease remission might portray the body’s 
attempt to inhibit the TNF-a proinflammatory downstream effects 33-35. The fact that higher 
sTNF-R2 baseline values were associated with prednisone non-response and early step-up 
treatment could represent another disease mechanism in these patients. Elevated baseline 
sTNF-R2 might be associated with high mucosal TNF levels and a defective TNF-TNFR2 
binding at the site of active inflammation, leading to increased shedding of sTNF-R2 in the 
circulation. 
This group of patients might benefit more from anti-TNF treatment early in the course of 
disease, than might patients with low baseline sTNF-R2 levels. In two other studies in treated 
CD patients with a disease duration over nine years, elevated sTNFRs were found in patients 
with clinically active disease 24,36. One study found increased sTNFR levels in all CD patients, 
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both during remission and active disease 36 whereas the other study described significantly 
lower levels of both sTNFRs in patients in remission. They also showed that sTNF-R2 levels 
decreased after infliximab therapy whereas it did not affect sTNF-R1 24. In rheumatoid arthritis 
and sarcoidosis patients, similar results were obtained where higher baseline levels of sTNF-R2 
correlated with (prolonged) therapeutic response to anti-TNF treatment 34,37. In the present 
study sTNF-R2 showed an accuracy of AUC = 0.845 in predicting steroid response in early CD 
patients. It would be interesting to further investigate whether sTNF-R2 could act as a marker 
in determining which CD patients will benefit most from steroids or anti-TNF treatment.
Next to the sTNFRs, sIL-2R and MMP-1 also emerged as potential markers of disease activity. 
Both were elevated at baseline compared with healthy controls, and decreased in patients in 
remission at follow-up and higher levels were found at follow-up in patients during exacerbation 
compared with healthy controls. Furthermore, sIL-2R was also independently associated 
with ileocolonic disease and a severe endoscopic score. The membrane-bound receptor for 
interleukin-2 is expressed among many leukocytes such as activated T cells and regulatory T 
cells, natural killer cells, activated B cells, monocytes, and eosinophils 38. Proteolytic cleavage 
seems to be responsible for the production of circulating sIL-2R. In line with our results, sIL-
2R levels were previously found to be elevated in CD patients (under treatment) compared 
with controls, and levels correlated with disease activity and treatment response 39-43. Despite 
its potential as biomarker, demonstrated in several studies, sIL-2R has not yet reached 
clinical practice. In sarcoidosis, sIL-2R has been proposed as marker of disease activity 44. 
Increased levels have also been observed in diseases like rheumatoid arthritis and systemic 
lupus erythematosus 45,46. Therefore, sIL-2R cannot be used as diagnostic tool but might be 
interesting as a marker of disease activity in CD.
Matrix metalloproteinases (MMPs) are enzymes with an important role in tissue remodelling, 
as they are capable of degrading extracellular matrix proteins. MMP-1 breaks down interstitial 
collagens and has been suggested to have an anti-fibrotic role, as its overexpression attenuated 
liver- and cardiac fibrosis in animal models 47,48. Previously, MMP-1 plasma concentrations 
were found to be elevated in patients with active ulcerative colitis compared with controls 49,50. 
However, to our knowledge, MMP-1 serum levels have not been evaluated in CD patients. MMP-
1 expression was reported to be increased in biopsy specimens of inflamed colonic mucosa of 
IBD patients and showed a good correlation with the histological degree of inflammation 51,52. 
In accordance with ulcerative colitis we find higher baseline levels of MMP-1 in active CD 
compared with controls. We extended on this finding with its decrease in serial measurements 
in patients during remission, whereas levels during exacerbation were higher than in healthy 
controls. Therefore, we believe MMP-1 might be a useful marker of disease activity. MMP-9 
seems to be an important marker in CD 53. Unfortunately, as MMP-9 levels in our study were all 
extrapolated above standard range (both in patients and in healthy controls), these values were 
not reliable for further analysis. However, we do believe that it would be worthwhile to further 
investigate this marker using higher dilutions.
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CCL-19, CXCL-13, sTNF-R1, and sIL-2R could differentiate between remission and 
exacerbation at follow-up blood collection. CCL-19 was the most accurate single marker (AUC 
= 0.833), but the best accuracy was reached by a combination of these four analytes (AUC = 
0.914). Further research is needed to elucidate if the combination of these markers can be 
used to identify patients with a disease exacerbation, without the need for endoscopy or faecal 
calprotectin examination. Chemokines CXCL-13 and CCL-19 are known to be required for the 
development and maintenance of secondary and tertiary lymphoid organs, as well as the entry 
of lymphocytes and dendritic cells into these lymphoid organs 54,55. Circulating levels possibly 
reflect the expression in the inflamed gut. Serum and mucosal CXCL-13 was found to be 
elevated in IBD patients compared with controls 56-58. The differentiating potential of elevated 
serum levels of CCL-19 and CXCL-13 between exacerbation and remission might be explained 
by the formation and resolution (respectively) of tertiary lymphoid organs in the inflamed gut 59.
Previous studies on mediators of inflammation in CD patients have assessed individual 
analytes or combined a limited set of analytes in serum or intestinal mucosa. In these 
studies, heterogeneous patient cohorts with divergent disease durations and IBD phenotypes 
were included, and almost invariably patients were receiving immunomodulatory treatment. 
A recent literature overview identified 89 research papers on cytokines and chemokines in 
IBD patients, with a median sample size of 31 CD patients mainly receiving pharmacological 
therapy 18. Results of these studies are therefore inconclusive, as analyte levels are associated 
with disease activity and potentially also with treatment modality. Our serial results showed 
that patients in remission and patients in relapse displayed different evolution of serum analyte 
profiles and therefore these results should be analysed and interpreted separately.
We identified several limitations and possible explanations for the difference in results between 
the pilot cohort and the consecutive cohort. Due to the exploratory nature of the pilot group, no 
adjustments were made to the P-value for multiple comparisons. Furthermore, as the sample 
size was small we could not perform multivariate analysis. Due to the disease heterogeneity in 
CD we were limited by relatively small groups of different disease phenotypes. The follow-up 
duration of patients was probably too short to determine the true value of these baseline analyte 
levels in predicting future disease course with respect to the development of complications. 
The strength of our study is that we analysed a full spectrum of analytes in two well-
characterised cohorts of CD patients at the time of diagnosis, all with endoscopically confirmed 
inflammation. Our baseline results are not biased by the influence of therapy, as all patients 
were untreated. Compared with other papers on this topic, we had access to a relatively large 
group of CD patients and performed serial measurements during follow-up. Our analysis was 
based on released proteins and not on mRNA levels which can be hampered by regulatory 
events that may inhibit the translation of mRNA to protein. Here, we extended on the proposed 
immunological basis for CD heterogeneity, with several candidate serum analytes that might 
reflect the underlying complex immune processes in CD and seem to be logical and promising 
candidates as non-invasive biomarkers to predict disease activity and course.
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CONCLUSION
There is a very small window of opportunity for the analysis of early inflammatory processes 
in CD patients, as therapy that influences the immune system is usually initiated soon after 
diagnosis. The serial measurements in patients at diagnosis and during follow-up identified 
sTNF-R1, sTNF-R2, sIL-2R and MMP-1 as potential markers of disease activity. Furthermore, 
sTNF-R2 and VCAM were associated with prednisone response and disease course. These 
candidate markers are easily accessible and implementable in daily practice and therefore 
warrant further investigation.
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SUPPLEMENTARY TABLES AND FIGURES
Supplementary table 1. Analyte serum concentrations and clinical phenotype at diagnosis of CD 
patients.
MONTREAL 
CLASSIFICATION
ANALYTE Median (Min-Max)
sTNF-R1 
pg/ml
sTNF-R2 
pg/ml
sIL-2R 
pg/ml
S100A8 
ng/ml*
VCAM 
ng/ml*
IL-37 pg/
ml
MMP-9  
ng/ml*
L1 
(n=4)
2803 
(1414-6066)
1760 
(1692-2006)
248 
(149-469)
11 (5-26)
L2 
(n=4)
7744 
(4451-12559)
2932 
(2082-4327)
1207 
(536-2241)
26 (1128)
L3 (n=12) 4324 
(2879-7936)
2184 
(1531-4202)
571 
(220-1118)
6 (3-21)
+P (n=5) 972 
(664-1751)
275 
(10-1067)
9700 
(6560-11500)
Not +P (n=15) 1514 
(1086-3000)
10 
(10-374)
11700 
(3490-12000)
P-value L1 vs. L2 
0.026
L1 vs. L2 
0.026
L1 vs. L2 
0.008
L3 vs. L2 
0.022
0.025 0.033 0.025
* Please note that this unit (ng/ml) differs from the other analyte units in this table (pg/ml)
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Supplementary table 3. Number of patients with undetectable serum analytes in the Crohn’s disease 
patients and healthy controls
Serum analytes CD patients pilot 
cohort (n=20)
CD patients at 
baseline (n=66)
CD patients at 
follow-up (n=39)
Healthy controls 
(n=20)
IL-1α 13 - - -
IL-1β 17 - - -
IL-1RA 2 - - -
IL-6 2 - - -
IL-10 12 - - -
IL-12 11 - - -
IL-13 10 - - -
IL-17 10 - - -
IL-18 0 - - -
IL-21 0 - - -
IL-23 10 - - -
IL-33 9 - - -
IL-37 12 53 32 15
TNF-α 16 - - -
IFN-γ 14 - - -
CCL-2 0 - - -
CCL-3 0 - - -
CCL-4 0 - - -
CCL-5 0 0 0 0
CCL-19 0 0 0 0
CXCL-8 0 - - -
CXCL-10 0 - - -
CXCL-13 0 0 0 0
GM-CSF 15 - - -
EGF 0 - - -
VEGF 0 - - -
sICAM 0 - - -
sVCAM 0 0 0 0
sTNF-R1 0 0 0 0
sTNF-R2 0 0 0 0
sIL-2R 1 2 5 2
sIL-6R 0 0 0 0
MMP-1 0 0 0 0
MMP-3 0 - - -
MMP-9 0 0 0 0
S100A8 0 0 0 0
- = not measured in the consecutive cohort or healthy controls
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Supplementary table 4. Thresholds of baseline serum analytes in Crohn’s disease (CD) patients to 
differentiate CD from HC.
Threshold Youden’s 
index
Sensitivity Specificity Positive 
Predictive 
Value
Negative 
Predictive 
Value
sTNF-R2 1403 0.509 91% 60% 88% 67%
sIL-2R 172 0.541 59% 95% 97% 41%
MMP-1 51686 0.450 50% 95% 97% 37%
Combined 0.8294077 0.571 62% 95% 98% 43%
Supplementary table 5. Threshold of baseline sTNF-R2 in Crohn’s disease patients to differentiate 
steroid responders from non-responders.
Threshold in 
pg/ml
Youden’s 
index
Sensitivity Specificity Positive 
Predictive 
Value
Negative 
Predictive 
Value
sTNF-R2 2372 0.746 89% 86% 67% 96%
Supplementary table 6. Thresholds of baseline serum analytes in Crohn’s disease patients to 
differentiate future relapsing disease from long-lasting remission.
Threshold in 
pg/ml
Youden’s 
index
Sensitivity Specificity Positive 
Predictive 
Value
Negative 
Predictive 
Value
sTNF-R2 1996 0.406 72 68 75% 65%
VCAM 1876350 0.362 86 50 69% 73%
Combined^ 0.4426898 0.466 50 97 92% 72%
^ y = 5.576 + -0.001*sTNF-R2 + 0.0001*VCAM
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Combination^ AUC=0.845
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Supplementary figure 1. Receiver operating characteristic (ROC) curves of baseline serum analytes 
(alone and combined) for differentiation between Crohn’s disease (CD) and healthy controls (HC).  
AUC = area under the curve.
 
Future relapsing disease vs
long-lasting remission
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sTNF-R2, AUC=0.693
Combination^, AUC=0.738
^y=5.576+-0.001*sTNF-R2+
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Supplementary figure 2. Receiver operating characteristic (ROC) curves of baseline serum analytes 
(alone and combined) to differentiate future relapsing disease from long-lasting remission.  
AUC = area under the curve.
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DISCUSSION AND SUMMARY
The driving immune factors involved in the early stages of inflammatory bowel disease (IBD) are 
still poorly understood, as most studies investigate heterogeneous patient cohorts, including 
both active and inactive disease, with variable disease duration, and under various types of 
anti-inflammatory treatment. However, on top of the list of key research priorities regarding 
optimization of IBD treatment strategy is selection of the right patient group and phase of 
disease, and identification of markers for patient stratification regarding disease course 1. In 
this thesis we investigated the dysregulated immune response in IBD patients, with a focus on 
the T lymphocyte compartment, to define immunological biomarkers for disease development 
and prognosis. We studied patients at diagnosis, and during their follow-up, both at local 
(intestinal mucosa) and systemic (serum) level. We related the immune characteristics to 
disease activity and course of disease. Differences in mucosal T lymphocyte subsets or serum 
analytes at diagnosis and in the course of IBD might have predictive value for disease course 
or response to different therapeutic agents. However, before they can be translated to clinical 
practice, the first steps in this process are identifying potential biomarkers and analysing their 
behaviour in IBD patients over time.
Intestinal T lymphocytes
In chapter 2-5 we focused on T lymphocyte subsets in the intestinal mucosa of IBD patients 
at diagnosis and during follow-up. Our model of investigation consisted of biopsied specimens 
of the gut mucosa from newly diagnosed, untreated IBD patients at the time of their first 
presentation and during their follow-up as well as biopsied specimens from healthy controls. 
Several T lymphocyte populations were analysed by flow cytometric and immunohistochemical 
analysis. Two comprehensive literature reviews were performed to investigate the current 
knowledge on T lymphocyte subsets.
T lymphocyte activation, maturation and tertiary lymphoid organs
In the literature review in chapter 2, we discussed the pathways of T lymphocyte activation, 
maturation and migration to the gut mucosa in IBD, especially of the naïve T lymphocytes 
(TN), which are normally thought to be excluded from inflamed tissues. Classically, these 
TN are believed to recirculate between lymph, blood and secondary lymphoid organs (SLOs), 
e.g. lymph nodes (LN), gut associated lymphoid tissue (GALT); found at predefined sites and 
developed before birth. Tertiary lymphoid organs (TLOs) are ectopic accumulations of lymphoid 
cells which develop postnatally in response to inflammation or inflammatory cues in patients 
with autoimmune disease or cancer 2. In LN, T lymphocytes and DCs are directed to the 
paracortical region by CCL-19 and CCL-21, and B cells are directed to follicles by CXCL-13. 
These chemokines are also expressed in TLOs and can facilitate the TLO entry of circulating 
CCR-7+ TN and TCM lymphocytes. We presented the growing signals of the presence of TLO 
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formation in the inflamed mucosa and submucosa of IBD patients, potentially facilitating the 
homing of TN and TCM lymphocytes to the gut through the high endothelial venules (HEVs) 
present in TLOs. This could allow T lymphocytes to differentiate into effector cells, after contact 
with their cognate antigen, independent of SLOs. This pathway could explain the observed 
presence of TN and TCM lymphocytes in the inflamed intestine. Furthermore, it is conceivable 
that targeted therapy against TLOs could restore immunologic homeostasis in IBD patients, 
as they are thought to exacerbate inflammation in autoimmune diseases, whereas in cancer, 
their presence predicts a favorable outcome, suggesting it to be a site of antigen activation and 
anti-tumor immunity 2.
We explored TLO formation in the gut and the presence of T lymphocytes at different stages 
of maturation in the inflamed intestine of IBD patients in chapter 3. HEVs were studied by 
immunohistochemistry with staining of MECA-79, and lymphocytes subsets were identified 
by flowcytometric immunophenotyping. We described our finding of a higher number of 
extrafollicular HEVs in the inflamed intestine of newly diagnosed IBD patients compared to 
the uninflamed intestine of healthy controls (HC). A high extrafollicular HEV density in the 
gut (HEVhigh) was associated with increased gut infiltration of TN and TCM compared to HEV
low 
patients. HEVhigh patients also displayed a higher number of colonic follicles in their biopsied 
specimens compared to HEVlow patients, as well as upregulated serum chemokines associated 
with TLO formation (CXCL-13 and CCL-19). It was our interpretation that the extrafollicular 
HEVs represent an early phase of TLO formation in the inflamed mucosa, as these vessels were 
absent in healthy controls. 
Future research should elucidate the true function of TLOs in IBD pathogenesis and if HEVhigh/
low distinction can serve as biomarker in IBD patients. Analyzing HEVs and TLOs during disease 
course is necessary to elucidate whether they are present after treatment and in disease 
remission. It would also be an interesting topic for further research to study if HEVlow patients 
benefit more from anti-α4b7 therapy than HEVhigh patients, as HEVlow patients have higher 
percentages of gut TEM lymphocytes, generally thought to be α4β7
+. HEV and TLO formation 
could also be tested as a new treatment strategy; a candidate target is TNFR signaling, as it 
has been shown to induce ectopic HEVs whereas it is not required for maintenance of HEVs in 
SLOs 3.
In chapter 4, we identified the intestinal T lymphocyte infiltrate in IBD patients with active 
endoscopic disease at diagnosis and during follow-up. The T lymphocyte infiltrate was studied 
by flow cytometry identifying several lymphocyte subpopulations in the biopsied specimens. 
The infiltrate during active endoscopic disease was composed of increased percentages of 
CD4+ T lymphocytes, Tregs and TCM lymphocyte, with lower percentages CD8
+ T lymphocytes 
and CD103+ T lymphocytes compared to HC, and endoscopic inactive IBD. When patients 
entered endoscopic remission, lymphocyte subset composition of the gut recovered to 
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percentages comparable with HC, irrespective of treatment strategy. Baseline percentages of 
T lymphocyte subsets were associated with disease outcome. In patients with ulcerative colitis 
(UC), lower baseline percentages of CD3+ lymphocytes was associated with a milder disease 
course, without the need of step-up to an immunomodulator. In CD patients, higher baseline 
percentages of CD4+ lymphocytes and higher percentages of Tregs were associated with a 
more complicated disease course; the development of strictures or penetrating disease. This 
might be explained by increased invasion of proinflammatory CD4+ lymphocytes accompanied 
by a subsequent, but insufficient, Treg expansion. 
Future studies in another IBD patient cohort should confirm the predictive value of intestinal 
percentages of CD4+ lymphocytes and/or percentages of Tregs in Crohn’s disease (CD) patients, as 
well as percentages of CD3+ lymphocytes in UC patients, and cut-off values should be established. 
Flow cytometric marker panels performed on (human) tissues are almost solely based on, 
and extrapolated from, blood-based studies. Therefore, it would be interesting to investigate 
other markers in the intestinal gut mucosa of IBD patients and healthy controls regarding 
T lymphocyte maturation (CCR-7, CD62L, CD45RO, CD28, and CD31) and T lymphocyte 
proliferation (CD69, KI-67) to define the optimal gut mucosal marker panel. Functional studies 
in newly diagnosed IBD patients, for example investigation of local cytokine production of 
different intestinal T lymphocyte subsets, would enhance our understanding on the specific 
role of different T lymphocyte subsets in the early inflammatory processes. 
αEβ7 integrin
Anti-integrin therapy targeting T lymphocyte trafficking to the gut is emerging as a new 
treatment option for IBD patients. The transmembrane integrin αEβ7 (CD103) on T lymphocytes 
is thought to contribute to T lymphocyte retention within the gut, therefore blockade by anti-β7 
treatment, potentially disrupts this retention (phase three trials in IBD patients ongoing). 
Furthermore, by intervening with the α4β7/MAdCAM-1 interaction, anti-β7 treatment should 
also block the gut homing of α4β7+ lymphocytes. Chapter 5 encompasses a critical overview 
on the immune cells expressing integrin αEβ7, with a focus on their homeostatic roles (in 
health) and potential pathogenic roles (in IBD). The letter displayed in chapter 5a challenges 
the proposed pathogenic role of αEβ7+ T lymphocytes in IBD patients, as our group showed 
that newly diagnosed, untreated IBD patients have statistically significant lower percentages 
of αEβ7+ T lymphocytes in their inflamed intestinal biopsy specimen compared to HC 4. 
Furthermore, we demonstrated that patients who entered endoscopic remission had increased 
percentages of intestinal αEβ7+ T lymphocytes, which became comparable to the αEβ7+ T 
lymphocyte percentages of HCs. Therefore, αEβ7+ T lymphocytes might even be necessary to 
achieve/maintain remission in IBD patients. 
A detailed review of the topic was presented in chapter 5b. Next to its expression on pro-
inflammatory T lymphocytes, αEβ7 is also expressed on other (regulatory) immune cell subsets 
(e.g. Tregs, DCs), and in other organs than the gut (e.g. the brain, lungs, liver, kidneys). This 
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might lead to unwanted adverse events in IBD patients treated with anti-β7 therapy, targeting 
both α4β7 and αEβ7 immune cells. The development of anti-β7 treatment was prompted by 
the idea of increased αEβ7+ T lymphocytes in the inflamed intestine of IBD patients, implying a 
pathogenic role for these cells. However, this has not yet been demonstrated. On the opposite, 
lower percentages of αEβ7+ T lymphocytes are found in IBD patients compared to HC. Further 
research on this topic should identify subsets and functionality of the αEβ7+ intestinal T 
lymphocyte subsets in IBD patients. This could be done by functional assays, also studying 
TGF-beta and retinoic acid. Subset analysis should be done with other markers like CD69, 
CD4/CD8 determination, markers of T lymphocyte maturation, but also studying Tregs and DCs 
along the intestine. This could define specific subgroups of patients that might benefit from 
anti-β7 treatment.
Serum biomarkers
Readily available, non-invasive, accurate markers of disease activity that can predict future 
disease course or response to treatment would substantially contribute to early patient 
stratification in IBD. For this thesis we investigated several candidate serum markers in newly 
diagnosed, untreated IBD patients (chapter 6 and 7). Our model of investigation consisted of 
the serum IBD patients at diagnosis and during their follow-up, as well as serum from HCs. 
Serological antibodies were studied by enzyme-linked immunosorbent assays and indirect 
immunofluorescence. Cytokines, chemokines, growth factors, soluble receptors and other 
mediators were studies by multiplex immunoassays.
Serological antibodies
Despite intensive investigation of serological antibodies in adult IBD patients, these studies 
were single time point studies after disease complications had already occurred. In chapter 
6 we assessed serum antibodies in newly diagnosed IBD patients at diagnosis, and during 
their follow-up. The combination of pANCA and ASCA enabled good discrimination between 
CD and UC patients. No associations were found with antibody presence at diagnosis and 
disease outcomes. Overall, antibody prevalence in our real-world IBD study was relatively 
low compared to the prevalence in previous, referral-based, studies 5,6. Antibody presence 
at baseline showed good correlation with serial measurement, but its concentrations did 
fluctuate over time, sometimes related to thiopurine use and anti-TNF treatment. Therefore, it 
would be interesting to study these antibodies in homogenous patient cohorts, before and after 
starting the same therapeutic agent (for example infliximab) to reveal if antibody status and/
or magnitude changes with drug treatment and with treatment response. The appearance and 
disappearance of pANCA in UC over time correlated with disease activity, and might be used 
in disease monitoring as it also showed strong correlation with calprotectin values. Future 
investigations with longitudinal investigation of pANCA in UC patients over time during several 
exacerbations should reveal if it can be used as a monitoring marker (in a subgroup of patients). 
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If new serological antibodies are tested in IBD patients, we prompt their analysis in a real world 
IBD population, preferably newly diagnosed patients with longitudinal serum collections. 
Candidate serum markers
In chapter 7 we identified candidate serum markers by multiplex immunoassays in untreated 
CD patients at diagnosis and studied these markers during follow-up. Serum levels of sTNF-R2, 
sIL-2R and MMP-1 were higher in CD patients than in HCs, and dropped significantly from 
baseline levels during disease remission, while they rose during disease exacerbation. Almost 
all pro-inflammatory cytokines, implicated in the pathogenesis of IBD, were undetectable in 
our CD patients. This could suggest a sequestration of these cytokines towards the inflamed 
gut mucosa or increased binding to soluble receptors. Serial measurements identified a 
statistically significant drop of most analyte levels from baseline levels, only in patients 
in remission at follow-up. This suggests an association between serum marker levels and 
mucosal disease activity. At follow-up, the combination of CCL-19, CXCL-13, sTNF-R1, and 
sIL-2R could identify patients with disease exacerbation from patients in remission with good 
accuracy. The combination of these markers might hold the potential to identify disease 
exacerbation in patients without the need for (invasive) endoscopy. 
Lower baseline sTNF-R2 and VCAM serum levels were associated with relapsing disease 
behaviour and higher baseline sTNF-R2 levels were associated with initial non-response to 
oral steroid therapy. 
Future research should reveal the predictive value of the mentioned serum analytes in IBD 
patients. In line with our findings, sIL-2R was recently proposed as marker for mucosal healing 
in IBD patients 7. As this marker is already used in clinical practice in other patient categories, 
for example patients with sarcoidosis, it seems to be the first designated marker to undergo 
further investigation in CD patients. 
Studies in IBD patients on candidate markers, simultaneously analysing serum as well as 
intestinal supernatant could reveal the correlations between serum and gut marker levels and 
could give an insight on the etiological disease mechanisms. 
Serum analyte investigation in newly diagnosed UC patients and during follow-up should 
uncover candidate markers in those patients. Furthermore, in line with our suggestion on 
serological antibodies, homogeneous IBD patient cohorts should be tested on serum analytes 
before and after starting a therapeutic agent to reveal their biomarker value, especially in 
predicting treatment response. 
Future research
In general, the differences in immunological phenotypes we found both regarding T lymphocyte 
subsets as well as serum analytes, between patients with active endoscopic disease 
compared to healthy controls and patients in endoscopic remission, underline the necessity 
of distinguishing these subgroups in future studies. Even though this may sound logical, this 
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approach is still not common practice, as IBD patients are often compared to healthy controls, 
independent of the presence of intestinal inflammation. 
Simultaneously to the increasing incidence of IBD, the therapeutic armamentarium is rapidly 
expanding, with multiple novel agents waiting to enter the market. This poses opportunities 
and challenges for health care workers; how to choose the most appropriate therapy for the 
individual patient? The current IBD literature is increasingly urging to evolve from a symptom 
based treatment paradigm towards a treat-to-target approach, based on objective criteria 
and patient-reported outcomes, to decrease the long-term burden of disease 8,9. Biomarkers 
would be of great help to implement treat-to-target strategies in a personalized way. 
In this thesis we identified several candidate biomarkers in IBD patients and their behaviour in 
patients over time. In the future, the most potent predictive biomarkers should be combined in 
a web-based tool to reveal a patient’s risk profile, matching an individual patient with treatment 
and managing options, to enhance personalized medicine and disease outcomes. To reach this 
goal, extensive studies in homogeneous, well characterized IBD patient populations need to be 
performed on candidate predictive markers. 
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Tot op heden weten we weinig over de immunologische elementen (het afweersysteem) die 
betrokken zijn in het vroege stadium van inflammatoire darmziekten (IBD). Dit komt doordat 
de meeste studies heterogene patiëntgroepen onderzoeken, met daarin zowel patiënten 
met actieve als patiënten met inactieve ziekte, met een wisselende ziekteduur en onder 
verschillende typen anti-inflammatoire medicatie. Toch staan er bovenaan de lijst met 
onderzoeksprioriteiten omtrent het optimaliseren van de behandelingsstrategieën bij IBD, de 
selectie van het juiste middel voor de meest geschikte patiëntengroep en fase van ziekte, en het 
opsporen van markers die kunnen voorspellen hoe het ziektebeloop van verschillende patiënten 
zal zijn1. Wij denken dat we, om deze vragen te beantwoorden, eerst meer moeten snappen 
over die immunologische elementen in het vroege IBD-stadium, dus aan het begin van de 
ziekte. In dit proefschrift onderzoeken we de verstoorde immuunrespons in IBD-patiënten, met 
speciale aandacht voor T-lymfocyten (afweercellen behorend tot de witte bloedcellen), in een 
poging tot het identificeren van immunologische markers die het ziektebeloop van patiënten 
kunnen voorspellen en die iets zeggen over de prognose van de patiënt. We bestudeerden 
patiënten met IBD op het moment van diagnose en gedurende hun ziekte, hierbij keken we op 
lokaal niveau (darmslijmvlies) en systemisch niveau (bloed). We relateerden immunologische 
karakteristieken aan ziekteactiviteit en ziektebeloop. Verschillen in typen T-lymfocyten in het 
slijmvlies of in analyten in het bloed bij patiënten met IBD op het moment van diagnose en 
gedurende de ziekte zouden voorspellende waarde kunnen hebben voor het ziektebeloop 
of de respons op verschillende behandelingen. Echter, de eerste stappen in dit proces zijn 
het identificeren van potentiële markers en het analyseren van hun gedrag in IBD-patiënten 
op verschillende momenten, voordat deze markers gebruikt kunnen worden in de klinische 
praktijk.
T-lymfocyten in de darm
In hoofdstukken 2 tot en met 5 hebben wij ons gefocust op verschillende T-lymfocyten 
subsets in het darmslijmvlies van patiënten met IBD op het moment van diagnose en 
gedurende hun ziekte. Ons onderzoeksmodel bestond uit het onderzoeken van darmbiopten 
van nieuw gediagnosticeerde IBD-patiënten en op een later moment gedurende hun ziekte. 
Hiernaast onderzochten we ook darmbiopten van gezonde volwassenen ter controle. 
Verschillende typen T-lymfocyten werden geïdentificeerd met behulp van flowcytometrisch 
en immunohistochemisch onderzoek. Twee gedetailleerde reviews van de literatuur werden 
uitgevoerd om de huidige stand van zaken omtrent T-lymfocyten subsets binnen IBD op een 
rij te zetten. 
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T-lymfocyt activatie, rijping en tertiair lymfoïde organen
In de literatuurreview in hoofdstuk 2 bediscussieerden we de manier van T-lymfocyt activatie, 
rijping en migratie naar het darm slijmvlies bij IBD, met de nadruk op naïeve T-lymfocyten 
(TN), waarvan normaal gesproken verondersteld wordt dat deze zich niet bevinden in ontstoken 
weefsels. De klassieke gedachte is dat deze TN circuleren tussen lymfevloeistof, bloed 
en secundaire lymfoïde organen (SLOs) zoals de lymfeklieren en de platen van Peyer; die 
gevonden worden op standaard plaatsen in het lichaam en ontwikkeld zijn voor de geboorte. 
Tertiair lymfoïde organen (TLOs) zijn ectopische ophopingen van lymfoïde cellen die zich na de 
geboorte ontwikkelen als reactie op ontsteking of ontstekingsprocessen in patiënten met een 
auto-immuunziekte of kanker 2.
In lymfeklieren worden T-lymfocyten en dendritische cellen naar de paracorticale regio 
gestuurd door CCL-19 en CCL-21, terwijl B-lymfocyten naar de follikels worden geleid door 
CXCL-13. Deze chemokines worden ook gevonden in TLOs, waar ze de toegang van CCR-7+ TN 
en central memory T (TCM) lymfocyten kunnen faciliteren. 
Wij presenteerden groeiend bewijs van de aanwezigheid van TLO vorming in het ontstoken 
slijmvlies van IBD-patiënten, waar ze mogelijk zorgen voor de migratie van TN en TCM 
lymfocyten naar de ontstoken darm via hoogendotheliale venulen (specifieke kleine bloedvaten, 
HEVs) aanwezig in TLOs. Dit zou er voor kunnen zorgen dat T-lymfocyten differentiëren naar 
effectorcellen, na contact met hun antigeen, onafhankelijk van SLOs. Deze route zou de 
aanwezigheid van TN en TCM lymfocyten in de ontstoken darm kunnen verklaren. Verder is het 
denkbaar dat therapie gericht tegen TLOs de immunologische balans in IBD-patiënten zou 
kunnen herstellen, waarbij de gedachte is dat TLOs opvlammingen in auto-immuunziekten 
kunnen bewerkstellingen. Bij kanker lijken ze juist samen te hangen met een gunstige 
prognose, wat suggereert dat het daarbij een plek is van antigeen activatie en anti-tumor 
immuniteit 2. 
We onderzochten de vorming van TLOs in de darm en de aanwezigheid van T-lymfocyten in 
verschillende fasen van rijping in de ontstoken darmwand van IBD-patiënten in hoofdstuk 3. 
We bestudeerden HEVs met behulp van immunohistochemische kleuring van de darmbiopten 
met MECA-79 en de verschillende T-lymfocyten subsets werden geïdentificeerd met 
flowcytometrisch onderzoek. We vonden meer extra-folliculaire HEVs in de ontstoken darm 
van nieuw gediagnosticeerde IBD-patiënten in vergelijking met de niet-ontstoken darm van 
gezonde volwassenen. Het hebben van meer extra-folliculaire HEVs (een zogenaamd HEVhoog 
profiel) was geassocieerd met een toegenomen infiltratie van TN en TCM lymfocyten in de 
darm in vergelijking met HEVlaag patiënten. HEVhoog patiënten hadden ook meer follikels in 
hun dikke darm biopten in vergelijking met HEVlaag patiënten, alsmede een hogere waarde 
van serum chemokines die geassocieerd zijn met de vorming van TLOs (CXCL-13 en CCL-19). 
Het was onze interpretatie dat deze extra-folliculaire HEVs een vroege fase van TLO vorming 
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in de ontstoken darm weerspiegelen, omdat deze bloedvaten afwezig waren in gezonde 
volwassenen. Toekomstig onderzoek zal moeten ophelderen wat de functie van TLOs in de 
pathogenese van IBD is en of het onderscheid tussen HEVhoog/laag kan dienen als marker in IBD-
patiënten. Het analyseren van HEVs en TLOs gedurende de ziekte is nodig om te ontdekken of 
ze verdwijnen tijdens behandeling, als de darm niet meer ontstoken is. Het zou interessant zijn 
om te onderzoeken of patiënten met een HEVlaag profiel meer baat hebben van behandeling met 
anti-α4b7 dan HEVhoog patiënten, omdat HEVlaag patiënten hogere percentages effector memory 
T-lymfocyten in de darm hebben, welke voornamelijk α4β7+ lijken te zijn. De vorming van HEVs 
en TLOs in IBD zou ook getest kunnen worden als doelwit voor nieuwe behandelstrategieën. 
Een kandidaat-molecuul hiervoor is tumor necrosis factor receptor signalering, aangezien 
werd aangetoond dat dit de nieuwvorming van HEVs kan induceren terwijl het niet nodig is voor 
het behoud van HEVs in SLOs 3. 
In hoofdstuk 4 identificeerden we het infiltraat van T-lymfocyten in de darm van IBD-patiënten 
met actieve endoscopische ziekte op het moment van diagnose en gedurende hun ziekte. Het 
T-lymfocyten infiltraat werd bestudeerd met behulp van flowcytometrisch onderzoek van de 
darmbiopten. Gedurende actieve endoscopische ziekte bestond dit infiltraat voornamelijk 
uit een toegenomen percentage van CD4+ T-lymfocyten, regulatoire T-lymfocyten en TCM 
lymfocyten, met afgenomen percentages van CD8+ T-lymfocyten en CD103+ T-lymfocyten in 
vergelijking met gezonde volwassenen en endoscopisch inactieve ziekte (niet-ontstoken 
darm na behandeling). Als patiënten endoscopisch inactieve ziekte bereikten, herstelden alle 
percentages van lymfocytensubsets in de darm tot waarden die vergelijkbaar waren met gezonde 
volwassenen, ongeacht de behandelstrategie. Bepaalde percentages van T-lymfocyten subsets 
op het moment van diagnose waren geassocieerd met de uitkomst van ziekte. In patiënten 
met colitis ulcerosa (CU) waren lage percentages van CD3+ lymfocyten geassocieerd met een 
milder ziektebeloop, waarbij het niet nodig was om een behandelstap omhoog te gaan (het 
starten van een immunomodulator). In patiënten met de ziekte van Crohn (CD) waren hogere 
percentages van CD4+ lymfocyten en van regulatoire T-lymfocyten geassocieerd met een 
complexer ziektebeloop, namelijk de ontwikkeling van darmstricturen of fistelende ziekte. Dit 
zou mogelijk verklaard kunnen worden door een versterkte toestroom van proinflammatoire 
CD4+ lymfocyten samen met een inadequate expansie van regulatoire T-lymfocyten. 
Toekomstig onderzoek in een ander cohort IBD-patiënten zou de voorspellende waarde van 
de percentages van CD4+ lymfocyten en/of regulatoire T-lymfocyten in CD-patiënten, alsmede 
de percentages CD3+ lymfocyten in CU-patiënten, moeten bevestigen. Hierbij zouden ook de 
afkapwaarden moeten worden vastgesteld. 
Flowcytometrisch onderzoek op menselijke weefsels is nagenoeg altijd gebaseerd op 
onderzoek in bloed. Het zou daarom interessant zijn om andere flowcytometrische markers 
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te onderzoeken in de darmbiopten van IBD-patiënten en gezonde controles, gericht op 
T-lymfocyten rijping (bijvoorbeeld CCR-7, CD62L, CD45RO, CD28, en CD31) en T-lymfocyten 
proliferatie (CD69, KI-67), om het optimale panel van darmmarkers te identificeren. 
Functionele onderzoeken in nieuw gediagnosticeerde IBD-patiënten, bijvoorbeeld het 
onderzoeken van lokale cytokine productie van verschillende T-lymfocyten subsets in de darm, 
zou ons begrip verbeteren over de specifieke rollen van de verschillende subsets in de vroege 
inflammatoire fase van de ziekte. 
αEβ7 integrine
Een nieuw ontwikkelde behandeloptie voor IBD-patiënten is anti-integrine therapie, welke de 
migratie van de T-lymfocyt naar de darm aanpakt. Er wordt gedacht dat de transmembraneuze 
integrine αEβ7 (CD103) op T-lymfocyten bijdraagt aan het vasthouden van T-lymfocyten in 
de darm, daarom zou een blokkade met een anti-β7 medicijn dit vasthouden verstoren. Op 
dit moment lopen de fase-3-studies van deze medicamenteuze therapie in IBD-patiënten. 
Daarnaast zou de anti-β7 behandeling, door het ingrijpen op de α4β7/MAdCAM-1 interactie, 
ook de migratie van α4β7+ lymfocyten naar de darm moeten blokkeren. Hoofdstuk 5 omvat 
een overzicht van de immuuncellen die de integrine αEβ7 tot expressie brengen, met een 
focus op hun homeostatische rol (in gezondheid) en hun potentiële pathogene rol (in IBD). 
Het commentaar, te vinden in hoofdstuk 5a, bediscussieert de voorgestelde pathogene 
rol voor αEβ7+ T-lymfocyten in IBD-patiënten. Onze onderzoeksgroep liet zien dat nieuw 
gediagnosticeerde IBD-patiënten statistisch significant lagere percentages van αEβ7+ 
T-lymfocyten in hun ontstoken darm-biopten hebben dan gezonde volwassenen4. Bovendien 
lieten we zien dat patiënten ten tijden van endoscopisch inactieve ziekte hogere percentages 
αEβ7+ T-lymfocyten in hun darmbiopten hadden, vergelijkbaar met de percentages van gezonde 
controles. Het zou daarom zelfs zo kunnen zijn dat αEβ7+ T-lymfocyten nodig zijn om remissie 
te bereiken en/of te behouden in IBD-patiënten. 
Een gedetailleerde review over dit onderwerp wordt gepresenteerd in hoofdstuk 5b. Naast de 
expressie van αEβ7 op pro-inflammatoire T-lymfocyten, wordt deze integrine ook teruggevonden 
op andere (regulatoire) immuuncellen (bijvoorbeeld regulatoire T-lymfocyten en dendritische 
cellen) en in andere organen dan de darm (bijvoorbeeld het brein, de longen, lever en nieren). 
Dit zou kunnen leiden tot ongewenste bijwerkingen in IBD-patiënten die behandeld worden 
met anti-β7 medicatie. De ontwikkeling van anti-β7 medicatie is gebaseerd op het idee dat 
IBD-patiënten een verhoogd aantal αEβ7+ T-lymfocyten in hun ontstoken darm zouden hebben, 
wat een pathogene rol voor deze cellen zou kunnen impliceren. Echter, tot op heden is dit 
niet aangetoond. Integendeel, lagere percentages van αEβ7+ T-lymfocyten worden gevonden in 
vergelijking met gezonde volwassenen. Toekomstig onderzoek op dit gebied zou zich moeten 
richten op het identificeren van de typen subsets en de functionaliteit van αEβ7+ intestinale 
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T-lymfocyten in IBD-patiënten. Dit zou gedaan moeten worden door middel van functionele 
analyses waarbij ook TGF-β en retinolzuur worden meegenomen. Subsetanalyse moet worden 
uitgevoerd met andere markers zoals CD69, CD4/CD8 en markers van de uitrijping van 
T-lymfocyten. Daarnaast zouden ook αEβ7+regulatoire T-lymfocyten en dendritische cellen in 
de darm onderzocht moeten worden. Dit onderzoek zou specifieke subgroepen van patiënten 
kunnen identificeren die wel behandeld kunnen worden met anti-β7 medicatie.
Serum biomarkers
Gemakkelijk beschikbare, minimaal invasieve, nauwkeurige markers van ziekteactiviteit 
bij IBD-patiënten die kunnen voorspellen hoe het ziektebeloop zal zijn of hoe de respons 
op een bepaalde behandeling zal zijn, zouden een substantiële bijdrage leveren aan vroege 
stratificatie van patiënten. In dit proefschrift onderzochten we verscheidene potentiële 
serummarkers in nieuw gediagnosticeerde, onbehandelde IBD-patiënten (hoofdstuk 6 en 7). 
Ons onderzoeksmodel bestond uit het serum van IBD-patiënten op het moment van diagnose 
en later in het beloop van hun ziekte, alsmede serum van gezonde volwassenen. Serologische 
antilichamen werden bestudeerd door middel van enzyme-linked immunosorbent assays 
(ELISA) en indirecte immunofluorescentie. Cytokines, chemokines, groeifactoren, oplosbare 
receptoren en andere mediatoren werden onderzocht door middel van een multiplex 
immunoassay.
Serologische antilichamen
Ondanks het feit dat er veel onderzoek is gedaan naar serologische antilichamen in volwassen 
IBD-patiënten, werd er in deze onderzoeken over het algemeen slechts op één tijdspunt een 
meting verricht, reeds nadat ziektecomplicaties waren opgetreden. In hoofdstuk 6 bepaalden 
wij de serum antilichamen in nieuw gediagnosticeerde IBD-patiënten ten tijde van hun initiële 
diagnose en tevens op een tweede moment tijdens het beloop van hun ziekte. De combinatie 
van pANCA en ASCA zorgde voor een goed onderscheid tussen patiënten met CD en CU. Wij 
vonden geen associatie tussen de aanwezigheid van antilichamen op het moment van diagnose 
en verschillende ziekte-uitkomsten. In ons onderzoek, in patiënten in de dagelijkse klinische 
praktijk van een groot perifeer ziekenhuis, was de prevalentie van antilichamen relatief laag 
in vergelijking met de prevalentie in eerdere studies, uitgevoerd bij patiënten in academische 
ziekenhuizen5,6. De aanwezigheid van antilichamen op het moment van diagnose was 
gecorreleerd met de aan- of afwezigheid bij de tweede meting. De concentraties fluctueerden 
echter wel tussen deze twee meetmomenten, soms gerelateerd aan thiopurine-gebruik en 
behandeling met anti-TNF medicatie. Het zou daarom interessant zijn om deze antilichamen in 
een homogeen patiëntencohort te onderzoeken, voor en na het starten van eenzelfde medicijn 
(bijvoorbeeld infliximab, een anti-TNF medicijn), om de aan- of afwezigheid van de antilichamen 
te onderzoeken, alsmede de mogelijke veranderingen door de behandeling en de samenhang 
met de effectiviteit van de behandeling. De aan- of afwezigheid van pANCA in patiënten met CU 
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correleerde met ziekteactiviteit en zou mogelijk gebruikt kunnen worden bij het monitoren van 
ziekte, mede omdat het een sterke correlatie met de calprotectine waardes liet zien. 
Toekomstig longitudinaal onderzoek van pANCA in patiënten met CU gedurende meerdere 
momenten tijdens hun ziekte, zowel tijdens actieve als tijdens inactieve ziekte, zou moeten 
laten zien of dit antilichaam als marker gebruikt zou kunnen worden. Als nieuwe serologische 
antilichamen getest worden in IBD-patiënten zou het goed zijn om dit in een cohort te doen uit 
de dagelijkse klinische praktijk, bij voorkeur vanaf het moment van diagnose, met longitudinaal 
vervolg en meerdere serumanalyses gedurende de ziekte. 
Potentiële serummarkers
In hoofdstuk 7 identificeerden we potentiële serummarkers voor CD door middel van een 
multiplex immunoassay in het serum van onbehandelde patiënten op moment van diagnose 
en wij vervolgden deze potentiële markers gedurende het ziektebeloop. Serumwaarden van 
sTNF-R2, sIL-2R en MMP-1 waren hoger in CD-patiënten dan in gezonde volwassenen, de 
waarden daalden significant ten opzichte van baselinewaarden ten tijde van periodes van 
remissie, terwijl ze stegen gedurende een opvlamming van de ziekte.
Nagenoeg alle pro-inflammatoire cytokines, welke verondersteld worden betrokken te zijn bij 
de pathogenese van IBD, waren ondetecteerbaar in het serum van onze patiëntengroep. Dit 
zou kunnen suggereren dat er een verplaatsing optreedt van deze cytokines van het bloed 
naar de ontstoken darm of dat er een verhoogde binding van deze cytokines aan oplosbare 
receptoren is. 
Seriële metingen lieten een statistisch significante daling van nagenoeg alle potentiele 
serummarkers zien in patiënten die inactieve ziekte hadden gedurende de tweede meting. Dit 
suggereert dat er een associatie is tussen de waarden van de verschillende serummarkers 
en mucosale ziekteactiviteit. Bij de tweede meting was de combinatie van CCL-19, CXCL-
13, sTNF-R1, en sIL-2R zeer accuraat in het identificeren van patiënten met actieve ziekte 
ten opzichte van patiënten met inactieve ziekte. De combinatie van deze markers zou dus 
mogelijk ziekte-opvlamming kunnen vaststellen zonder de noodzaak tot invasief endoscopisch 
onderzoek.
Lagere baselinewaarden van sTNF-R2 en VCAM waren geassocieerd met ziekte met veel 
opvlammingen terwijl een hogere baselinewaarde van sTNF-R2 was geassocieerd met een 
slechte respons op initiële behandeling met orale corticosteroïden. 
Toekomstig onderzoek zou de voorspellende waarde van de bovenstaande potentiële 
serummarkers moeten bewijzen. In overeenstemming met onze bevindingen werd sIL-2R 
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recent voorgesteld als marker van mucosale genezing in IBD-patiënten 7. Deze marker wordt 
al in de klinische praktijk gebruikt in andere patiëntencategorieën, bijvoorbeeld patiënten 
met sarcoïdose, en lijkt zodoende de meest aangewezen marker voor verder onderzoek in 
CD-patiënten. Verder onderzoek in IBD-patiënten naar potentiële markers waarbij simultaan 
gemeten wordt in zowel serum als in supernatant van de darm zou de relatie tussen serum- en 
darmwaarden van verschillende markers kunnen onthullen en daarmee meer inzicht kunnen 
geven in het etiologische mechanisme van de ziekte. 
Onderzoek naar serummarkers in nieuw gediagnosticeerde patiënten met CU op moment van 
diagnose en gedurende het ziektebeloop zou ook in die patiëntengroep de potentiële markers 
openbaren. Daarnaast zou onderzoek naar serummarkers in homogene IBD-patiënten 
cohorten voor en na het starten van bepaalde medicamenten kunnen aantonen of het mogelijk 
is om de respons op een bepaalde behandeling te voorspellen. 
Toekomstig onderzoek
In het algemeen onderstrepen onze bevindingen van verschillende immunologische profielen 
op het gebied van T-lymfocyteninfiltraat en serumanalyten, tussen patiënten met actieve 
endoscopische ziekte in vergelijking met gezonde volwassenen en patiënten met endoscopisch 
inactieve ziekte, de noodzaak tot het opsplitsen van deze subgroepen patiënten in al het 
komende onderzoek. Ondanks dat dit logisch klinkt, is het in de praktijk helaas nog niet 
gebruikelijk om dit onderscheid te maken en worden IBD-patiënten vaak vergeleken met 
gezonde volwassenen, onafhankelijk van de aan- of afwezigheid van actieve ziekte in de darm.
Synchroon aan de toegenomen incidentie van IBD, breidt het therapeutisch arsenaal snel uit, 
met vele nieuwe middelen die bijna op de markt komen. Dit zorgt voor kansen en uitdagingen 
voor artsen: hoe kiezen we het beste medicijn voor een specifieke patiënt? De huidige IBD-
literatuur verplaatst de focus steeds meer van een symptoomgerichte behandelstrategie 
naar een zogenaamde targetgerichte behandelstrategie, waarbij de behandeling gestuurd 
wordt door objectieve criteria en door patiënt gerapporteerde uitkomstmaten, met als doel de 
ziektelast op lange termijn te verlagen 8,9. Biomarkers zouden van substantieel belang zijn in het 
implementeren van deze targetgerichte behandelstrategieën op een gepersonaliseerde manier.
In dit proefschrift identificeerden we verscheidene potentiële biomarkers in IBD-patiënten en 
legden we hun aanwezigheid vast op verschillende momenten tijdens de ziekte. In toekomstig 
onderzoek zouden de best voorspellende markers gecombineerd moeten worden tot een online 
tool waarin het mogelijk is om het risicoprofiel van de individuele patiënt te matchen met 
de verschillende behandelopties om gepersonaliseerde geneeskunde te bereiken en betere 
ziekte-uitkomsten te krijgen. Om dit te bereiken is uitgebreid verder onderzoek nodig naar 
mogelijke biomarkers in homogene, goed gedefinieerde IBD-patiëntengroepen.
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ABBREVIATIONS
ACCA    anti-chitobioside carbohydrate antibodies 
ALCA    anti-laminaribioside carbohydrate antibodies 
AMCA    anti-mannobioside carbohydrate antibodies 
ASCA    anti-Saccharomyces cerevisiae antibodies 
AUC    area under the curve 
CCR   chemokine receptor 
CD   Crohn’s disease 
DC   dendritic cell 
FACS   Fluorescence-activated cell sorting 
GALT   gut associated lymphoid tissue 
GZMA   granzyme A 
HBI   Harvey-Bradshaw Index 
HC   healthy controls 
HEVs  high endothelial venules 
IBD   inflammatory bowel diseases 
IBDU   inflammatory bowel diseases type unclassified 
ICAM-1   intercellular adhesion molecule 1 
IEL   intraepithelial T lymphocyte 
IFX  infliximab 
ITGAE    gene expression of integrin alpha E 
IQR    interquartile range 
LFA-1    lymphocyte function-associated antigen 1 
LPL    lamina propria T lymphocytes 
LTα1β2   Lymphotoxin α1β2 
mAb    monoclonal antibody 
MAdCAM-1 mucosal adressin-cell adhesion molecule-1 
MHC    major histocompatibility complex 
MLN   mesenteric lymph node 
MMPs   matrix metalloproteinases 
pANCA   perinuclear anti-neutrophilic cytoplasmic antibodies 
PE   phycoerythrin 
PNAd   peripheral lymph node addressin 
PPs   Peyer’s patches 
RA   retinoic acid 
ROC   receiver operating characteristic 
RTE   recent thymic emigrants 
SES-CD   simple endoscopic score for Crohn’s disease 
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SLOs   secondary lymphoid organs 
STNFRs   soluble TNF receptor 
TCR  T cell receptor 
TGF-β   Transforming Growth Factor-β 
TNF-α   tumour necrosis factor-α 
TRECs   T cell receptor excision circles 
Tregs   regulatory T cells 
TCM   central memory T lymphocytes 
TEM   effector memory T lymphocytes 
TEMRA   effector memory T cells re-expressing CD45RA 
TN   naive T lymphocytes 
TRM   tissue-resident memory T cells 
TLOs   tertiary lymphoid organs 
UC   ulcerative colitis
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gewoon onwijs veel lol en een mooie tijd gehad. Jaren van een dikke vette lach en af en toe 
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vervolgens wordt gekeken hoe we plannen kunnen uitwerken, liefst in samenwerking met 
andere experts. Ondanks dat alleen mijn naam op de cover van dit proefschrift staat, heb ik het 
werk zeker niet alleen gedaan. Mijn dank gaat dan ook uit naar iedereen die, direct of indirect, 
heeft bijgedragen aan de totstandkoming van dit proefschrift. 
Zonder alle patiënten die toestemming gaven voor deelname aan mijn onderzoeken was dit 
proefschrift er sowieso nooit geweest. Dank voor jullie onvoorwaardelijke vertrouwen! We 
kunnen het alleen maar samen doen, hopelijk zijn we weer een stapje dichterbij de ontrafeling 
gekomen. 
Dr. P.J. Wahab en dr. M.J.M. Groenen, beste Peter en Marcel, ik weet nog goed dat ik tegenover 
jullie zat aan het einde van mijn senior coschap en dat jullie vol enthousiasme aan het vertellen 
waren over het onderzoek en jullie toekomstplannen. Ik heb nooit getwijfeld over de keuze die 
ik heb gemaakt voor het onderzoek in het Rijnstate omdat ik nooit reden had om te twijfelen. 
Dank voor jullie vertrouwen! Peter, ik bewonder jouw enthousiasme en je onvermoeibare inzet 
maar ook je kritisch denken, bescheidenheid en inlevingsvermogen. Dit heeft het onderzoek 
en mij als persoon heel erg vooruit geholpen de afgelopen jaren! Dank voor het af en toe 
binnenstormen achterin dat hok waar ik verscholen zat. Niemand gooit de deur zo hard dicht 
als jij, maar ook niemand heeft hem zo duidelijk voor mij open gezet. Marcel, de rust en 
duidelijkheid die jij af en toe kon scheppen waren erg welkom, daarbij altijd oog houdend voor 
de klinische kant van het wetenschappelijk onderzoek. Heerlijk vond ik ook jouw opgewektheid 
en humor, waarmee je iedereen altijd weer aan het lachen kreeg. Dank voor je luisterend oor 
en je vertrouwen, dank voor het tegenwicht dat je af en toe biedt. Ik kijk er naar uit om straks 
onder jouw hoede de opleiding te vervolgen bij de MDL in het Rijnstate!
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Dr. E.G. van Lochem, lieve Ellen, ook de eerste keer dat ik jou zag kan ik me nog goed heugen. 
Ik was een beetje zenuwachtig, want die artsen die kende ik wel, maar een immunoloog 
had ik nog nooit één op één ontmoet. Dit bleek natuurlijk onzin, want ook bij jou straalde 
het enthousiasme er vanaf en mijn keuze was snel gemaakt. Ellen, ik waardeer je kritische 
kanttekeningen en de frisse invalshoeken die je met je mee brengt. Dank voor het altijd tot 
het uiterste willen gaan, waarbij je mij dan altijd weer wist over te halen tot het geheel nét 
even anders aan te vliegen. Of me over te halen toch nog even die ene figuur erbij te maken, 
omdat een stuk daar zoveel beter van zou worden. Ik vraag me geregeld af hoeveel uur jij in je 
dag hebt zitten en hoe je alles gedaan krijgt wat je doet. Als enige immunoloog werk je in een 
vakgroep van medisch microbiologen, werk je in twee ziekenhuizen, heb je tal van neventaken, 
heb je bedrevenheid in het doen van onderzoek en doe je ook nog leuke dingen met je gezin! 
Gelukkig blijven we elkaar nog veel tegenkomen de komende jaren!
Prof. dr. J.P.H. Drenth, beste Joost, dank voor je vertrouwen in mij en onze onderzoeksgroep. 
Gelukkig konden we goede afspraken maken en is het daadwerkelijk gelukt om alles af te 
ronden. Hartelijk dank voor de prettige samenwerking. 
Leden van de manuscriptcommisie, prof. dr. I. Joosten, prof. dr. M.G. Netea, prof. dr. G. Dijkstra, 
dank voor de tijd en energie die jullie gestoken hebben in de beoordeling van mijn manuscript 
en de bereidheid deel te nemen in mijn promotiecommissie. Daarnaast wil ik de leden van de 
corona bedanken voor het optreden als opponent.
Dr. C.S. Horjus Talabur Horje, lieve Carmen, ik bewonder de passie die je hebt voor het 
onderzoek en de tijd en energie die je er nog steeds in steekt. Ik vind het fijn dat we een 
paar jaar intensief samen op konden gaan in het doen van onderzoek voordat jij promoveerde. 
Heerlijk om met elkaar te kunnen discussiëren op hetzelfde niveau en om aan een paar 
woorden genoeg te hebben! Leuk dat ik ook je gezin heb leren kennen en dat je wat meer tijd 
hebt voor ontspanning nu je promotie achter de rug is. 
Lieve Britt, wat ontzettend gaaf dat jij het onderzoek weer voortzet! Ook al moet je nog steeds 
je naam veranderen in een voornaam met de letter C, verder pas je helemaal in het rijtje. Je 
hebt heel veel op je bordje liggen om uit te werken, wat ontzettend leuk is, maar soms ook 
lastig. Hopelijk mag ik je hierbij blijven helpen en kan ik je af en toe met raad en daad bij staan. 
Het is voorbij voor je er erg in hebt. Geniet van deze periode!
Achter Ellen staat een fantastisch mooi immunologie lab met alle medewerkers die 
ontzettend hard hebben gewerkt aan het verwerken van al het bloed en de biopten, 
dank daarvoor! Elly van Koolwijk, zonder jouw hulp was dit allemaal überhaupt niet 
gelukt, dank voor je inzet, het meedenken en je kritische kanttekeningen zo nu en dan! 
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Jos Meijer en Maaike Rijnders, dank voor het harde werken aan het TLO stuk! Sabine 
Middendorp, dank voor je hulp bij mijn eerste review artikel, leuk om gelijk al met je samen te 
kunnen werken. Dank ook voor je kritische blik op het TLO stuk. Stefan Nierkens, dank voor 
je hulp bij het cytokine stuk en ook bracht je me in contact met Julia: fijn! Julia, thank you so 
much for all of your statistical input in the different manuscripts. I have learned a lot from 
you, especially that every MD researcher needs good statistical back up to work out the more 
complex analysis. Thanks for your critical input, the heatmaps and showing me the decent 
ways to prove the reviewers wrong. Femke, wat leuk dat jij wat zag in het CD103 review stuk en 
dat je eraan mee wilde werken, dank voor je kritische blik.
Fijne Rijnstate MDL vakgroep, Jordy, Marcel G, David, Carmen, Tze, Marleen, Frank, Rob, 
Marcel S, Jan-Maarten, Peter, wat zijn jullie een mooie groep samen en wat creëren jullie een 
fijne sfeer. Dank voor de hulp bij het includeren van patiënten, jullie vertrouwen en steun. Ik 
kijk er heel erg naar uit om vanaf februari bij jullie aan de slag te gaan als AIOS! Jullie worden 
ondersteund door een mooie groep mensen. Karin, Julia en Linda, dank voor de geweldige 
ondersteuning en dank ook voor de gezelligheid, leuk om jullie binnenkort weer meer te zien! 
Spreekuurassistentes, dank voor het goed inplannen van de patiënten voor de IBD-studie 
en voor het waarschuwen als er weer één aan zat te komen! Endoscopieverpleegkundigen, 
dank voor jullie hulp rondom de inclusie en afname van de biopten! Henk Meussen, dank 
voor de samenwerking in de IBD groep en daarbuiten, leuk dat je altijd zo geïnteresseerd 
was in mijn onderzoeksbezigheden! Dorette, Femke, Petra en Patricia, ook met jullie was de 
samenwerking fijn, wisselend in intensiteit van persoon tot persoon. Dank voor het waarnemen 
van de onderzoekszaken en het includeren tijdens mijn afwezigheid!
Lieve Wendy en Jolien, wat heerlijk dat ik zulke goede vriendinnen heb gevonden tijdens mijn 
onderzoeksjaren! Bij jullie kon ik altijd even binnen vallen, met goed en met slecht nieuws, voor 
een kletsje of voor serieuze zaken. Fijn om met jullie alle IBD-groep zaken te kunnen bespreken 
en om alle projecten uit te werken, maar ook om af en toe lekker met elkaar uit eten te gaan. 
Jolien, dank voor het luisterend oor en je gezelligheid, we hebben ook veel plezier gehad op de 
lange latten, afgewisseld door een lekker Chouffje, maar goede wijntjes uitkiezen kun je ook 
als de beste! Wendy, wat fijn dat je naast me staat vandaag, net zoals zoveel andere dagen! Veel 
dingen moet ik gewoon altijd even met jou bespreken en onze gedachtes liggen vaak op één 
lijn. Ik bewonder jouw ijzersterke geheugen, invoelend vermogen en doorzettingskracht. Dank 
voor je oprechte vriendschap!
Beste professor Brons, lieve Ebelien, jouw vriendschap was fijn om te ervaren tijdens mijn 
onderzoekstijd en gelukkig ook daarna. Jij bent de constante factor tussen die almaar 
wisselende arts-assistenten. Over het algemeen raak jij altijd de vrolijke noot en het is fijn dat 
we elkaar daarin konden vinden, met daarbij af en toe ons klaaguurtje. Blijf wie je bent en blijf 
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zitten waar je zit, want ik kom er aan! Kunnen we straks samen pennen uit onze witte jas laten 
vallen ;). 
Van die almaar wisselende arts-assistenten groep zijn er inmiddels al heel wat MDL-arts. Wat 
was fijn om bij jullie in het hok te zitten. Het kon er gezellig en serieus zijn, er kon af en toe flink 
wat gemopperd worden, maar bovenal werd er heel wat gelachen. In eerste instantie samen 
met het Sandra, Fia, Matthijs, Bart en Bjorn. Het shadowteam was compleet met Ebelien erbij 
en ik heb erg genoten van onze etentjes, voor het volumineuze gelach werden we soms boos 
aangekeken, maar dat maakt het niet minder gezellig. Jammer dat het nu steeds lastiger 
wordt om een datum te prikken! Later werden Rian, Robin, Polat, Frans, René, Sjoukje, Tom 
en Lalini nog aan de groep toegevoegd. Ook al was ik nog geen AIOS, het voelde toch alsof ik 
onderdeel was van de groep, dank daarvoor, en ook dank voor de support en interesse in mijn 
onderzoek!
Mijn collega’s bij de interne geneeskunde dank ik voor het warme welkom en de ontzettend 
fijne werksfeer. Fijn dat het gewaardeerd wordt als je je kwetsbaar opstelt, bij jullie ben ik echt 
dokter geworden. Dank hiervoor Louis Reichert en Arianne van Bon en alle andere internisten.
 
Matthijs van Luin, jouw enthousiasme werkt altijd erg aanstekelijk, leuk om je betrokkenheid 
bij de IBD-patiënt en het MDO te zien. Te gek dat het Rijnstate zo voorop loopt met de 
spiegelmetingen van IBD medicatie dankzij jou. Voldoende onderzoeksvragen die we hiermee 
nog zouden kunnen beantwoorden… Leuk om je nu weer af en toe aan de lijn te hebben!
Het Rijnstate ziekenhuis en het Vriendenfonds dank ik voor alle ondersteuning in zowel 
faciliteiten als mogelijkheden.
Noud, wat leuk dat ik de afgelopen jaren met jou over promotiezaken kon praten, nu hebben we 
het allebei achter de rug J! Fijn dat jij en Kristy ons voor zijn met Kasper, dan kunnen we het af 
en toe een beetje van jullie afkijken. Laten we onze kerstavondtraditie er in houden. 
Birgit, Daan, Anke, Piet, Renate dank voor de gezellige avondjes en momenten van ontspanning 
ter afwisseling van het harde werken.
Anne, nog steeds vriendinnen, al een jaar of 15 (oeps, we worden oud!). Van NG (wis-/schei-/
natuurkunde)maatjes naar studie- en stadgenoten. Hopelijk blijven we elkaar vinden.
Dear Charles and Daniel, we met during our group travel in China, when I was still in my first 
PhD year (on the loose for three months, yay!). Since then we have ridden bicycles and played 
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Backpacker in many different countries together! Thanks for the many laughs and serious 
conversations, hoping for many more to come.
Eef en Bo, wat fijn dat we nog steeds contact hebben. We studeerden maar een jaartje met z’n 
3en maar toch is het aan gebleven! Ook al zien we elkaar niet vaak, het is toch altijd gelijk weer 
goed. Wat vond ik het bijzonder om met z’n drieën tegelijk zwanger te zijn. Ik kijk er naar uit 
om leuke dingen met elkaar te blijven doen. 
Lieve Lienke, ik ken je al vanaf dag -10 bij Geneeskunde, namelijk de eerste dag introductie, 
wat fijn dat je naast me staat vandaag! We hebben vaak al aan een half woord genoeg. Ik vind 
het jammer dat we elkaar een stuk minder zien met onze drukke leventjes en de wat langere 
reisafstand, maar gelukkig is het altijd weer goed samen en zie ik dat je daar in Grave heel erg 
goed zit met Sander. Mede-nerds Angelique en Anneke dank voor de gezellige bijpraatavondjes. 
Liek, fijn dat ik af en toe voor wijze raad bij je terecht kan, hopelijk komen we elkaar ergens in 
de komende jaren een keer op de werkvloer tegen!
Gerben en Nynke, wat fijn om zoveel met jullie te (hebben) kunnen delen; lekker eten, goeie 
muziek, spelletjes doen, goeie gesprekken en leuke reisjes. In Canada kwam dit allemaal 
samen in die ene camper. Met een kleine Gerbynke onderweg hebben we vast nog heel wat 
avonturen voor de boeg, maar dan met z’n zessen in plaats van z’n vieren. Op naar twee 
campers in Noorwegen?
Jop en Sietske, Jop, dankzij jou heb ik de liefde van m’n leven leren kennen, dat is op zichzelf al 
heel veel credits waard! Wat fijn dat jij en Sietske ook katsgelukkig zijn samen. Leuke weekendjes 
Nijmegen/Groningen (Noord-Zuidlijn) zijn nu veranderd naar Elst/Rotterdam (Betuwelijn) en zo 
nu en dan een concertje of festivalletje. Dat krijg je met een goede muzieksmaak! Wat ons 
betreft mogen jullie in de toekomst nog wel een stukje dichterbij komen wonen, maar tot die 
tijd zijn de logeerpartijtjes ook een feest!
Lieve Ino’s, lieve Eline, Tessa, Carlijn en Marleen, jullie hebben me de afgelopen jaren door dik 
en dun gesteund met fijne etentjes, weekendjes weg, dansjes tijdens het stappen, kaassouflé 
nadien, maar altijd met luisterend oor, wijze raad of gewoon een dikke knuffel. Ik hoop dat we 
dit nog lang voortzetten, al dan niet met wat meer babinos in de toekomst ;). 
Lieve familie Broersen en familie Smids, dank voor jullie het meeleven in goede en slechte 
tijden, fijn om zo’n grote familie te hebben!
Familie Besjes, lieve Karin, Jan, Geert Jan en Sophia en ik schaar Monique en Jan-Pieter hier 
ook onder. We kennen elkaar al jaren, we hebben veel meegemaakt en jullie hebben ook dit 
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proefschrift van begin tot eind kunnen volgen. Dank voor jullie oprechte interesse en de fijne 
momenten samen. GJ en Sophia, ik kijk uit naar de Oostenrijkse trouwerij!
Lieve pap, mam en Rem, wat ben ik blij met jullie als gezin! Het was voor jullie vaak wat 
ongrijpbaar waar ik nou mee bezig was al die jaren, met dit boekje wordt het waarschijnlijk 
een stuk inzichtelijker. Pap, van jou heb ik mijn eigenwijsheid en werkethos geërfd, beiden 
kwamen goed van pas de afgelopen jaren. Mam, dank voor het af en toe op de rem trappen 
en de knuffels. Fijn om jullie onvoorwaardelijke liefde te hebben en te weten dat jullie er altijd 
voor me zijn. Remco, wij lijken soms meer op elkaar dan we zullen denken. Wat ben ik trots op 
hoe jij je leventje leidt en wat ben ik blij met jou als broer! Pap, mam, Remco: ik hou van jullie! 
Allerliefste Maarten en Juliët. Jullie zijn mijn thuis, waar op de wereld we ook zijn. Maarten, 
al 14 jaar zijn we samen, maar nog altijd is elke dag met jou fijn. We hebben het geluk dat we 
zoveel dingen samen leuk vinden: reizen, muziek, lekker eten, tegenwoordig zelfs wijntjes of 
biertjes drinken en nu ook lekker gek doen met Juul. We hebben wel geleerd om intens van het 
moment te genieten: life is a picture, but you live in a pixel. Mijn dank aan jou is, net als mijn 
liefde voor jou, oneindig. Laten we nog veel avonturen beleven en vaak proosten op het leven. 
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CURRICULUM VITAE
Carolijn Smids werd op 24 februari 1988 geboren in Leiden en groeide op in Arnhem. In 2006 
behaalde zij haar VWO-diploma aan het Lorentz Lyceum in Arnhem. Aansluitend startte zij 
met de studie verpleegkunde in Nijmegen. Na het behalen van haar propedeuse werd ze in 
2007 alsnog ingeloot voor de studie geneeskunde aan de Radboud Universiteit in Nijmegen. 
In 2010 startte Carolijn met haar coschappen waarbij haar interesse in de Maag-, Darm- 
en Leverziekten werd gewekt tijdens haar seniorcoschap in het Rijnstate ziekenhuis te 
Arnhem. Haar wetenschappelijke stage maakte haar enthousiast voor de onderzoekswereld. 
In december 2013 begon zij in het Rijnstate ziekenhuis aan het promotieonderzoek getiteld 
“Profiling the immune response in early Inflammatory Bowel Disease” onder supervisie 
van dr. M.J.M. Groenen, dr. E.G. van Lochem, dr. P.J. Wahab en prof. dr. J.P.H. Drenth 
In maart 2017 begon Carolijn met de opleiding tot Maag-Darm en Leverarts in het Rijnstate te 
Arnhem bij opleider dr. L.J.M. Reichert (Interne Geneeskunde) en opleider dr. M.J.M Groenen 
(Maag-, Darm- en Leverziekten). Carolijn woont samen met Maarten Besjes en hun dochter 
Juliët in Elst.
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